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ABSTRACT
Chemical degradation studies on micrococcin P1 have established that the stereochemistry of 
the valine residue in the natural product is S and not R as previously assigned in the literature. 
This confirms Ciufolini’s hypothesis that the Bycroft-Gowland structure of MP1 differs from the 
natural product on stereochemical grounds.
A range of conditions for the synthesis of amino acid-derived thiazoles have been investigated 
and previously reported conditions found to be unreliable. Evidence has been provided to 
suggest that racemisation in the Hantzsch thiazole synthesis occurs in the elimination step of the 
reaction. The peptide backbone of micrococcin P1 has been prepared in 10 steps and 44% 
overall yield, incorporating S-valine based on the results of our degradation studies.
A microwave-assisted method for the conversion of sterically hindered (3-ketoesters to enamines 
has been devised, which is suitable for single- and multimode instruments, and for scale-up to 
produce multigram quantities of material. The central heterocyclic domain of the micrococcin 
thiopeptides has been prepared in 15 steps and 9% overall yield via a highly convergent strategy 
incorporating the Bohlmann-Rahtz pyridine synthesis and featuring an efficient two-directional 
thiazole elaboration.
The micrococcin thiopeptide macrocycle has been synthesised in 20 steps and 4% overall yield. 
Three micrococcin P1 side chain dipeptides have been prepared, each incorporating different 
protecting groups, enabling a range of different approaches to the natural product to be 
investigated.
HPLC analysis of degradation products from newly isolated cyclothiazomycin thiopeptides and 
comparison with synthetic material has provided evidence that the alanine-derived residue in the 
cyclothiazomycin core domain is of S stereochemistry, and not R as previously assigned in the 
literature.
ACKNOWLEDGMENTS
Firstly, I would like to thank the glorious Dr. Mark Bagley for his encouragement and guidance 
over the past three years, and for giving me the opportunity to work towards such a challenging 
target. I thank Dr. Nick Tomkinson for providing help and support above and beyond the call of 
duty, as well as for career advice, motivational chats, viva practice and being scary. I thank Prof. 
Thomas Wirth for helpful discussions during progress meetings and Prof. David Knight and Dr. 
Mark Elliot for helpful discussions during coffee breaks.
I would also like to thank co-workers past and present, in particular Dr. Xin Xiong for teaching me 
how to work in a lab, Dr. Chris Glover for moral support and therapy, and Caz Widdowson for 
asking ‘is it bigger than a duck?’ Special thanks also go to Dr. Ian Jones, Kerri Jones, Dr. Nonny 
Jones, Dr. Caterina Lubinu, Dr. Matt Dix, Paola Murziani, Laura Howard, Katie Petherbridge, 
Vincenzo Fusillo, Deb Knowles, Paul Taylor, Dr. Tim Gibbs and all other members of lab 1.119 
(2002 -  2007) for making work pHun.
My thanks also go to the administrative and technical staff of the chemistry department, in 
particular to Dr. Robert Jenkins and Robin Hicks, whose awesomeness cannot be overstated.
Finally, I thank my friends and family for their constant support over the past three years, for 
putting up with (continuous) ranting, feigning interest in chemistry, providing coffee, going for 
therapeutic walks in the park and expeditions to Ikea, and for being pHantastic...©
iv
ABBREVIATIONS
aa Amino acid
Ac Acetyl
Alloc Allyloxycarbonyl
AOP (7-azabenzotriazol-1 -yl)oxytris-(dimethylamino)phosphonium
hexafluorophosphate
APCI Atmospheric Pressure Chemical Ionization
aq Aqueous
Ar Unspecified aryl substituent
Arg Arginine
Asn Asparagine
Boc terf-Butoxycarbonyl
Boc20  Di-tert-butyldicarboxylate
Bn Benzyl
BOI 2-(Benzotriazol-1 -yl)oxy-1,3-dimethylimidazolinium hexafluorophosphate
BOP Benzotriazol-1 -yl-dimethylaminophosphonium hexafluorophosphate
bp Boiling point
Bpoc 2-(4-Biphenylyl)isopropoxycarbonyl
BroP Bromotris(dimethylamino)phosphonium hexafluorophosphate
Bu Butyl
BuLi Butyl lithium
c Concentration
cat. Catalytic/catalyst
CBMIT 1,1 ’-Carbonylbis(3-methylimidazolium) triflate
Cbz Benzyloxycarbonyl
CDI 1,1 ’-Carbonyldiimidazole
Cl Chemical Ionisation
CIP 2-Chloro-1,3-dimethylimidazolinium hexafluorophosphate
CloP Chlorotris(dimethylamino)phosphonium hexafluorophosphate
COSY Correlation Spectroscopy
DAA 2,4-Dinitrophenyl-(S)-alaninamide
DAST Diethylaminosulphur-trifluoride
Dba Dibenzylidineacetone
DBU 1,8-Diaza[5.4.0]undec-7-ene
DCC Dicyclohexylcarbodiimide
DCE 1,2-Dichloroethane
v
DDQ Dichlorodicyanobenzoquinone
DEPC Diethylcyanophosphonate
DEPT Distorntionless enhancement by polarisation transfer
DHAA Dehydrohomoalanine
DIPEA Diisopropylethylamine
DMAP A/,A/-Dimethylaminopyridine
DME 1,2-Dimethoxyethane
DMF A/./V-Dimethylformamide
DMP Dimethoxypropane
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DPPA Diphenylphosphoryl azide
EDCI 1 -[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride
ee Enantiomeric excess
El Electron Impact
Enz Enzyme
eq. Equivalent
equiv. Equivalent
ES Electrospray
Et Ethyl
exch. Exchange
FAB Fast Atom Bombardment
FDAA 1-Fluoro-2,4-dinitrophenyl-5-(S)-alanine amide
FDPP Pentafluorophenyl diphenylphosphinate
Fmoc 9-Fluorenylmethoxycarbonyl
FTIR Fourier Transform Infra Red
g Grams
GC-MS Gas xhromatography mass spectrometry
GDP Guanosine-5’-diphosphate
Gin Glutamine
Glu Glutamic acid
GTP Guanosine-5’-triphosphate
h Hour(s)
HATU 0-(7-Azabenzotriazol-1-yl)-A/, N, N ’, A/-tetramethyluronium
hexafluorophosphate
HBTU 0-(Benzotriazol-1-yl)-A/, N, N\ A/’-tetramethyluronium hexafluorophosphate
vi
HOAt 1 -Hydroxy-7-azabenzotriazole
HOBt 1 -Hydroxybenzotriazole
HOCt Ethyl 1 -hydroxy-1,2,3-triazole-4-carboxylate
HPLC High pressure liquid chromatography
HMBC Heteronuclear multiple bond correlation
HMPA Hexamethylphosphoramide
HRMS High resolution mass spectrometry
HSQC Heteronuclear single quantum coherence
Hz Hertz
IBX o-lodoxybenzoic acid
IC50 Concentration of an inhibitor required for 50% inhibition of an enzyme in vitro
IR Infra Red
J Coupling constant (in Hz)
kg Kilograms
L Laevorotatory
LDA Lithium diisopropylamine
Leu Leucine
lit. Literature
LRMS Low Resolution Mass Spectrometry
Lu Lutidine
M Molar
MALDI Matrix-Assisted Laser Desorption
MDa Megadaltons
Me Methyl
mg Milligrams
pg Micrograms
MHz Megahertz
min Minutes
MinC Minimum induction Concentration
mL Millilitres
pL Microlitres
mM Millimolar
pM Micromolar
Mol Mole
mp Melting point
mRNA Messenger ribonucleic acid
MRSA Methicillin resistant Staphylococcus aureus
MS Mass Spectrometry
Ms Mesyl (methanesulfonyl)
MW Microwave
NAD Nicotinamide adenine dinucleotide
NIS A/-lodosuccinimide
nM Nanomolar
nm Nanometre
NMR Nuclear Magnetic Resonance
nOe Nuclear Overhauser effect
NOSEY Nuclear Overhauser and Exchange Spectroscopy
P Para
PG Protecting group
Ph Phenyl
PhMe Toluene
PP Pyrophosphate
ppm Parts per million
PPTS Pyridinium p-toluenesulphonate
Pr Propyl
Pro Proline
p-Tol p-Tolyl
PTSA p-Toluenesulphonic acid
py Pyridine
PyAOP
PyBOP®
[(7-Azabenzotriazol-1-yl)oyx]tris-(pyrrolidino)phosphonium
hexafluorophosphate
Benzotriazol-1-yl-oxytris-pyrrolidinophosphonium hexafluorophosphate
PyBroP Bromotri(pyrrolidino)phosphonium hexafluorophosphate
PyCloP Chlorotri(pyrrolidino)phosphonium hexafluorophosphate
quant. Quantitative
R Specified substituent
rac Racemic
Rf Retention factor
RNA Ribonucleic acid
RNAP Ribonucleic acid polymerase
rRNA Ribosomal ribonucleic acid
ROESY Rotating-frame Overhauser Enhancement Spectroscopy
r.t. Room temperature
Ser Serine
Silica/Si02 Merck Kieselgel 60 H silica or Matrex silica 60
TATU O-Benzotriazol-l-yl-1,1,3,3-tetramethyluronium tetrafluoroborate
TBAF Tetra-n-butylammonium fluoride
TBDMS fert-Butyldimethylsilyl
TBS tert-Butyldimethylsilyl
TBTU 0-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
TEAP Triethylammonium phosphate
T eoc (T rimethylsily l)ethoxycarbony I
Tert Tertiary
TES Triethylsilyl
Tf Triflate (trifluoromethanesulfonate)
TFA Trifluoroacetic acid
TFAA Trifluoroacetic anhydride
TFFH Tetramethylfluoroformamidinium hexafluorophosphate
TFP Tri(2-furyl)phosphane
THF Tetrahydrofuran
Thr Threonine
Tip Thiostrepton-induced protein
TLC Thin Layer Chromatography
TMS Trimethylsilyl
TMSE 2-(Trimethylsilyl)ethyl
TOF Time of Flight
tRNA Transfer ribonucleic acid
Ts Tosyl (para-toluenesulfonyl)
Tyr Tyrosine
UV Ultraviolet
Val Valine
vs. Versus
W Watts
2D 2-Dimensional
ix
TABLE OF CONTENTS
DECLARATION.................................................................................................................................... i
STATEMENT O NE...............................................................................................................................i
STATEMENT TWO...............................................................................................................................i
ABSTRACT..........................................................................................................................................iii
ACKNOWLEDGMENTS.................................................................................................................... iv
ABBREVIATIONS................................................................................................................................v
TABLE OF CONTENTS......................................................................................................................x
Chapter One -  Introduction...........................................................................................................1
1 -  The Thiopeptide Antibiotics.........................................................................................................2
1.1 -  Introduction............................................................................................................................ 2
1.2 -  Classification by Central Heterocyclic Domain..................................................................2
1.3 -  Biological Properties.............................................................................................................4
1.3.1 -  Biological Activity...........................................................................................................4
1.3.2 -  Ribosomal Inhibitors..................................................................................................... 7
1.3.3 -  Inhibition of Elongation Factor Tu .............................................................................. 11
1.3.4 -  TipA Promotion............................................................................................................ 13
1.4 -  Total Syntheses of Thiopeptide Antibiotics.......................................................................17
1.4.1 -  Promothiocin A............................................................................................................. 17
1.4.2 -  Amythiamicin D ............................................................................................................ 19
1.4.3 -  Thiostrepton................................................................................................................. 21
1.4.4 -  GE2270A and GE2270T............................................................................................. 23
1.4.5 -  Siomycin A ....................................................................................................................27
1.5 -  The Micrococcin Thiopeptides........................................................................................... 30
1.5.1 -  Isolation......................................................................................................................... 30
1.5.2 -  Early Biological Studies.............................................................................................. 30
1.5.3 -  Degradation Studies....................................................................................................31
1.5.4 -  The Walker-Lukacs Structure.................................................................................... 31
1.5.5 -  The Bycroft-Gowland Structure.................................................................................. 32
1.5.6 -  Ciufolini's Synthesis of Bycroft-Gowland MP1......................................................... 32
1.5.7 -  Shin’s Synthetic Epimers of MP1...............................................................................34
1.5.8 -  The Stereochemistry of MP1 Reinvestigated............................................................35
Chapter Two -  Results and Discussion.................................................................................... 37
2 -  Reinvestigation of MP1 Stereochemistry by Chemical Degradation Studies...................... 38
2.1 -  Introduction.......................................................................................................................... 38
2.2 -  Walker’s degradation studies............................................................................................. 38
x
2.2.1 -  Walker’s synthesis of thiazole 100............................................................................. 39
2.2.2 -  Racemisation of amino acid-derived thiazoles..........................................................39
2.3 -  Determination of stereochemistry in cyclic peptides....................................................... 40
2.3.1 -  Synthesis and use of Marfey’s Reagent................................................................... 41
2.3.2 -  HPLC analysis of derivatised amino acids................................................................41
2.4 -  Synthesis and degradation of model peptide 115............................................................42
2.4.1 -  Synthesis of cyclic peptide 115.................................................................................. 42
2.4.2 -  Degradation and analysis of hexapeptide 115......................................................... 43
2.5 -  Degradation of natural MP1............................................................................................... 44
2.5.1 -  Chemical degradation of MP1.....................................................................................44
2.5.2 -  HPLC analysis of MP1 degradation products.......................................................... 45
2.6 -  Conclusion........................................................................................................................... 49
Chapter Three -  Results and Discussion...................................................................................51
3 -  Modification of the Hantzsch Thiazole Synthesis................................................................... 52
3.1 -  Introduction.......................................................................................................................... 52
3.1.1 -  Biomimetic synthesis of thiazoles.............................................................................. 53
3.1.2 -  Rhodium carbenoid insertion......................................................................................53
3.1.3 -  Alternative synthetic routes to thiazoles.....................................................................54
3.2 -  The Hantzsch Thiazole Synthesis.....................................................................................55
3.2.1 -  The Hantzsch thiazole synthesis............................................................................... 55
3.2.2 -  Racemisation of amino acid-derived substrates...................................................... 55
3.2.3 -  Modifications made by Holzapfel............................................................................... 56
3.2.4 -  Modifications made by Meyers...................................................................................56
3.2.5 -  Modifications made by Nicolaou................................................................................ 57
3.2.6 -  Modifications made by Bach.......................................................................................58
3.3 -  Reinvestigation of the Hantzsch Thiazole Synthesis...................................................... 58
3.3.1 -  Comparison of the literature methods for the synthesis of 102b............................ 59
3.3.2 -  Modification of literature procedures..........................................................................60
3.3.3-Activation using methanesulfonyl chloride................................................................60
3.3.4 -  Activation using other reagents.................................................................................. 63
3.3.5 -  Synthesis of threonine-derived thiazole 132.............................................................63
3.4 -  Synthesis of the peptide backbone of M P 1..................................................................... 64
3.4.1 -  Synthesis of backbone pentapeptide 143................................................................. 65
3.4.2 -  Elimination to form protected backbone fragment 139............................................66
3.5 -  Conclusion........................................................................................................................... 67
Chapter Four -  Results and Discussion.................................................................................... 68
4 -  Synthesis of the Central Heterocyclic Domain of M P1...........................................................69
4.1 -  Introduction.........................................................................................................................69
xi
4.1.1 -  The Hantzsch pyridine synthesis............................................................................... 70
4.1.2 -  The Wakatsuki-Yamazaki-Bonnemann reaction...................................................... 70
4.1.3 -  The Boger-Panek pyridine synthesis........................................................................ 71
4.2 -  Synthetic approaches to thiopeptide core domains........................................................ 72
4.2.1 -  Proposed biosynthetic pathway to the pyridine and tetrahydropyridine cores of the 
thiopeptide antibiotics.............................................................................................................. 72
4.2.2 -  Aza-Diels-Alder approach...........................................................................................73
4.2.3 -  Diels-Alder dimerisation.............................................................................................. 73
4.2.4 -  Coupling of an azomethine ylide and a chiral sulfinimine....................................... 74
4.2.5 -  Synthesis via a 1,5-diketone.......................................................................................75
4.2.6 -  The Bohlmann-Rahtz pyridine synthesis..................................................................75
4.2.7 -  Retrosynthetic analysis of the central heterocyclic domain of MP1....................... 77
4.3 -  Synthesis of (3-ketoester 172............................................................................................. 77
4.3.1 -  Conversion of carboxylic acid 140 to (3-ketoester 172............................................ 77
4.4 -  Synthesis of enamine 169................................................................................................. 78
4.4.1 -  Ammonia-saturated solvents......................................................................................79
4.4.2 -  Ammonium acetate..................................................................................................... 79
4.4.3 -  Conductive heating vs. microwave conditions......................................................... 80
4.4.4 -  Scale-up using a multimodal microwave................................................................... 81
4.5 -  Alternative routes to enamine 169.....................................................................................82
4.5.1 -  Enamine formation via thiazole nitrite 174................................................................ 82
4.5.2 -  Enamine formation via (3-ketonitrile 176.................................................................... 83
4.6 -  Synthesis of thiazole alkynone 170 .................................................................................. 83
4.6.1 -  Synthesis of thiazole alkynone 170............................................................................ 84
4.6.2 -  Scale-up limitations with the oxidation of propargylic alcohol 181......................... 84
4.7 -  Synthesis of protected core domain 168 ..........................................................................85
4.7.1 -  The Bohlmann-Rahtz pyridine synthesis..................................................................85
4.7.2 -  Two-directional thiazole elaboration..........................................................................86
4.8 -  Synthetic approaches to micrococcinic acid.................................................................... 87
4.8.1 -  Degradation of micrococcin P1 to micrococcinic acid..............................................87
4.8.2 -  Kelly’s synthesis of micrococcinic acid..................................................................... 87
4.8.3 -  Our synthetic approach to micrococcinic acid.......................................................... 88
4.9 -  Conclusion........................................................................................................................... 90
Chapter Five -  Results and Discussion.................................................................................... 91
5 -  Assembly of the MP1 Macrocycle............................................................................................. 92
5.1 -  Introduction.........................................................................................................................92
5.1.1 -  Acid halogenating reagents........................................................................................92
5.1.2 -  Chloroformates............................................................................................................ 93
5.1.3 -  Carbodiimide reagents................................................................................................ 93
5.1.4 -  Imidazolium reagents.................................................................................................. 94
5.1.5 -  Organophosphorus reagents......................................................................................95
5 .1 .6 - Phosphonium reagents............................................................................................. 97
5.1.7 -  Uranium reagents........................................................................................................98
5.1.8 -  Alternative macrocyclisation strategies used in thiopeptide synthesis................. 101
5.2 -  Deprotection of core domain 168.....................................................................................103
5.2.1 -  Ester hydrolysis with lithium hydroxide....................................................................104
5.2.2 -  Ester hydrolysis with trimethyltin hydroxide............................................................104
5.2.3 -  AMerminus deprotection of 168.................................................................................106
5.3 -  Deprotection of backbone peptide 139........................................................................... 107
5.3.1 -  Literature methods for A/-deprotection.....................................................................107
5.3.2 -  C-terminus deprotection............................................................................................ 108
5.4 -  Construction of macrocycle 2 51 ......................................................................................108
5.4.1 -  Coupling of core domain 248 and backbone peptide 249..................................... 108
5.4.2 -  Deprotection of fragment 250 ...................................................................................109
5.4.3 -  Macrolactamisation....................................................................................................110
5.5 -  Synthesis of the MP1 side chain......................................................................................112
5.5.1 -  Synthesis of side chain fragment 256......................................................................112
5.5.2 -  Synthesis of side chain fragment 257......................................................................112
5.5.3 -  Synthesis of side chain fragment 258......................................................................113
5.5.4 -  Selective removal of Boc in the presence of TBDMS........................................... 113
5.6 -  Elaboration of macrocycle 251 to MP1........................................................................... 114
5.6.1 -  One-pot macrolactamisation and side chain coupling.......................................... 114
5.6.2 -  Acetate protection of macrocycle 251......................................................................115
5.6.3 -  TBDMS-protection of macrocycle 251 .....................................................................116
5.7 - Conclusion.......................................................................................................................... 117
Chapter Six -  Results and Discussion.....................................................................................118
6 -  Reinvestigation of the Stereochemistry of Cyclothiazomycin..............................................119
6.1 -  Introduction........................................................................................................................ 119
6.1.1 -  Chemical degradation of cyclothiazomycin.............................................................119
6.1.2 -  Isolation of new cyclothiazomycins..........................................................................120
6.2 -  Reinvestigation of the stereochemistry of cyclothiazomycin.........................................121
6.2.1 -  Synthesis of lactam 284............................................................................................ 122
6.2.2 -  HPLC analysis of lactam 284....................................................................................124
6.3 -  Conclusion......................................................................................................................... 125
Chapter Seven -  Summary........................................................................................................ 126
7 -  Summary................................................................................................................................... 127
7.1 -  Reinvestigation of MP1 stereochemistry by chemical degradation studies................127
7.2 -  Modification of the Hantzsch thiazole synthesis............................................................ 127
7.3 -  Synthesis of the central heterocyclic domain of M P1................................................... 127
7 .4 -Assembly of the MP1 macrocycle....................................................................................127
7.5 -  Reinvestigation of the stereochemistry of cyclothiazomycin.......................................127
Chapter Eight -  Experimental....................................................................................................128
8 -  Experimental..............................................................................................................................129
8.1 -  Experimental techniques..................................................................................................129
8.2 -  General experimental methods........................................................................................ 129
8.2.1 -  General method for the derivatisation of amino acids with Marfey’s reagent 129
8.3 - Experimental....................................................................................................................... 130
Appendices..................................................................................................................................177
Appendix One..............................................................................................................................178
Appendix Two..............................................................................................................................179
Appendix Three.......................................................................................................................... 180
Appendix Four............................................................................................................................ 181
References.................................................................................................................................. 182
xiv
Chapter One -  Introduction
The Thiopeptide Antibiotics
1.1 -  Introduction
1 . 2 -  Classification by Central Heterocyclic Domain
1 . 3 -  Biological Properties
1 . 4 -  Total Syntheses of Thiopeptide Antibiotics
1 . 5 -  The Micrococcin Thiopeptides
Chapter 1 -  The Thiopeptide Antibiotics
1 -  The Thiopeptide Antibiotics
1.1 -  Introduction
The thiopeptide antibiotics are naturally occurring, sulfur containing, highly modified, macrocyclic 
peptides, nearly all of which inhibit protein synthesis in bacteria.1 These complex natural 
products, grouped as thiazolyl peptides for Berdy’s classification of antibiotics according to 
chemical structure,2 share a number of common structural features: a tri- or tetrasubstituted 
nitrogen heterocycle clustered in a central polyazole domain that is part of a macrocyclic 
framework consisting of modified heterocyclic residues, including thiazoles, oxazoles and 
indoles, and dehydroamino acids. These biologically active substances are secondary 
metabolites produced by actinomycetes, Gram-positive mycelial sporulating bacteria, largely of 
the genus Streptomyces that can be subdivided into 29 different antibiotic families containing well 
over 76 structurally distinct entities. In spite of their chemical and taxonomical diversity, many of 
them broadly seem to share a similar biological profile, displaying almost no activity against 
Gram-negative bacteria, whereas against Gram-positive bacteria they are highly active inhibitors 
of protein synthesis and are, in many cases, effective against methicillin resistant 
Staphylococcus aureus (MRSA), a bacterial strain that is resistant to most conventional 
treatments. This biological property, as well as an increased understanding of their mode of 
action and the failure of traditional therapies to counter the emergence of bacterial resistance, 
has led to renewed interest in this antibiotic class.
1.2 -  Classification by Central Heterocyclic Domain
The individual chemical identity of structurally distinct compounds isolated from natural sources 
and classified as thiopeptide or thiazolylpeptide antibiotics is relatively diverse. In spite of many 
similarities in biosynthetic origin, these secondary metabolites have been isolated from a number 
of different strains of actinomycetes, predominantly soil bacteria but also from marine sources, 
and elicit a wide range of different biological responses. The complexity of the many 
mechanisms employed by pathogens to avoid intoxication, and used by these metabolites in 
order to inhibit bacterial protein synthesis, are only now coming to light, facilitated by advances in 
crystallography, NMR spectroscopy and our understanding of Streptomyces transcriptional 
mechanisms and ribosomal function. Although further research may reveal that many of these 
processes are interrelated, at present most can be attributed to specific regions or motifs in 
metabolite structure particular to certain families or groups of families related by functional group 
commonality. For this reason, classification of thiopeptide antibiotics by structure, in particular in 
the nature of the central heterocyclic domain, also categorises their biological properties and is 
useful for highlighting structural relationships between the 29 different antibiotic families identified
2
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to date. Examining the structure of individual thiopeptides reveals that there are five distinct 
classes of these natural products assigned according to the oxidation state of the central 
heterocyclic domain. Each class can be further subdivided into families that group cyclic 
peptides with a high degree of structural homology or in some cases that were isolated from the 
same antibiotic producing organism (Table 1).
Table 1 Thiopeptide antibiotic families classified according to their central heterocyclic domain
Series a and b Series c Series d Series e
Bryamycin (A-8506)3 Sch 40832 A10255 Glycothiohexide a
Sch 18640 (68-1147) Amythiamicin MJ347-81F4
Siomycin Berninamycin Multiomycinb
Thiactin3 Cyclothiazomycin Nocathiacin
Thiopeptin GE2270 Nosiheptide
Thiostrepton GE37468
Geninthiocin
Methylsulfomycin
Micrococcin
Promoinducin
Promothiocin
QN3323
Radamycin
Sulfomycin
Thioactin
Thiocillin
Thiotipin
Thioxamycin
YM-226 183-4
S-54832
a Shown to be identical to thiostrepton;b Shown to be identical to nosiheptide
Hensens first suggested grouping thiopeptide antibiotics according to the structure and oxidation 
state of the central heterocyclic domain, in order to distinguish between different constituents of 
the thiopeptins (2).3 This classification system has since been extended to describe the five 
distinct heterocyclic domains, representative examples of which are illustrated in Figure 1. The 
parent of the thiopeptide antibiotics, thiostrepton (1), is classified as a 1b’ series thiopeptide, 
whereas some of the thiopeptin factors (2) possess the fully reduced ‘a’ series central domain, 
tetrasubstituted dehydropiperidine or saturated piperidine heterocycles, respectively. The related 
‘c’ series of thiopeptides to date only consists of a single antibiotic, Sch 40832 (3), and has an 
unusual imidazopiperidine core. With increasing unsaturation, in line with Hensens’ 
classification, by far the most prolific thiopeptide class is the ‘series d  antibiotics, possessing a
2,3,6-trisubstituted pyridine domain. This domain is shared by 19 different families including the 
first thiopeptide to be isolated, micrococcin P1 (4). Finally ‘series e’ thiopeptides such as 
nosiheptide (5), exhibit a structurally related central motif, oxidised in comparison with their 
series d counterparts, containing a tetrasubstituted hydroxypyridine.
3
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NH
HO,
HO
HN
OH
HO'
OH 0
thiostrepton A (1), R = h n
thiostrepton B, R = N H 2
HQ
HN
HN
HOHO
HN
"=N
NH
RO
H3C
NH
R =
HO'"
Sch 40832 (3)
OH
HO'"
OH
NH
MeMe
HO
HN
Me
OHMe'
Me
thiopeptins (2)HO' Me
OH
HN
n h2
HN
HN
NH2
OMe
OH
Series a, Series £>,
X = Y = H X,Y = bond:
A-ia A ib
A3a A3b
A4a A4b
Ba Bb
HO
HN
HN
,NH
micrococcin P1 (4) ) - . .0H
HQ
NH
NH
HN
HO
OH
NH
nosiheptide (5)
Figure 1 Representative examples of the five thiopeptide families
1.3 -  Biological Properties
1.3.1 -  Biological Activity
The thiopeptide antibiotics largely inhibit the growth of Gram-positive bacteria, although the 
activity of some of these metabolites as antifungal or anticancer agents, against Gram-negative
4
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bacteria, as renin inhibitors or against Plasmodium falciparum, the malaria parasite, has also 
been reported. In spite of considerable structural homology the site and mode of action for these 
antibiotics actually varies in different thiopeptide families and can be categorised, broadly, into 
two classes: those that bind to a region of the 23S ribosomal RNA (rRNA) known as the L11 
binding domain (L11BD) and those that bind to a protein (Ef-Tu) complex involved in the 
elongation cycle.
The antibacterial activity of the thiopeptide antibiotics in vitro is comparable to that of the 
penicillins, with little or no adverse toxicological effects in mammalian cells, disrupting protein 
synthesis in the bacterial cell’s protein factory, the ribosome. Prokaryotic and eukaryotic 
ribosomes interpret the information in messenger RNA (mRNA) and use it to assemble the 
corresponding sequence of amino acids in a protein.4 Although bacterial and mammalian 
ribosomes do exhibit many structural similarities, they differ considerably in size, the latter being 
approximately 30% larger and containing so-called expansion sequences in the rRNA as well as 
a number of additional ribosomal proteins. The job of the ribosome is translation, that is to read 
each codon of the mRNA in turn and match it with the anticodon of the corresponding transfer 
RNA (tRNA) bound amino acid, assembled by the respective synthetase, and thus build up the 
protein, residue by residue, that it encodes. All ribosomes are composed of two subunits of 
unequal size; the bacterial ribosome, with a relative sedimentary rate of 70S, consisting of a 
large 50S and a small 30S subunit. These two subunits are associated through non-covalent 
interactions and organise to give a ribonucleoprotein particle 2.6-2.8 MDa in size, with a diameter 
of 200-250 A, that functions as a platform for bacterial protein synthesis. In Escherichia coli each 
subunit consists of proteins and rRNA fragments, the small 30S subunit containing 21 proteins 
(S1-S21) and a 16S rRNA strand whereas the 50S subunit comprises 34 proteins (L1-L34) and 
two strands of rRNA, the 23S and 5S (Figure 2).
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Figure 2 Composition of the 70S bacterial ribosome5 6
Colour key. Left: small 30S subunit; proteins S1-S21 (blue) and 16S rRNA strand (pink). Right: large 50S 
subunit; proteins L1-L34 (blue), 23S rRNA (pink) and 5S rRNA (yellow). Credit to David S. Goodsell of The 
Scripps Research Institute.
The sites on the ribosome involved in the sequential construction of the nascent protein from the 
individual amino acid components are denoted as the A site, where aminoacyl-tRNA (aa-tRNA) 
containing the next amino acid residue docks on instruction from the codon of its corresponding 
mRNA, the P site, where the growing peptide chain waits in readiness to form the next peptide 
bond, and the E site, that receives the tRNA for its exit at the end of the sequence (Scheme 1). 
Once bacterial protein synthesis has been initiated by interaction of the 3’ end of the 16S rRNA in 
the 30S subunit with a complementary sequence on mRNA,7 the initiator tRNA binds directly to 
the P site (Scheme 1a) and each aa-tRNA in accordance with its corresponding codon is 
delivered to the A site as a ternary complex (Scheme 1b) formed by combination with the 
elongation factor Tu (Ef-Tu) and GTP. GTP hydrolysis causes a conformational change in the 
ternary complex that releases Ef-Tu GDP from the ribosome to be recycled back to Ef-Tu GTP, 
leaving the aa-tRNA bound in the A site (Scheme 1c). The next peptide bond is then formed on 
the large ribosomal subunit by the transfer of the peptide to the A site, generating a peptidyl- 
tRNA whilst leaving behind its own tRNA in the P site (Scheme 1d). Translocation of the 
peptidyl-tRNA from the A site back to the P site is then mediated by a different elongation factor, 
Ef-G (Scheme 1e), which vacates the A site and moves the deacylated tRNA to the E site ready 
for exit (scheme 1f). When the next aa-tRNA-containing ternary complex binds (Scheme 1 g), the
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tRNA docked in the E site is released and the protein elongation cycle repeats itself (Scheme 1c) 
until protein termination factors liberate the finished peptide and dissociates the ribosome.
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Scheme 1 Overview of protein translation
The small 30S subunit is depicted in yellow, the 50S subunit is depicted in blue. A, P and E denotes sites 
on the ribosome that can be occupied by tRNA. The A site is where aa-tRNA binds, the P site is where 
peptidyl-tRNA binds before peptide bond formation and the E site is the exit site for deacylated tRNA. 
Translation cycle consists of: (a) initiator tRNA binds in the P site; (b) aa-tRNA Ef-Tu GTP is delivered to 
the A site; (c) aa-tRNA is bound in the A site; (d) peptide is transferred to the A site with formation of next 
peptide bond; (e) translocation of peptidyl-tRNA from the A site back to the P site is mediated by Ef- 
G GTP; (f) deacylated tRNA waits in the E-site; (g) aa-tRNA-Ef-Tu GTP is delivered to the A site releasing 
the deacylated tRNA from the E site. Reprinted from ref 4. Copyright 2003 Wiley-VCH Verlag GmbH & Co. 
KgaA, Weinheim.
1.3.2 -  Ribosomal Inhibitors
Seven different classes of antibiotics in clinical practice target the bacterial ribosome, including 
the aminoglycosides, tetracyclines, macrolides and streptogramins. Ribosomal inhibitors that
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interact with rRNA may exhibit a favourable resistance profile in the clinic as most pathogens 
have multiple copies of the rrn operons that encode rRNA thus resistance-inducing mutations are 
rarely dominant.8
Peptidyl-tRNA
70S ribosome 
(2.3 x 10*)
SOS subunit 30S subunit
(1.45x10® ) (0 85 x 10®)
SS RNA 23S RNA 16S RNA
120 nucleotides 3.000 nucleotides 1.500 nucleotides
4 +
Proteins Proteins
L 1.L 2..................... 134 S1.S2. S3......................S21
(avg. M( -  1.5 x 104) (avg. -  1.6 x 104)
Figure 3 The bacterial ribosome
Many thiopeptide antibiotics interfere with bacterial protein synthesis on the ribosome, although 
the precise inhibitory mechanism operating for the majority of these agents has not been 
established. The most closely studied mode of action of all of the thiopeptides is that of 
thiostrepton (1), which has been applied in rational structure-based drug design in an attempt to 
address problems with this antibiotic’s low solubility and poor bioavailability.9 In vivo thiostrepton 
inhibits the binding of the aminoacyl-tRNA-containing ternary complex to the ribosomal A site 
(Figure 3).10 The energy for protein translation is provided by the action of the elongation factors 
Ef-Tu and Ef-G, these hydrolysis reactions taking place on the large ribosomal subunit at a 
GTPase centre located on a double hairpin structure within domain II of 23S rRNA,11 where 
ribosomal protein L11 and the pentameric complex L10.(L12)4 assemble cooperatively, and on a 
ribotoxin hairpin loop within domain VI of 23S rRNA.12 The action of thiostrepton inhibits peptide 
elongation probably by impeding a conformational change within protein L11, when bound in a 
region of the 23S rRNA known as the L11 binding domain (L11BD).13 The RNA-binding domain 
of protein L11 recognises an rRNA tertiary structure that is stabilised by thiostrepton,14 the 
antibiotic preventing one or more conformational transitions critical for stimulating the GTPase 
action of the elongation factors,15 necessary to drive the directional movement of transfer and 
messenger RNA on the ribosome.16
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Both thiostrepton (1) and micrococcin (4) inhibit the growth of the malaria parasite Plasmodium 
falciparum, inhibiting organellar protein synthesis by targeting the large subunit encoded by a 35- 
kb organelle, which is one of two extrachromosomal DNAs possessed by the parasite.17 
Thiostrepton has been shown to bind to malarial plastid rRNA18 and has a 50% inhibitory 
concentration (IC50) of 3.2 nM, whereas growth inhibition by micrococcin has an IC50 of 35 nM.19
Two types of resistance mechanisms have been observed to thiostrepton in Gram-positive 
bacteria whereas Gram-negative organisms are completely resistant to its action, as thiostrepton 
cannot penetrate the bacterial cell wall. In Gram-positive organisms, one resistance mechanism 
is defined by the absence of a protein homologous with L11 in E. coli, and designated BM-L1120 
in Bacillus megaterium and BS-L1121 in Bacillus subtilis, giving rise to protein-deficient ribosomes 
with a reduced affinity for thiostrepton in vitro but that retain substantial protein synthetic activity. 
Mutants of B. subtilis were found to be resistant to both thiostrepton and sporangiomycin, further 
substantiating the hypothesis that these antibiotics inhibit protein synthesis by an identical 
mechanism and that the mutation alters the site on the 50S ribosomal subunit that is responsible 
for antibiotic binding.22 In a similar fashion a mutant strain of Bacillus megaterium possessed an 
altered form of protein BM-L11 causing the strain to be resistant to the action of micrococcin.23 
However, the tRNA uncoupled hydrolysis reaction catalysed jointly by the ribosome and the 
protein factor Ef-G, which is inhibited by thiostrepton, is markedly stimulated by micrococcin upon 
organisms sensitive to this drug,24 a disparity worthy of note in considering the seemingly 
common mode of action of thiopeptide ribosomal inhibitors. Both thiostrepton and micrococcin 
bind to the GTPase region in domain II of 23S rRNA and in so doing they alter the accessibility of 
adenosine (A)-1067 and A1095 in the 23S rRNA towards chemical reagents, indicating that 
thiopeptide ribosomal inhibitors interact directly with these nucleotides.25 These two drugs had 
different effects on the chemical reactivity of A1067 in a terminal loop of E. coli ribosomes in 
vitro, micrococcin enhanced its reactivity whereas thiostrepton protected the N-1 position 
reducing reactivity, a difference that correlates with the opposite effects of the two antibiotics on 
GTPase activity.26 This can be rationalised in a model for the tRNA uncoupled system where the 
dissociation of Ef-G‘GDP from the ribosome is the rate-limiting step of Ef-G-dependent GTP 
hydrolysis.27 Thiostrepton and micrococcin act by increasing the dissociation rates of both Ef- 
G ‘GTP and Ef-G‘GDP, although micrococcin with lesser potency has a weaker dissociating 
effect on Ef-G*GTP than thiostrepton. In this model, the action of micrococcin would increase 
the turnover of Ef-G, increasing the rate of GTP hydrolysis, whereas Ef-G-GTP dissociation 
induced by thiostrepton would be too rapid to allow for GTP hydrolysis, reducing the rate, thus 
explaining the apparently different inhibitory effects of the two drugs. The structural basis for the 
contrasting activities of ribosome binding thiazole antibiotics has been studied using NMR and a 
thiostrepton-resistance methyltransferase assay, which rationalised the different binding profiles 
of thiostrepton, nosiheptide (5), siomycin (68, section 1.4.5) and micrococcin based upon the
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interaction of the quinaldic acid residue in thiostrepton, or an equivalent aromatic group, with the 
A1067 residue located in the L11BD.28 However, it may well be the case that the key step in 
protein synthesis inhibition differs from organism to organism and depends upon cellular growth 
conditions, although clearly the conformational constraint of protein L11 perturbs the function of 
the ribosomal factor-guanosine nucleotide complexes and thus inhibits cell growth.27
Actinomycetes antibiotic producers have to adopt a resistance mechanism to defend themselves 
against their own self-intoxication.29 In general Streptomyces are quite sensitive to thiostrepton 
and yet the producing organism, S. azureus, is totally unaffected by the drug.30 An RNA-pentose 
methylase enzyme,31 produced constitutively from its own promoter, is responsible for the 
autoimmunity in thiostrepton producers32 and this has been demonstrated in vitro upon ribosomal 
RNA from other bacteria. The methylase enzyme, thiostrepton resistance methylase, introduces 
a single methyl group into the A1067 residue of the 23S rRNA in Escherichia coli to give a 
modified 2’-0-methyladenosine-containing ribosome that is completely resistant to the 
antibiotic,33 a phenomenon that has been observed in 23S rRNA mutants of Halobacterium 
halobium.34 Base changes at position 1159 in halobacteria, which corresponds to A1067 of the 
E. coli rRNA, from A to U or G, as well as base methylation causes high-level resistance to 
thiostrepton.35 The thiostrepton-resistance (tsi) gene hybridises with a sulfomycin resistance 
determinant from S. viridochromogenes ATCC 29776,36 encodes the 23S rRNA A1067 
methyltransferase in S. laurentii and is located within a cluster of ribosomal protein operons, not 
clustered with genes that encode the biosynthetic enzymes.37 The tsr gene product has been 
overexpressed from S. azureus in E. coli to characterise the enzymic reaction and establish that 
recognition is dependent upon the secondary structure of the ribosomal hairpin loop that contains 
nucleotide 1067.38 The study of thiostrepton-resistant mutants is thus not only of relevance to 
account for the origin and determinants of antibiotic resistance, but also as a valuable tool in 
establishing the complex function and specific dynamic processes in operation during bacterial 
protein synthesis to provide new leads and focus for structure-based drug-design.
RNA-pentose methylation confers resistance in other actinomycetes, including S. laurentii, 
another thiostrepton producer, P. parontospora, from which sporangiomycin was isolated, and S. 
sioyaensis, the producer of the siomycins.39 Radiographical studies on the inhibition of bacterial 
protein synthesis by siomycin supports many of the mechanistic findings for thiostrepton and 
lends credence to a common, or very closely related, mode of action that operates for all 
thiopeptide ribosomal inhibitors. The incorporation of radioactive amino acids and base pairs, 
into the nascent peptide or mRNA, respectively, was studied in the presence of siomycin.40 
Although the action of the antibiotic prevented the incorporation of radioactive amino acids into 
Bacillus subtilis cells, 14C base pairs were incorporated into the mRNA, indicating that the agent 
acted as a ribosomal rather than transcription inhibitor, that was selective for Gram-positive and
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mycobacteria. Antibiotic binding at the ribosomal G site could cause a distortion of the A site, 
which would explain why siomycin inhibits translocation of the peptidyl-tRNA from the A to the P 
site, and prevents the binding of both Ef-G*GTP and the ternary complex aa-tRNA* Ef-Tu* GTP 
to the ribosome at the G and A sites, respectively.41
Actinomycetes that produce thiopeptide metabolites with very different chemical structures have 
been shown to adopt the same resistance mechanism and to give rise to antibiotics that function 
by a common mode of action. The growth of Streptomyces bernensis, the producer of the 
berninamycins (6), is totally resistant to the action of thiostrepton, even though structurally these 
two antibiotics are grouped in a different thiopeptide series.42 Similarly, nosiheptide has been 
shown to partially inhibit both the enzymatic binding of aminoacyl-tRNA to the ribosome and the 
simultaneous hydrolysis of GTP, but only when present at quite a high molar excess over the 
ribosomes.43 In spite of differences in antibiotic structure, all of these compounds bind to the 
complex of 23S RNA and protein L11 and affect various functions of the ribosomal A site, 
although thiostrepton is considerably more potent in its action than nosiheptide.44 The specific 
pentose-methylation of the 23S rRNA renders the ribosomes of S. bernensis and S. actuosus 
totally refractory to berninamycin and nosiheptide, respectively, and prevents the binding of 
thiostrepton,45 indicating both a common mode of action of these drugs and a common 
mechanism of self-defence employed by the respective producing organisms.
OH
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1.3.3 -  Inhibition of Elongation Factor Tu
Elongation factor Tu (Ef-Tu) is the most abundant protein of the bacterial cell and participates in 
peptide elongation by mediating the recognition and delivery of noninitiator aminoacyl-tRNA, as a 
ternary complex with GTP, to the mRNA codon in the acceptor site of the bacterial ribosome. 
When its GTPase action is triggered, Ef-Tu*GDP, which does not bind aa-tRNA, dissociates 
from the ribosomal complex, leaving behind the aa-tRNA in the ribosomal A site in readiness for 
peptide translocation. Many types of antibiotics act by binding to Ef-Tu, which either prevents the 
dissociation of Ef-Tu*GDP from the ribosomal complex, as is the case for the polyketide 
kirromycin (7), or inhibits the binding of aa-tRNA to Ef-Tu*GTP, exemplified by pulvomycin (8).
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The thiopeptide GE2270A (MDL 62,879) (42, section 1.4.4) inhibits bacterial protein synthesis at 
an IC50 of 0.4 pM by binding to Ef-Tu at a distinct site from kirromycin and so differs in its mode 
of action from thiopeptide ribosomal inhibitors.46 GE2270A interacts directly with the GTP-bound 
form of Ef-Tu and this inhibits the formation of a stable ternary complex by preventing the binding 
of aa-tRNA to Ef-Tu*GTP.47 Although it does not change the GTPase activity of Ef-Tu, antibiotic 
binding does prevent the ribosomal catalysis of this process and slows down the dissociation of 
the Ef-Tu*GTP complex to even a greater degree than aa-tRNA. GE2270A forms a strongly 
bound 1:1 molar complex with Ef-Tu, which can be observed by a mobility shift in an electric 
field, only reversed by protein denaturation. The strong affinity between Escherichia coli Ef- 
Tu* GDP and GE2270A has been explained by X-ray diffraction studies of the complex at a 
resolution of 2.35 A, which showed, in addition to 18 protein-antibiotic Van der Waals interactions 
(<3.5 A), a highly unusual salt bridge between Arg 223 and Glu 259 that folds over the GE2270A 
side chain when bound in a pocket formed by three segments of amino acids, Glu 215-Arg 230, 
Thr 256-Leu 264 and Asn 273-Leu 277, located in the second domain of Ef-Tu*GTP.188 The 
exchange of guanine nucleotides induces conformational changes in Ef-Tu complexes, as 
confirmed by proteolytic cleavage experiments. The superposition of the Ef-Tu*GDP*GE2270A 
and Ef-Tu*GTP structures suggests that antibiotic binding causes steric constraints that prevent 
complete formation of the GTP conformation. Thus, it seems likely that on binding to domain II, 
GE2270A impedes the GDP to GTP conformational change and prevents the formation of an Ef- 
Tu* GTP* aa-tRNA ternary complex by blocking the aa-tRNA binding site in the antibiotic-bound 
complex.48
This mode of action has been shown to operate for the GE2270 thiopeptides, GE37468 (9) and 
the amythiamicins (23, section 1.4.2) and has been used to develop a screening programme for 
thiopeptide antibiotics with similar binding properties, by selecting activities antagonised by 
exogenous Ef-Tu.4950 Inhibitors of this GTP-dependent translation factor have been shown to 
possess antimalarial activity in blood cultures of Plasmodium falciparum, the most active being 
amythiamicin A with an IC50 of 0.01 pM, and to bind to recombinant P. falciparum plastid Ef-Tu, 
indicating that endogenous plastid protein synthesis is a potential target for thiopeptides that 
inhibit prokaryotic protein synthesis by this mechanism.51
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Little is known about how the producers of Ef-Tu binding thiopeptides avoid self-intoxication, 
although resistance mechanisms are complicated by the fact that some actinomycetes possess 
more than one tuf gene to encode Ef-Tu translation factors. In Planobispora rosea, the 
GE2270A producer, both the tuf1 and tuf3 genes encode Ef-Tu-like proteins, the former encoding 
the regular elongation factor EF-Tu1.52 This bacterial protein is totally resistant to GE2270A, ten 
times more resistant to kirromycin than Ef-Tu 1 of Streptomyces coelicolor and not at all resistant 
to pulvomycin, an antibiotic that also inhibits the formation of the aa-tRNA EF-Tu GTP complex. 
Kirromycin resistance is accounted for by the replacement of Tyr 160 with a Gin at the kirromycin 
binding site, the interface of domains 1 and 3 of Ef-Tu in its GTP-bound conformation. The 
mutations that confer GE2270A resistance would appear to map to a number of amino acids in 
domain 2, located at the GE2270A binding pocket, in close proximity to residue 226 at the 
domain 1-2 interface, which is part of the binding site of the 3’-end of aa-tRNA. Ef-Tu mutants of 
Bacillus subtilis that were resistant to Ef-Tu-binding thiopeptide antibiotics also showed 
significant changes of conserved amino acids, which may account for their similar resistance 
behaviour.49,53
1.3.4- TipA Promotion
Actinomycetes multidrug resistance mechanisms often rely upon transport proteins or modifying 
enzymes and transcriptional regulatory proteins to recognise multiple drugs and respond to 
stress-response signals. Streptomyces lividans 1326, a strain that is not known as a
thiazolylpeptide producer, reacts to thiostrepton by inducing resistance to a number of 
structurally heterogeneous antibiotics with the accumulation of thiostrepton-induced proteins 
(Tip), two of which, TipAL (253 amino acids) and TipAS (144 amino acids), the latter 
corresponding to the C-terminal region of TipAL, are in-frame translation products of the same 
gene, tipA.54 TipAS, the independently translated thiopeptide binding domain present in vast 
molar excess (>20:1) over TipAL, renders the organism resistant by sequestering the drug in the 
cytosol and by modulating a drug-dependent positive feedback loop that controls its own 
expression.55 Their transcription is induced by a number of thiopeptide antibiotics, including
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thiostrepton, promothiocin (15, section 1.4.1) and nosiheptide, by complex formation with TipAL 
in the absence of added co-factors, that activates transcription of a monocistronic mRNA from 
the tipA promoter (ptipA) and so elicits autogenous expression of its own promoter. The TipAL 
protein is a dimer in solution with an A/-terminal domain (residues 1-109), containing both an 
helix-turn-helix that binds DNA (residues 5-25) and a long coiled-coil dimerisation region 
(residues 74-109), and a C-terminal domain (residues 110-253), represented by TipAS, for 
thiopeptide recognition (Figure 4A). The formation of a covalent bond between cysteine 214 (not 
cysteine 207)56 and a dehydroalanine residue in the thiopeptide irreversibly generates a 
ligand-TipAL complex (Figure 4B) and enhances the affinity of the bound protein for its operator 
site, inducing the recruitment of RNA polymerase (RNAP) to the promoter ptipA57 and activating 
its transcription at least 200-fold. On binding thiostrepton, conformational changes within TipAL 
enhance its association with ptipA and lower the rate of dissociation from the binding site, 
increasing the affinity of RNAP for ptipA in an alternative mechanism of transcriptional 
activation.58 By analogy with the mercury resistance regulator (MerR) protein, the ligand-bound 
TipAL dimer activates transcription and increases the affinity of the ligand-bound TipAL to the 
tipA promoter, by inducing folding of the unstructured A/-terminal part of apo TipAS, a globin-like 
a-helical fold with a deep surface cleft and an unfolded A/-terminal region that is the linker to the 
DNA-binding domain of TipAL.59 TipAL and other MerR regulators bind as dimers to an inverted 
repeat sequence located within the spacer region of their promoters. In contrast to the MerR 
regulatory proteins, TipAL can bind to its target site and activate transcription in the absence of 
the ligand, elevated external osmolarity causing an increase in intracellular negative DNA 
supercoiling that enhances ptipA expression.60 On binding thiopeptide antibiotics, the A/-terminal 
coiled-coil linker parts of the TipAL complex become rigid. This conformational change clamps 
the DNA-binding domains of the dimer and twists the DNA helix of the promoter, bringing the two 
consensus recognition sequences into alignment to allow RNAP to initiate transcription (Scheme 
2).
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Figure 4 Structure of the folded part of apo TipAS
Left: ribbon representation showing a-helices, N- and C-termini and ligand binding residue C214 as a 
space-filling model. Right: colour map of ligand-induced chemical shift changes on TipAS-thiostrepton 
complex formation. Red indicates strongly affected residues, orange indicates moderately affected 
residues and blue indicates weakly affected residues. The thiopeptide antibiotic shown alongside the 
TipAS-ligand binding site is thiostrepton. Reprinted from ref. 59. Copyright 2003 European Molecular 
Biology Organization.
RNAP
Scheme 2 Suggested mechanism of 7/pA-induction by TipAL thiopeptide complex formation 
Cartoon colour coding: thiopeptide antibiotic, red; DNA, yellow; TipAL, green, blue and brown. Reprinted 
from ref. 59. Copyright 2003 European Molecular Biology Organization.
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A number of novel thiopeptide antibiotics have been identified from actinomycete metabolite 
libraries by screening for pf/pA-inducing activities in a specific microbiological disc assay, 
including geninthiocin (10),61 promoinducin (11 ),62 thiotipin (12),63 thioxamycin (13),64 thioactin 
(14) and the promothiocins (15, section 1.4.1).65 Minimum induction concentrations (MinCs) for 
ptipA induction activity were found to vary depending upon the structure of the thiopeptide ligand 
(Table 2) with the series d thiopeptides promothiocin B, geninthiocin and berninamycin A being 
the most active. Promothiocin derivatives without dehydroalanine residues (promothiocin MO: 
methyl ester), as well as thiostrepton B, which does not possess the characteristic 
polydehydroamino acid-containing side chain, did not form TipAS antibiotic complexes but 
nevertheless were found to induce both the promoter and the synthesis of TipAS protein, 
confirming that covalent attachment was not required for stable interaction in vitro or in vivo and 
that the macrocyclic thiopeptide contained a TipA recognition motif. This autogenously controlled 
antibiotic resistance system responds to these antibiotics by synthesising a single mRNA that 
includes TipAS, to sequester the antibiotic and thus limit activation of the TipAL-dependent 
promoter. It may well be the case that these proteins, in addition to providing a low-level 
antibiotic resistance system, regulate resistance to other stress-response signals, such as those 
induced by heavy metals or changes in redox potentials, indicating a biological relevance far 
beyond growth inhibition in competing organisms.
Table 2 Thiopeptide ptipA induction activity
Thiopeptide MinC / nM
Promothiocin B 0.63
Geninthiocin 1.0
Berninamycin A 1.0
Thiostrepton A 1.4
Promothiocin A 24
Promoinducin 30
Thiotipin 32
Thioactin 38
Thioxamycin 63
A10255G 66
Thiostrepton B 67
Cyclothiazomycina >700
Amythiamicin Aa >800
GE2270Aa >1000
Promothiocin MOa 3300
a Contains no dehydroalanine residues
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promoinducin (11) R = Me, R' = C H (O H )M e, n = 3; 
thiotipin (12) R = H, R’ = Me, n = 2geninthiocin (1 0 )
thioxamycin (13) R = hn 
thioactin (14) R = NH 2
1.4 -  Total Syntheses of Thiopeptide Antibiotics
In recent years, considerable advances have been made towards the synthesis of the thiopeptide 
antibiotics. The complex molecular architecture of this family of antibiotics has attracted 
significant interest from research groups worldwide, and culminated in the successful total 
syntheses of promothiocin A, amythiamicin D, thiostrepton, GE2270A and T and siomycin A.
1.4.1 -  Promothiocin A
The promothiocin thiopeptides were isolated by Seto et al. from Streptomyces sp. SF2741. 
These compounds were identified as promothiocin A (15a) (03^ 37^ 0882) and promothiocin B 
(15b) (C42H43N 13O10S2) following a combination of IR spectroscopy, high-resolution FAB mass 
spectrometry, 2D NMR experiments and amino acid analyses, which provided one mole each of 
alanine, glycine and valine and led to the elucidation of the constitution, but not the 
stereochemistry of both of the promothiocin factors. The total synthesis of promothiocin A by 
Moody and Bagley66,67 established unequivocally the (S)-configuration of the three stereogenic 
centers in the natural product and this was subsequently supported by degradation studies and 
molecular modelling (Figure 5).68 Chiral-HPLC analysis of the acid hydrolysates confirmed the L- 
configuration of both alanine and valine, whereas the (S)-2-(1-amino-1-ethyl)thiazole-4- 
carboxylate residue provided the best calculated fit in a DADAS90 conformational study.
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Minimum tipA promoter induction concentrations of promothiocins A and B were reported as 0.2 
and 0.1 pg/mL, respectively.
Figure 5 Structure of the promothiocins
The first chemical synthesis of a thiopeptide natural product was the preparation of promothiocin 
A by Moody and Bagley.66,67 This landmark synthesis featured the then little-used Bohlmann- 
Rahtz heteroannulation reaction to establish the central oxazole-thiazole-pyridine domain 19,69 
by saponification, amide formation, thionation and Hantzsch thiazole synthesis. The Bohlmann- 
Rahtz synthesis of pyridine 18 from ethyl 3-amino-3-(4-oxazolyl)propenoate 16, prepared from 
(S)-/V-tert-butoxycarbonylalaninamide by dirhodium(ll)-catalysed carbenoid insertion into the 
amide N-H followed by cyclodehydration with triphenylphosphine-iodine under basic conditions, 
saponification, homologation using the magnesium enolate of ethyl potassium malonate and 
enamine formation, and 1-benzyloxybut-3-yn-2-one (17), obtained by Grignard addition and 
propargylic oxidation, proceeds in two steps by initial Michael addition at 50 °C and subsequent 
double bond isomerisation-cyclisation at 140 °C in the absence of solvent (Scheme 3). The 
elongation of the linear peptide by N- and C-terminus functionalisation, followed by 
macrolactamisation under basic conditions via the pentafluorophenylester gave macrocycle 2 0 . 
Benzyl ether cleavage with boron trichloride dimethyl sulfide complex gave alcohol 21, which was 
oxidised to carboxylic acid 22 using o-iodoxybenzoic acid (IBX) in DMSO followed by treatment 
with sodium chlorite, and then coupled with an O-protected serinamide derivative using 1-(3- 
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI). Protodesilylation and 
dehydration by mesylate formation followed by treatment with triethylamine, installed the 
dehydroalanine side chain, completing the first total synthesis of one of the thiopeptide antibiotics 
and verifying the (S)-stereochemistry of all three stereogenic centres in the metabolite isolated 
from Streptomyces sp. SF2741.
promothiocin A  (15a), R = N H 2
promothiocin B (15b), R = hn
o
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1.4.2 -  Amythiamicin D
The amythiamicins (23) were obtained from the fermentation broth of Amycolatopsis sp. MI481- 
42F4, isolated from soil samples collected in Tokyo, Japan and detected by a paper disc 
diffusion screen based upon their in vitro antibacterial activity against Staphylococcus aureus70 
These antibiotics, although inactive against most Gram-negative bacteria and fungi, inhibit the 
growth of Gram-positive bacteria, including multi-drug resistant strains such as Staphylococci 
aureus MS9610 and methicillin-resistant S. aureus (MRSA),71 and show no signs of toxicity when 
administered intraperitoneally to mice at a dose of 100 mg/kg. The structure of the different 
components was elucidated by a combination of NMR spectroscopic techniques, chemical 
degradation and FAB mass spectrometry.7273 Amino acid analyses of amythiamicin A 
(CsoHsiNisOsSe), B (CsoFUaN^OgSe) and C (CsoFUoN^OgSe) found them to contain one mole of 
glycine and one extra mole of both L-proline and L-serine, determined by chiral HPLC, with 
respect to amythiamicin D (043^ 2^ 20 7S6) (Figure 6 ).
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Figure 6 Structure of the amythiamicins
As the composition of the macrocyclic loop was found to be the same for all four thiopeptides, 
differences in their amino acid analyses were attributed to variations in the peptide side chain. 
Although the absolute configuration of the two valine-derived and one aspartate-derived thiazole 
residues in the amythiamicin macrocycle could not be determined from the isolated natural 
product, due to racemisation under acid-catalysed hydrolysis conditions, the total synthesis of 
amythiamicin D by Moody et al. has since verified the structure and absolute stereochemistry of 
this thiopeptide family, substantiated by X-ray crystallographic data, confirming the L- 
stereochemistry of all constituent amino acids.74 75 Moody et al. employed a biomimetic strategy 
for the synthesis of the 2,3,6-tris(thiazolyl)pyridine domain 26 of the amythiamicins which was 
further elaborated to amythiamicin D, establishing the (S)-stereochemistry of the three 
stereogenic centres of the natural product (Scheme 4). The formal aza-Diels-Alder cycloaddition 
of dehydroalanine dienophile 24 and 2-azadiene 25 proceeded in modest yield by microwave 
irradiation76 in toluene at 120 °C for 12 hours. Elongation of the central pyridine domain 26 gave 
linear peptide 27, which was cyclised by deprotection of both the C- and /V-termini using 
trifluoroacetic acid (TFA) followed by treatment with diphenylphosphoryl azide (DPPA) and 
Hunig’s base in DMF to give the macrocyclic natural product amythiamicin D.
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1.4.3 -  Thiostrepton
Thiostrepton (1), the parent compound of the thiopeptide antibiotics, was first isolated in 1954 
from Streptomyces azureus777879 and S. hawaiiensis,80 and later from S. laurentii (1977).81 The 
substance isolated from S. hawaiiensis was originally named bryamycin but was later shown to 
be identical to thiostrepton.82
The majority of the structure of thiostrepton was determined by Dorothy Crowfoot Hodgkin 
through X-ray crystallography in 1970,83 although several degradation studies were conducted in 
the years between the isolation of the natural product and Hodgkin’s study in an attempt to 
elucidate the structure. Since that date, further X-ray crystallographic studies on tetragonal 
crystals using the anomalous dispersive signal from sulphur collected at the Cu Ka wavelength 
enabled Hunter and co-workers to solve the structure of the macrocycle of thiostrepton84 and the 
landmark total synthesis of 1 by Nicolaou et al. has verified its structural identity.85
Nicolaou and co-workers utilised an elegant biomimetic strategy to establish the 
dehydropiperidine domain of thiostrepton. With the stereoselective synthesis of the quinaldic 
acid-containing macrocycle86 and construction of all requisite components,87,88 a highly 
convergent total synthesis of this complex antibiotic was realised.89 The regioselective and 
endo-selective hetero-Diels-Alder dimerisation of 2-azadiene 30, obtained from thiazolidine 29 by 
treatment with silver carbonate, proceeded without facial selectivity to give dehydropiperidine 32 
as a 1:1 mixture of diastereomers in a cascade sequence with in situ lysis of imine intermediate 
31 and release of aldehyde 28 to be recycled to dimerisation precursor 29 (Scheme 5).90 
Stereospecific reduction of cycloadduct 32 using sodium cyanoborohydride generated piperidine 
33 and demonstrated that a biomimetic heterodimerisation approach can provide expedient 
access to the central domain of either series a (33) or b (32) thiopeptide antibiotics.
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Scheme 5 Biomimetic synthesis of series a or b piperidine domain
The application of this work in the total synthesis of thiostrepton was realised by capturing the 
free amino group of the dehydropiperidine intermediate with the acyl chloride of an azide 
derivative of alanine (34), to produce imine 35 exclusively, as a diastereomeric mixture (Scheme 
6 ).. After peptide elaboration, closure of the thiazoline-containing macrocycle was successful for 
only one (36) of two monoacids, formed by the action of trimethyltin hydroxide in 1,2- 
dichloroethane, to give the desired macrocycle 37 following reduction with PMe3-H 20  and 
treatment with HATU-HOAt-/Pr2NEt. The construction of the two macrocyclic domains was 
effected by attachment of a phenylseleno-disubstituted peptide 39, as a precursor for the 
dehydroalanine subunits in the side chain, to acid 38, followed by AMerminal deprotection, 
coupling with quinaldic acid linear peptide 40 and macrolactonisation under Yamaguchi 
conditions with 2,4,6-trichlorobenzoyl chloride.. The synthesis was completed by /BuOOH- 
mediated oxidation of all three phenylseleno groups in bis-macrocycle 41, which brought about 
spontaneous selenoxide syn elimination, followed by silyl ether deprotection with hydrogen 
fluoride-pyridine, with concomitant elimination to form the thiazoline-conjugated Z  double bond. 
This landmark route gave synthetic thiostrepton with identical physical properties to an authentic 
sample, constituting a highly convergent and stereoselective synthesis of a complex thiopeptide 
antibiotic that may pave the way for related synthetic studies in the future.
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1.4.4 -  GE2270A and GE2270T
The GE2270 (MDL 62,879) class of series d thiopeptides is the largest family of these natural 
products with over 10 structurally-related components (Figure 7).91 The main factor of this 
complex, GE2270A (CseHssN^OioSe), isolated in a screening programme designed to detect 
inhibitors of protein synthesis from the fermentation broth of Planobispora rosea ATCC 53773, 
was extracted from the mycelium and purified by column chromatography on silica gel.92 The 
original structure was proposed following chemical degradation, UV, IR and NMR spectroscopic 
studies93 and mass spectrometric techniques,94 but was subsequently revised on further 
investigation, correcting the sequence of thiazole amino acids in the cyclic peptide through 
analysis of the hydrolysates95 with some assignment of absolute stereochemistry.96 The isolation 
and characterisation of 9 of the minor components, separated from the GE2270 antibiotic 
complex by HPLC, was reported in 1995 and facilitated by altering the fermentation conditions, a 
study that showed that P. rosea modifies the GE2270 backbone by introducing a variable 
number of methylene units.97 The structures of the individual factors, E, D1, D2, C1, C2a and
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C2b (not to be confused with subscripts a and b, used to denote differences in the central 
domain in the thiopeptin factors), B1, B2 and T were determined by 2D NMR spectroscopy and 
differ from GE2270A in the nature of the 5-substituent on two thiazole residues in the peptide 
backbone, the asparagine A/-substituent and the oxidation state of the azole in the 6 -pyridine 
side chain. All of the GE2270 factors were found to inhibit protein synthesis in Gram-positive 
microorganisms and anaerobes, with particular activity noted against Propionibacterium acnes 
(MIC for GE2270A against L1014 ATCC 6919 <0.004 pg/ml) and Mycobacterium tuberculosis 
(MIC for GE2270A of 1 pg/ml), as well as exhibiting some activity against Gram-negative 
bacteria. These antibiotics inhibit bacterial protein synthesis by acting specifically on the GTP- 
bound form of Ef-Tu, the elongation factor required for the binding of aminoacyl-tRNA to the 
ribosomal A site and so function in a similar fashion to kirromycin-like antibiotics and pulvomycin 
(section 1.3).
R HN
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NHN
HN
42OH
O PhNH
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Factor R 1 R 2 R 3 R4, R 5
A C H 2O M e c h 3 c h 3 H
B1 C H 2O M e c h 3 H H
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Figure 7 Structure of the GE2270 factors
The first chemical syntheses of thiopeptides GE2270A and GE2270T were realised by Nicolaou 
et al. in 2006.98 The route to both total syntheses proceeded via dehydropiperidine 43, prepared 
by the biomimetic hetero-Diels-Alder dimerisation already successfully utilised in the synthesis 
thiostrepton. Elimination of ammonia and dehydrogenation of 43 furnished the pyridine core 
domain 44, which was subsequently elaborated to 45; HATU-mediated peptide coupling with 46 
followed by ester hydrolysis with Me3SnOH afforded esters 48a and 48b, only one of which 
underwent macrolactamisation on A/-deprotection and treatment with FDPP to furnish macrocycle 
49 (Scheme 7). An alternative approach to compound 49 was also investigated wherein pyridine 
domain 50 was hydrolysed to give a mixture of esters 51a and 51b. Coupling with peptide 52 
and deprotection furnished 55a and 55b, and as previously observed, only the desired 
macrocycle 49 was formed, 55b failing to cyclise (Scheme 8 ).
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Macrocycle 49 was then elaborated to oxazoline 57 by ester hydrolysis, coupling with serine 
methyl ester, treatment with DAST and deprotection. Advanced intermediate 57 was 
subsequently converted to both GE2270A and GE2270T (Scheme 9).
/c o 2r
Me3SnOHC:*jR-Me
MeHN
i) L-Ser-OMe, HATU
ii) DAST
0TBS iii) TBAF N - c
HN,   \ —/
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-  U P ^ NH^ H A T U C Z G E2270T
OMe
Scheme 9 Elaboration of 49 to GE2270A and GE2270T
GE2270A was also synthesised by Bach and co-workers in 2007 using an elegant strategy which 
differed markedly from those used in previous thiopeptide syntheses, in that the thiazole moieties 
were appended to the pyridine core by way of metal-catalysed cross-coupling reactions (Scheme 
10)." Peptide building block 61 was coupled to organozinc reagent 62 in a Negishi cross 
coupling. The resulting fragment was submitted to a second Negishi coupling with thiazole 64 to 
afford 65. Formation of organotin reagent 66 and intramolecular Stille coupling furnished 
macrocycle 67 from which the natural product was prepared in four further steps.
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1.4.5 -  Siomycin A
The siomycins (68) are a family of four thiopeptides with structures closely related to that of 
thiostrepton (1) (Figure 8 ). The siomycin antibiotic complex was first isolated from cultures of 
Streptomyces sioyaensis in 1959 and was found to be active against Gram-positive bacteria and 
mycobacteria.100 Further purification of the crude preparation ten years later101 found that this 
sulfur-containing peptide antibiotic actually consisted of one major component, siomycin A (68a), 
and three minor components, siomycin B, C and the latter of which was discovered 21 years 
after isolation of the original antibiotic complex.102 Siomycin B (68b) (SIM-B, C65H75N17O16S5) is 
derived from siomycin A (SIM-A, C7iH8iN19Oi8S5) during storage whereas siomycin C (68c) (SIM- 
C, C72H82N18 0 19S5) and Di (68d) (SIM-D1, C70H79N19O18S5) are true natural products of 
Streptomyces sioyaensis. Chemical degradation studies103 in conjunction with a range of 
spectroscopic experiments, in particular 13C and 1H NMR studies,104 105 106 were carried out in 
order to determine the relationship between the siomycin structure and that of thiostrepton, which 
had recently been characterised by X-ray crystallography, and also to explain the similar 
physicochemical and biological properties of these antibiotics. The isolation and identification of
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the degradation products formed by reduction, oxidation, acidic hydrolysis and ammonolysis of 
the natural product was supported by extensive 1H, 13C and nOe NMR spectroscopic data, as 
well as 15N NMR spectroscopy, and eventually confirmed that the siomycins differ from 
thiostrepton only in a dehydroalanine-valine unit attached to the quinaldic acid in place of an 
alanine-isoleucine residue.
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Figure 8 Structure of the siomycins
Siomycin A (68a) was successfully synthesised by Hashimoto et al. in 2006.107 Macrocyclic 
precursor 72108 was prepared by the coupling of dehydropiperidine 69,109 dihydroquinoline 7011° 
and peptide 71. Compound 72 was then deprotected and submitted to HATU-mediated peptide 
coupling with pentapeptide 74 (Scheme 11) .111 Treatment of the mixture of 75a and 75b with 
DAST effected cyclisation of the serine residue and adjacent thioamide to give the desired 
thiazoline 76. Subsequent cleavage of the Teoc, acetonide and TMSE protecting groups with 
zinc(ll) chloride furnished 77 in readiness for the second macrolactamisation and attachment of 
the side chain (Scheme 12). Cyclisation of 77 and coupling with peptide 78 was achieved in a 
one pot procedure by stirring 77 with HATU and DIPEA, followed by addition of 78. The 
structural identity of reaction 79 could not be verified at this stage, but was confirmed following 
global deprotection with HF.pyridine and oxidative elimination with terf-butylhydroperoxide, as the 
natural product was isolated in 7% yield from 76.
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1.5 -  The Micrococcin Thiopeptides
Micrococcin was the first thiopeptide antibiotic to be isolated, and is one of the least structurally 
complex members of this class of compounds. Despite their relatively low molecular weight and 
lack of the intricate molecular architecture possessed by thiostrepton, the micrococcin 
thiopeptides have posed a challenge to synthetic chemists for more than half a century. What 
follows is an account of their isolation and the many attempts made to assign the correct 
structure by chemical degradation, spectroscopy and even the total synthesis of two epimeric 
micrococcin analogues.
1.5.1 -  Isolation
The micrococcin antibiotic complex was first isolated in 1948 by Su from a newly identified strain 
of Micrococcus (later named Micrococcus NCTC 7128), found in a sample of sewage from the 
city of Oxford.112 Micrococcin was reported to be ‘an odourless, tasteless, amorphous, cream- 
coloured powder’ and no studies were undertaken to determine the structural identity of the 
compound. Indeed, only a melting point and UV spectrum were published, and the optical 
rotation reported to be ‘between +50° and +75°’. Following the first isolation of this antibiotic, 
methods for purification113 and large scale production were investigated, the most successful of 
which utilised a Marmite™-containing culture medium.114,115 An antibiotic isolated from a spore- 
bearing bacillus of the B. pumilis group found in soil collected from East Africa116 was found to 
exhibit similar biological and physical properties to Su’s micrococcin, and was named 
micrococcin P.117 More recently, micrococcin P1 has been isolated from Staphylococcus 
equorum\NS 2733, a strain of bacteria present on the surface of French Raclette cheese.118119
1.5.2 -  Early Biological Studies
Initial studies on the biological activity of Su’s micrococcin were hampered by the extremely low 
solubility in water and high molecular weight of the antibiotic.120 Su had reported that 
micrococcin exhibited antibacterial activity against Gram-positive microorganisms in vitro but the 
aforementioned lack of solubility and consequent poor bioavailability in vivo immediately limited 
the usefulness of micrococcin clinically. Nevertheless, a small number of in vivo studies were 
conducted, the first of which entailed administration of a suspension of the antibiotic by injection 
into mice.121 It was found that although micrococcin was removed from the bloodstream by 
phagocytic cells, it remained in the body and was not excreted. Whilst inside the organism, 
micrococcin retained antibiotic activity and exhibited no toxic effects. The effect of injection of a 
suspension of micrococcin on rabbits infected with tuberculosis was also studied.122 The rabbits 
that were treated with micrococcin suspensions died earlier than the control animals, but were 
found to have fewer lesions in their lungs, liver and kidneys. It was also noted that despite
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promising in vitro activity against several strains of tuberculosis bacteria, resistance to 
micrococcin developed rapidly and before an effective concentration could be reached. In the 
light of such discouraging results, micrococcin has found no clinical applications to date.
1.5.3 -  Degradation Studies
Prior to the advent of NMR spectroscopy as a technique for routine use, chemical degradation 
studies were frequently employed as a means of structure determination for natural products. 
Micrococcin was the subject of a number of such investigations conducted by Walker et al. in the 
1950’s and 1960’s. Acidic hydrolysis of Fuller’s micrococcin P and analysis of the resulting 
fragments led to the proposal of a molecular weight in the region of 2200.123 Further studies on 
the acid-soluble degradation products of micrococcin P led to the identification of aminoacetone 
and D-2-aminopropan-1-ol (D-alaninol) ,124 although this was subsequently found to be D-(R)- 
isoalaninol in NMR studies (section 1.5.4). After investigation of the acid-insoluble fraction of 
micrococcin degradation products, it was concluded that the natural product possesses an 
extended chromophore containing several thiazoles.125 The acid-insoluble component was 
named micrococcinic acid (80), which could be converted into dimethyl micrococcinate (81) on 
treatment with methanolic hydrogen chloride.126 The structures of 80 and 81 were confirmed 
following 1H-NMR spectroscopic127 and X-ray crystallographic studies.128
HO
OH
MeO
OMe
1.5.4 -  The Walker-Lukacs Structure
Walker’s numerous degradation studies on micrococcin P were followed by a 13C-NMR 
investigation, culminating in the ‘Walker-Lukacs’ structure of micrococcin P (82).129 The 
assignment of the absolute stereochemistry of the amino acids was made based on amino acids 
isolated on acidic hydrolysis of the natural product; the connectivity of the residues was assigned 
based on assumed structural homology with thiostrepton (1) and nosiheptide (5).
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1.5.5 -  The Bycroft-Gowland Structure
Prompted by the publication of the Walker-Lukacs structure of micrococcin P, Bycroft and 
Gowland proposed an alternative structure following their own investigation of micrococcin P 
using 1H- and 13C-NMR spectroscopy in conjunction with degradation studies.130 It transpired 
that micrococcin P was in fact a mixture of two components present in a ratio of approximately 
7:1. The major component was named micrococcin P, (83; also referred to as micrococcin P1 or 
MP1) and the minor component micrococcin P2 (84; micrococcin P2, MP2), and it was found that 
reduction of MP2 with sodium borohydride furnished MP1. The identification of the two 
components of the micrococcin antibiotic complex is in agreement with Walker’s earlier 
degradation studies, accounting for the isolation of both D-(fl)-isoalaninol and aminoacetone on 
acidic hydrolysis of the natural product. As with the Walker-Lukacs structure, the assignment of 
absolute stereochemistry was based on Walker’s original degradation studies.
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1.5.6 -  Ciufolini's Synthesis of Bycroft-Gowland MP1
The Bycroft-Gowland structure of micrococcin P1 was accepted for more than 20 years, until 
Ciufolini’s total synthesis of 83 demonstrated that Bycroft-Gowland MP1 is not identical to the 
natural product. Ciufolini’s landmark total synthesis of 83 began with the preparation of pyridine 
core 90 (Scheme 13).
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Bis-thiazole enone 85 and ketone 86 were combined to form 1,5-diketone 87 via Michael 
addition. Treatment with ammonium acetate followed by DDQ oxidation furnished the central 
pyridine moiety; A/-Boc protection and hydrolysis of the ethyl ester afforded core domain 90 in 
readiness for elaboration to the natural product.131 BOP-mediated coupling with side chain unit 
91 gave fragment 92 which was further elaborated to yield 93, with the dehydrodemethylvaline 
unit present in the side chain and free carboxylic acid on the 3-thiazole in preparation for 
coupling with tripeptide sector 94 (Scheme 14). Coupling afforded advanced intermediate 95, 
which on deprotection and macrolactamisation gave Bycroft-Gowland micrococcin P1 (83) in 23 
steps and 5.7% yield (longest linear route) .132 Careful examination of the spectroscopic data of 
83 and comparison with that of the natural material (4) showed that the proposed structure, 
accepted for more than two decades was incorrect and set in motion many studies to rectify this 
problem.
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Scheme 14 Completion of the synthesis of Bycroft-Gowland MP1
1.5.7 -  Shin’s Synthetic Epimers of MP1
The confusion surrounding the structure of the micrococcin thiopeptides was heightened with the 
publication of two total syntheses by Shin et al. of ‘micrococcin Pi’,133 in fact an epimer of 
Bycroft-Gowland MP1 containing L-(S)-isoalaninol in place of the correct D-(/I?)-isoalaninol 
residue (98), and ‘micrococcin P’ (99),134 which is an epimer of Walker-Lukacs micrococcin, 
again possessing L-(S)-isoalaninol in the side chain. Despite the claim that these compounds 
exhibited spectroscopic and physical properties identical to the natural material, neither 98 nor 99 
represent the correct structure of natural MP1, the (/^-stereochemistry of the isoalaninol residue 
having been conclusively established in degradation studies by Walker and Bycroft.130
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1.5.8 -  The Stereochemistry of MP1 Reinvestigated
Following Ciufolini’s discovery that Bycroft-Gowland micrococcin P1 was not spectroscopically 
identical to the natural product, it was necessary to ascertain where the structural differences 
between the two compounds lay. Extensive NMR studies using HSQC and HMBC techniques 
were used to validate the Bycroft-Golwland hypothesis with regard to the order of the amino acid 
residues, and it was concluded that the difference between natural MP1 and Bycroft-Gowland 
MP1 was purely stereochemical.135 A re-examination of the literature with respect to the 
assignment of the stereochemistry of the amino acids reveals that the valine residue was initially 
assigned as being ‘probably of the D-configuration’ on the basis of comparison of degradation 
product 100 with synthetic material prepared from L-valine.136 Walker et al. were able to 
reproducibly isolate 100 from the acidic hydrolysis of micrococcin with an optical rotation of -6.2  
(c 0.5, H20). Walker then prepared 100 from L-valine and recorded values for optical rotation 
varying between 0 and -20.8, leading the conclusion that the natural product contains D-valine. 
Walker’s synthesis of 100 employed the Hantzsch thiazole synthesis, a reaction which is known 
to racemise a-aminothioamides (101),137138 and also harsh acidic conditions to deprotect thiazole 
102a. In view of these ambiguous results, a reinvestigation of Walker’s study was undertaken139 
whereby both enantiomers of 100 were prepared via a known alternative route,140 and the 
enantiomeric purity of key intermediates (S)- and (R)- 102b confirmed by HPLC (Scheme 15).
The close agreement in the optical rotations recorded for (S)-100 isolated from micrococcin P1 
and (S)-100 prepared from enantiomerically pure (S)-102b, and the equal but opposite optical 
rotation of (fl)-100 from (R)- 102b led to the proposal that the valine residue in micrococcin P1 
should be reassigned as S. Figure 9 provides a summary of the various structures of the 
micrococcin thiopeptides proposed over the past fifty years, a long-standing mystery which, due 
to the scarcity of the natural product, awaits chemical synthesis to provide a solution.
from 102a 
iv)
BocHN
101a R = Ph (S)-102a R = Ph (S)-100 [cx] D23 -7.2 (c  0.5, H20 )
101b R = O 'Bu (S)-102b R = O'Bu, 97% ee (fl)-100 [a ]D23 +7.2 (c0 .5 , H20 )
(R)- 102b R = O'Bu, 97%  ee 100 from MP1 [a ]D -6.2 (c 0.5, H 20 )
(S)-100 from 102a [a ] D25 +5.2 (c  0.5, H ^ )
Reagents and conditions: i) From 101a, ethyl bromopyruvate, EtOH, reflux; From 101b, K H C O 3, ethyl bromopyruvate, 
DME, then TFAA, 2,6-lutidine; ii) From 102b, LiOH, H 20 , MeOH, r.t.; iii) HCI in dioxane, r.t.; iv) From 102a, 20%  HCI (aq), 
reflux.
Scheme 15 Reinvestigation of the stereochemistry of the valine-derived thiazole
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HO-
HN
HO-
HN
Walker-Lukacs micrococcin (82) R 1 = H, R2 = OH 
Shin's micrococcin P (99) R1 = OH, R 2 = H
Bycroft-Gowland MP1 (83) 
Bycroft-Gowland MP2 (84) 
Shin's micrococcin P1 (98) 
Proposed structure MP1 (4)
R 1 = OH, R2 = H, R3 = C H M e2, R 4 = H 
R 1, R2 = O (rc-bond), R3 = C H M e2, R4 = H 
R 1 = H, R2 = OH, R 3 = C H M e2, R4 = H
R 1 = OH, R * = H, Rd = H, R4 = C H M e2>2 -
Proposed structure MP2 (103) R 1, R2 = O (7t-bond), R 3 = C H M e2, R4 = H
Figure 9 Structures of the micrococcin thiopeptides
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2 -  Reinvestigation of MP1 Stereochemistry by Chemical Degradation 
Studies
2.1 -  Introduction
Degradation studies were widely used as a means of structure determination for the thiopeptide 
antibiotics prior to the advent of sophisticated spectroscopic techniques such as COSY, NOESY, 
HSQC and HMBC-NMR spectroscopy and high resolution FAB-MS which can now be used 
routinely. As well as yielding an array of smaller compounds of synthetic interest to chemists 
(Figure 10),141 142 143,144,145,146 degradation studies can provide valuable information unavailable by 
conventional spectroscopic techniques, in particular the absolute stereochemistry of 
stereogeneic centres within a natural product.
MeCbC
C02Me
dim ethyl sulfom ycinam ate
MeO
W
MeO §
NH " /  N 7/
COR
m ethyl sulfom ycinate, R = O M e  
sulfom ycinic am ide, R = N H 2
micrococcinic acid
02CS,
HN
C 02 ,NH
OH
sulfom ycinine berninam ycinic acid
HO2C
cyctothiazom ycin lactam
c o 2h
saram ycetic  acid
Figure 10 Thiopeptide degradation products
2.2 -  Walker’s degradation studies
As discussed previously (sections 1.5.3 and 1.5.8), the chemical degradation of micrococcin P1 
was studied extensively by Walker et al. between 1957 and 1967. Walker and co-workers 
reported the reproducible isolation of laevorotatory 2-(1-amino-2-methylpropyl)thiazole-4- 
carboxylic acid (100) from the acidic hydrolysis of the natural product.136 Subsequent synthesis 
of 100 from L-valine and comparison of the optical rotation of the synthetic and isolated material 
led to the assignment of the valine-derived stereogenic centre in MP1 as ‘probably of the D- 
configu ration’.
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2.2.1 -  Walker’s synthesis of thiazole 100
Walker’s synthesis of thiazole 100 (Scheme 16) began with L-valine (104), which was 
benzoylated using Schotten-Baumann conditions, esterified with diazomethane and treated with 
methanolic ammonia to afford amide 107. Dehydration to nitrile 108 followed by thionation with 
liquid hydrogen sulphide furnished thiazole precursor 101a. As discussed previously (section 
1.5.8) the Hantzsch thiazole synthesis was employed in the preparation of 102a. Walker reports 
an optical rotation of -3.7 (c 2.5, ethanol) for thiazole (S)-102a, significantly lower than that 
reported by Holzapfel [-42.0 (c2.6, chloroform]137 and Meyers [-37.5 (c2.6, chloroform)].138
R HN
iii) iv)
CO2R BzHN CONH2 
107
BzHN
V)
CN
Vi)
BzHN CSNH2 Bz HN
vii)
C 0 2 E t HCI H2f' CO2 H
108 101a 102a 100i) \~ ^  1 0 4  R 1 = H, R2 = H  
... r—  1 0 5  R 1 = Bz, R2 = H 
} 1 0 6  R 1 = Bz, R2 = M e
Reagents and Conditions i) Schotten-Baum ann conditions; ii) D iazom ethane; iii) N H 3 in M e O H , 110  °C , 8 h, 5 8% ;
iv) P O C b , pyridine, 0  °C , 30 mins, 72% ; v) liquid H 2S, 5 5  °C , 8 h, 89% ; vi) ethyl brom opyruvate, ethanol, reflux, 96% ;
vii) 2 0 %  w /v  HCI, reflux, 4  h, 75% .
Scheme 16 Walker’s synthesis of thiazole 100
2.2.2 -  Racemisation of amino acid-derived thiazoles
The Hantzsch synthesis of thiazoles by reaction of an amino acid-derived thioamide and a- 
bromocarbonyl compound at reflux in ethanol147,148 is known to result in epimerisation at the a- 
stereogenic centre as a result of the concomitant formation of one equivalent of hydrogen 
bromide (Scheme 17).137,138 Hence, Walker’s use of these conditions in the preparation of 
thiazole 102a is the likely cause of the erroneous assignment of the stereochemistry of the valine 
residue in micrococcin P1. Modifications of the original Hantzsch synthesis to circumvent the 
problem of racemisation will be discussed in detail in the next chapter. Furthermore, 
deprotection of thiazole 102a using refluxing hydrochloric acid would exacerbate the problem, as 
thiazole hydrochloride salt 100 is known to racemise completely in aqueous solution at room 
temperature in 3 hours.139
Scheme 17 Racemisation of amino acid-derived thiazoles in the Hantzsch thiazole synthesis
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2.3 -  Determination of stereochemistry in cyclic peptides
In view of the problematic racemisation encountered when treating a-amino acid-derived 
thiazoles with acids, a method for the degradation and analysis of macrocyclic heterocyclic 
peptides needed to be established which does not result in racemisation of stereogenic centres 
adjacent to thiazoles, thus enabling the assignment of absolute stereochemistry of the amino 
acid residues present in the natural product. The general method is outlined in Scheme 18 using 
a model cyclic peptide.
i) 0 3, C H 2C I2, rt, 3  h f 1 0 9
NH HN OH HN R
ii) 6  M HCI, 110 °C , 2 4  h H*N acetone, 1 M N a H C 0 3  
45  °C , 1 h OH
Scheme 18 General method for the racemisation-free degradation of cyclic peptides
The first step in the sequence is treatment of the natural product with ozone, in order to 
derivatise the thiazoles,149 destroying their aromaticity and preventing racemisation.150 The 
residue from the ozonolysis step is then subjected to acidic hydrolysis with 6 M hydrochloric acid 
to afford the constituent amino acids. Treatment of the hydrolysis products with Marfey’s reagent 
(1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA, 109)151 affords compounds with the general 
structure 110, containing a chromophore which makes the derivatives readily detectable by UV 
spectroscopy and ideal for analysis by HPLC. This method has been used to determine the 
absolute stereochemistry of amino acid residues in numerous cyclic peptides including 
dendroamide A (111), patellamide E (112),. nostocyclamide M (113),152 and hirsutide (114).153
1
HNNH
ONH HN
111 112
NH
HN
NH HN
40
Chapter 2 -  Reinvestigation of MP1 Stereochemistry by Chemical Degradation Studies
2.3.1 -  Synthesis and use of Marfey’s Reagent
Marfey’s reagent was prepared according to literature procedures by the reaction of L- 
alaninamide with 1,5-difluoro-2,4-dinitrobenzene (Scheme 19). The product was then reacted 
with a range of amino acids to form diastereomeric derivatives 110a-e.
HCI H2N
n h 2
nh2 ii)
o 2n
1 1 0 a  (S )-valine  
isih2 1 1 0 b  (fl)-va lin e
1 1 0 c  (2S ,3/?)-threon ine  
11 Od (S)-isoalan inol 
1 1 0 e  (fl)-isoalan ino l
Reagents and Conditions i) 1 M N aO H , acetone, M g S 0 4) r.t., 3  h, then  1 ,5-d ifluoro-2,4-d in itrobenzene, acetone, 
r.t., 3 0  min, 6 7 % ; ii) am ino acid, w ater-acetone, 1 M N a H C 0 3 , 3 5  °C , 1 h then 2 M  HCI.
Scheme 19 Synthesis and use of Marfey’s reagent
2.3.2 -  HPLC analysis of derivatised amino acids
Amino acid derivatives 110a-e were analysed by reverse-phase HPLC using a chiral Hypersil 5p 
reverse phase column, gradient eluting with 10% - 50% acetonitrile in 50 mM TEAP buffer (pH 3) 
at a flow rate of 0.25 ml min'1 and detected at 340 nm. The retention times are given in Table 3.
Table 3 Retention times of FDAA-derivatised amino acids
Compound Structure Retention time /mins
109
NO 2
nh2 35
110a
110b
HN
OH
O
HN
OH
40
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StructureCompound Retention time /mins
2.4 -  Synthesis and degradation of model peptide 115
2.4.1 -  Synthesis of cyclic peptide 115
In order to verify that the degradation method outlined in section 2.3 was suitable for the analysis 
of the valine residue in micrococcin P1, cyclic hexapeptide 115 was prepared in 7 steps from (S)- 
valine according to Pattenden’s method (Scheme 20) .140 Valine was Boc-protected and 
converted to amide 117. Thionation of the amide with Lawesson’s reagent afforded thioamide 
101b which was elaborated to thiazole 102b using Meyers’ modification of the Hantzsch thiazole 
synthesis.138 N- and C-terminus deprotection furnished (S)-100 and subsequent treatment with 
pentafluorophenyl diphenylphosphinate (FDPP) gave the desired cyclic peptide in 30% yield.
R1HN
iv)
BocHN
104  R 1 = H , R 2 = C 0 2H 
—  116 R 1 = Boc, R 2 = C 0 2H
v)
C 0 2Et Vi) HCIH2N
102b
ii)
iii)
117  R 1 = Boc, R * = C O N H 22 _
101b  R 1 = Boc, R * = C S N H 22 _
Reagents and Conditions i) Boc20 ,  FB uO H -H 20 ,  r.t., 16  h, 98% ; ii) E tO C O C I, Et3N, T H F , 0  °C , 1 h, then  3 5 %  aq N H 3, 
0  °C , 1 h, 95% ; iii) Lawesson's Reagent, C H 2C I2, reflux, 24  h, 66% ; iv) Ethyl brom opyruvate, K H C 0 3, D M E , -2 0  °C , 16  
h, then T FA A , 2,6-lutidine, -2 0  °C , 3 0  mins, 59% ; v) U O H , M e O H -H 20 ,  r.t., 16  h, 9 0% ; vi) 4  M  H C I in d ioxane, r.t., 2  h, 
96% ; vii) FD PP, D IP E A , M eC N , r.t., 18 h, 30% .
Scheme 20 Synthesis of cyclic hexapeptide 115
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2.4.2 -  Degradation and analysis of hexapeptide 115
Cyclic hexapeptide 115 was subjected to the degradation conditions previously applied to a 
number of cyclic peptide natural products (section 2.3). It was hoped that the resulting HPLC 
trace would show only the presence of (S)-valine thus indicating that the degradation proceeded 
without racemisation and that the same conditions could be applied to micrococcin P1. In order 
to accurately replicate conditions which would be used for the degradation of the natural product 
and verify the sensitivity of the method, one milligram of hexapeptide 115 was analysed as 
illustrated in Scheme 21.
Scheme 21 Degradation and analysis of model peptide 115
Analysis of the resulting solution by reverse-phase HPLC' showed the presence of (S)-valine- 
DAA (110a, retention time 39.5 minutes) and unreacted Marfey’s reagent (109, retention time 37 
minutes) (Figure 11). Spiking the sample with a solution of racemic valine-DAA (110a and 110b) 
resulted in an increase in intensity of the peak at 39.5 minutes and the appearance of a new 
peak at 46 minutes, indicating the absence of (R)-valine in the original sample and thus 
confirming that the degradation of 115 proceeded without racemisation of the valine residues.
' Chiral Hypersil 5p reverse phase column, gradient eluting with 10% - 50% acetonitrile in 50 mM TEAP 
buffer (pH 3), 0.25 ml min*1, detected at 340 nm.
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115 110a
Reagents and Conditions: i) O zone, C H 2CI2, r.t., 3 h, then 6  M HCI, 110 °C , 24 h; ii) M arfey 's  
reagent, w ater-acetone, 1 M N a H C 0 3, 4 5  °C , 1 h, then 2  M HCI.
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VWD1 A. WMtangth'340 nm (MCB1EAM182 D)
mAU
175
150
125
100
75
0
Figure 11 HPLC analysis of FDAA-derivatised 115 degradation products
2.5 -  Degradation of natural MP1
2.5.1 -  Chemical degradation of MP1
Encouraged by the successful degradation of model cyclic peptide 115, the same method was 
applied to micrococcin P1 in order to confirm our hypothesis that the Bycroft-Gowland structure 
of MP1 (83) differs from the natural product in the stereochemical configuration of the valine 
residue.139 To this end, one milligram of micrococcin P1 was subjected to ozonolysis, acidic 
hydrolysis and finally FDAA derivatisation (Scheme 22).
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Bycroft-Gowland MP1 (83) R 1 = C H M e 2, R = H 
Proposed Structure M P1 (4) R1 = H, R 2 = C H M e 2
Reagents and Conditions: i) Ozone, C H 2CI2, r.t., 3 h, then 6  M HCI, 110  °C, 24 h; 
ii) M arfey's reagent, w ater-acetone, 1 M N a H C 0 3, 4 5  °C , 1 h, then 2 M HCI.
1 1 0 c
HN
OH
OH
ii)
1 1 0 a 
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Scheme 22 Degradation of natural MP1
2.5.2 -  HPLC analysis of MP1 degradation products
The following figures show the HPLC traces obtained after the degradation of MP1 and the 
subsequent spiking experiment performed on the natural product samples in order to confirm the 
identities of the peaks. Figure 12a shows the derivatised degradation products of MP1, with 
peaks at 26 minutes, 32 minutes, 33 minutes, 35 minutes, 37 minutes and 40 minutes.
Figure 12a HPLC analysis of FDAA-derivatised MP1 degradation products
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On spiking with (S)-valine-DAA (110a) (Figure 12b), the peak at 40 minutes shows a marked 
increase in intensity, confirming the presence of (S)-valine in natural micrococcin P1. Spiking 
with rac-valine-DAA (Figure 12c) results in the same increase in intensity of the peak at 40 
minutes (110a) and also gives rise to a new peak at 46 minutes (110b; (/?)-val-DAA) which is 
absent in the natural product. This confirms the presence of (S)-valine and also the absence of 
(R)-valine in the natural product, and is in keeping with earlier findings regarding the 
stereochemistry of the valine residue.139
VWD1 A Wavaleogth*340 nm (MC B\EAM 128L Dj
h as
Figure 12b FIPLC of MP1 degradation products spiked with 110a
VW01 A. W«v*n0th-34O nm (MCBVEAM128RA 0)
s m
Figure 12c HPLC of MP1 degradation products spiked with 110a and 110b
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The stereochemistry of the isoalaninol residue had been confirmed as R by Walker et al. during 
the course of their degradation studies on micrococcin and is not in doubt.124,130 Spiking with 
110d resulted in an increase in intensity of the peak at 33 minutes, confirming, as expected, the 
presence of (F7)-isoalaninol in micrococcin P1 (Figure 12d). Surprisingly, (S)-isoalaninol was also 
identified in the mixture of degradation products (Figure 12e), demonstrating that although this 
method of cyclic peptide degradation prevents racemisation at stereogenic centres adjacent to 
thiazoles, it is not always reliable for the determination of stereochemistry of all the stereogenic 
centres present in a natural product. A possible mechanism for the racemisation of the 
isoalaninol side chain is illustrated in Scheme 23.
VWD1 A. W M n tfh -3 4 0  nm (M C 8«W 20LW O j'
mAU
400
300
200
100 5
0
I 88 *
Figure 12d HPLC of MP1 degradation products spiked with 110a, 110b and 110d
VWOI A. W « ^ h -3 4 0  nm <MCB*IP1»LRS D) '
Figure 12e HPLC of MP1 degradation products spiked with 110a, 110b, 110d and 110e
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Scheme 23 Acid-catalysed racemisation of the (/?)-isoalaninol side chain of MP1
The key step in the above mechanism is the SN2 attack of the carbonyl oxygen atom on the 
protonated alcohol of the isoalaninol residue (step a). This results in inversion of the
stereochemistry at that centre and yields protonated oxazoline b. Ring-opening affords product 
c, which can undergo the same reaction sequence resulting in the observed racemisation of this 
stereogenic centre. Curiously, racemisation at this stereogenic centre was not reported by 
Walker et al. despite the use of similar acidic hydrolysis conditions."
The stereochemistry of one of the two threonine residues present in micrococcin P1 had been 
confirmed as L by Walker et al. as L-threonine was isolated following acidic hydrolysis of the 
natural product.123 While it is likely that the other threonine residue is also of L-stereochemistry, 
on refluxing in aqueous hydrochloric acid it is degraded to form the ethyl ketone moiety of 
micrococcinic acid (80) and thus would not be isolated under the conditions used by Walker 
(Scheme 24).
H2N' / S'II
©  H 
H20"-A-MeW
//
7 N-
Me Me
H,N
S-
II h2n©
©
Me
H30 
S. ~^5=^
Scheme 24 Degradation of L-threonine to an ethyl ketone under aqueous acidic conditions
On spiking the natural product sample with L-threonine-DAA (110c), the peak at 26 minutes'" 
increased in intensity, confirming that micrococcin P1 contains L-threonine (Figure 12f). The 
intensity of the peak due to 110c in the original HPLC sample (Fig. 12a) is significantly lower 
than the peak intensities observed for the valine and isoalaninol derivatives. A probable reason 
for this is that threonine produced on degradation of the natural product undergoes further 
reactions (Scheme 25). Possible products include (Z)-2-aminobut-2-enoic acid (118) formed by
" Walker etal. used 20% aq. hydrochloric acid, reflux, 16 h.
'" 26 minutes in the original HPLC run (Fig. 12a); 28 minutes in Fig. 12f as all retention times were shifted 
by + 2 minutes in this run
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elimination of water, and 2-oxobutanoic acid (119) formed by the same mechanism as the ethyl 
ketone moiety of micrococcinic acid (Scheme 24). 2-Oxobutanoic acid cannot undergo the SNAr 
reaction with Marfey’s reagent, and would therefore remain non-derivatised and appear absent 
by HPLC analysis at the detection wavelength used.
(MC«^1.VR«TO) 'WV01 A.
S3
Figure 12f HPLC of MP1 degradation products spiked with 110a, 110b, 110d, 110e and 110c
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Scheme 25 Further reaction of threonine under aqueous acidic conditions
2.6 -  Conclusion
Chemical degradation studies on micrococcin P1 have confirmed that the stereochemistry of the 
valine residue in the natural product is S and not R as previously assigned in the literature. Thus 
the likely structures of the micrococcin thiopeptides are as illustrated below.
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3 -  Modification of the Hantzsch Thiazole Synthesis
3.1 -  Introduction
Thiazoles occur widely in nature, and many thiazole-containing natural products possess 
important biological properties. In addition to the thiazolyl peptide antibiotics already discussed 
(section 1.3), compounds such as mechercharmycin A154 (120) and thiazoline-containing 
telomestatin155 (121) exhibit potent cytotoxicity.
NH HN
120 121
Thiamine (vitamin Bi, 122) occurs naturally in yeast, rice husks and cereals, and a lack of 
thiamine in the diet results in beriberi and damage to the nervous system (polyneuritis). 
Thiamine pyrophosphate (123) is a coenzyme involved in the decarboxylation of pyruvate; the 
quaternised thiazole ring is essential to its biological activity (Scheme 26).
Enz— H
MeHO.
NH2
Me' Me
OPP OPPPP MeMeMe' MeMeMe1 22  R =  O H
1 241 23  R =  O,
/ / \
O OH HS.
HOx /MeH " n  lVle HO.
Me
1 2 4
ppp ppppp Me'Me'Me MeMeMe'
Scheme 26 Thiamine pyrophosphate-catalysed decarboxylation of pyruvate
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3.1.1 -  Biomimetic synthesis of thiazoles
In nature, thiazoles present in heterocyclic peptides are formed by the cyclisation of a cysteine 
residue either during the growth of the peptide chain, or by subsequent modification of the 
completed linear peptide.156 A biomimetic strategy can be employed in the synthesis of 
heterocyclic peptides whereby a cysteine residue is cyclised and the resulting thiazoline oxidised 
to afford the desired thiazole (Scheme 27).157158
Scheme 27 Biomimetic thiazole synthesis
A similar approach was utilised by Bagley et al. in their synthesis of dimethyl sulfomycinamate 
(126) in which a serine residue was cyclised onto a thioamide (Scheme 28).141
MeO 2 '
Burgess
reagent
NH
M nC >2OH
0s04, N a l 0 4 d ] « X : CH2
Scheme 28 Cyclisation of serine onto a thioamide
3.1.2 -  Rhodium carbenoid insertion
In the course of their total synthesis of amythiamycin D ,74,75 Moody and co-workers employed 
rhodium carbene N-H insertion methodology to furnish aspartate-derived thiazole 129 (Scheme 
29) 159 Amide 127 underwent chemoselective N-H insertion with the rhodium carbenoid formed 
by the reaction of dirhodium tetraoctanoate and 2-diazo-3-oxobutanoate. The resulting 
ketoamide 128 was converted to the desired thiazole on heating with Lawesson’s reagent.
Bn02C
O N2
y —^  Bn02C  ^ LaweSSOn’S Bn02C
' co2Me I h Reagent
^C02Me
BocHN T f  R h20ct4 BocHN BocHN C02Me
129
Scheme 29 Synthesis of thiazoles using rhodium carbene methodology
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3.1.3 -  Alternative synthetic routes to thiazoles
In addition to the reactions discussed in the preceding sections, there are alternative literature 
procedures for the preparation of thiazoles which are of limited use in the synthesis of thiopeptide 
antibiotics due to the substitution pattern of the thiazoles they produce, but are outlined below for 
completeness.
The Cook-Heilbron thiazole synthesis (Scheme 30) is the reaction of an a-aminonitrile with CS2, 
COS or an isothiocyanate to give a 2,4-disubstituted 5-aminothiazole.160
Scheme 30 The Cook-Heilbron thiazole synthesis
The Andreasch thiazole synthesis is the reaction between maleic or fumaric acid and thiourea 
(Scheme 31 ) .161
CO2 H
CO2 H HO2 C HO2 C
Scheme 31 The Andreasch thiazole synthesis
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3.2 -  The Hantzsch Thiazole Synthesis
3.2.1 -  The Hantzsch thiazole synthesis
Discovered in 1889 by Arthur Hantzsch, the original reaction entails heating a thioamide in the 
presence of an a-halocarbonyl compound in benzene (Scheme 32).147
Scheme 32 The original Hantzsch thiazole synthesis
Modifications of the original Hantzsch protocol have been numerous, including formation of the 
thioamide in situU8 Many of the recent adaptations of this reaction have been focussed towards 
enabling the use of racemisation-prone amino acid derived substrates. These modifications 
have led to the widespread use of the Hantzsch thiazole synthesis in thiopeptide synthesis and 
will be discussed in detail in this chapter.
3.2.2 -  Racemisation of amino acid-derived substrates
The successful total synthesis of natural products such as micrococcin P1 (4) which contain 
amino acid-derived thiazoles is reliant upon the ability to prepare these structural motifs in high 
yield and enantiomeric purity. The Hantzsch thiazole synthesis is a useful method for the 
synthesis of such thiazoles as the necessary thioamide precursors are readily prepared from 
commercially available, enantiopure starting materials. However, a means of circumventing the 
problematic racemisation caused by the concomitant liberation of an equivalent of hydrogen 
bromide is necessary (Scheme 33). Conducting the reaction in the presence of a base 
neutralises the acid liberated, but results in the formation of hydroxythiazoline intermediate 130 
which needs to be activated in order to undergo elimination to the thiazole product (Scheme 33).
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BocHNBocHN BocHN
dehydration
(\ HCOs 
,^NHNH2 NaHC0 3
BocHN BocHN BocHN
BocHN
Scheme 33 The effect of base on the Hantzsch thiazole synthesis
3.2.3 -  Modifications made by Holzapfel
Holzapfel et al. reported the first modified version of the Hantzsch thiazole synthesis in 1990 as a 
result of their need for optically pure glutamine-derived thiazoles.137 The Holzapfel modification of 
the Hantzsch thiazole synthesis is outlined in Scheme 34.
BocHN
Br
NH2
C 0 2Et
K H C O 3, D M E , 
r.t., 5  min
BocHN C 0 2Et
OH py, T FA A , D M E , 
0  °C , 30 m in
BocHN 'C 0 2Et
Scheme 34 The Holzapfel-Hantzsch thiazole synthesis
The thioamide is stirred with solid potassium hydrogen carbonate in DME and ethyl 
bromopyruvate added in order to form the intermediate hydroxythiazoline. The mixture is then 
cooled to 0 °C and a solution of pyridine and trifluoroacetic anhydride in DME added to effect 
elimination to the thiazole product. The use of a low reaction temperature and basic conditions 
prevent racemisation. Holzapfel et al. successfully used this method to prepare enantiomerically 
pure thiazoles derived from (/^-glutamine, (S)-glutamine, (S)-alanine, (S)-valine, (S)-leucine, (S)- 
isoleucine and (S)-phenylalanine.
3.2.4 -  Modifications made by Meyers
The next modification of the Hantzsch thiazole synthesis was made by Aguilar and Meyers in 
1994.138 They reported that in their hands, the reaction conditions developed by Holzapfel et al. 
afforded either partially or completely racemised thiazoles. In the light of these unexpected 
findings, the reaction was reinvestigated. The initial hydroxythiazoline formation was conducted 
at -15 °C in DME with solid potassium hydrogen carbonate, and a wide range of bases and
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temperatures screened for the subsequent dehydration step. The optimum conditions for the 
dehydration of alanine-derived hydroxythiazoline 131 were found to be treatment with a solution 
of 2,6-lutidine and trifluoroacetic anhydride at -15 °C (Scheme 35).
BocHN
Br
NH2
C 0 2Et
K H C 0 3, D M E , 
-15  °C , 16 h
BocHN C 0 2Et
OH 2 ,6 -L u , T F A A , D M E , 
-15  °C , 30 min
BocHN C 02Et
131
Scheme 35 The Meyers-Hantzsch thiazole synthesis
The Meyers modification of the Hantzsch thiazole synthesis has been utilised successfully in the 
synthesis of many natural products including (+)-nostocyclamide162 and promothiocin A (15a).6667 
The Meyers-Hantzsch reaction conditions employed in the syntheses of both (+)-nostocyclamide 
and promothiocin A differ slightly from those published by Meyers in that the addition of ethyl 
bromopyruvate in the first step, and the addition of the trifluoroacetic anhydride - 2 ,6 -lutidine 
solution in the second step were conducted at -40 °C, and the reaction mixture allowed to warm 
to -20 °C, then stirred for the times indicated in Scheme 35.
3.2.5 -  Modifications made by Nicolaou
In the course of his landmark total synthesis of thiostrepton (1), Nicolaou et al. revisited the 
procedures developed by Holzapfel and Meyers.85 The Nicolaou-Hantzsch thiazole synthesis is 
conducted at a higher temperature than the Meyers-Hantzsch reaction and employs both 
pyridine and triethylamine in the elimination step of the reaction (Scheme 36). Also, the pyridine 
and trifluoroacetic anhydride are added separately and sequentially to the reaction mixture, not 
as a pre-mixed solution as used by Holzapfel and Meyers. The Nicolaou-Hantzsch thiazole 
synthesis leads to the trifluoroacetylation of any free NH groups in the target molecule.
BocHN
Br
NH2
C 0 2Et
N a H C C h , D M E , 
r.t., 24  h
BocHN C 0 2Et
OH py, TFA A , D M E , 
0  °C , 2 h, then  
Et3N, w a rm  to r.t.
BocN
s-
o  c f 3
-C 0 2Et
Scheme 36 The Nicolaou-Hantzsch thiazole synthesis
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3.2.6 -  Modifications made by Bach
Bach and co-workers employed a further variation of the Hantzsch thiazole synthesis to prepare 
valine-derived thiazole 102b en route to the total synthesis of GE2270A (42)." The Bach- 
Hantzsch thiazole synthesis (Scheme 37) utilises the longer reaction times of the Nicolaou 
modification, the low reaction temperature as used by Meyers, and pyridine as the base for 
elimination, as used by Holzapfel.
BocHf
Br
NH2
C 0 2Et
K H C O s, D M E , 
-1 5  °C , 24  h
BocHf>
py, TFA A , D M E , 
-1 5  °C , 2 h
BocHf C 02Et
102b
Scheme 37 The Bach-Hantzsch thiazole synthesis
3.3 -  Reinvestigation of the Hantzsch Thiazole Synthesis
While the Hantzsch thiazole synthesis is a valuable addition to the heterocyclic chemist’s toolkit, 
it is clear that this reaction is somewhat capricious when applied to amino acid-derived 
substrates. Indeed three of the successful thiopeptide total syntheses (promothiocin A, 
thiostrepton and GE2270A) use a different modification of the Hantzsch thiazole synthesis. 
Following the discovery that the stereochemistry of the valine residue in micrococcin P1 had 
been misassigned in the literature (Chapter 2), it was decided that results from the chemical 
degradation studies should be verified by total synthesis of the natural product. The total 
synthesis of micrococcin P1 requires the synthesis of enantiomerically pure thiazole building 
blocks 102b and 132.
,s
Boc
N
HN
/  HN132 o
,NH
BocHN N
102b
Figure 13 Disconnection of MP1 illustrating amino acid-derived thiazole building blocks
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3.3.1 -  Comparison of the literature methods for the synthesis of 102b
(S)-A/-terf-(Butoxycarbonyl)thiovalinamide (101b) was prepared in 3 steps from (S)-valine 
(Scheme 20) and subjected, it turn, to the Hantzsch, Holzapfel, Meyers and Nicolaou methods 
for thiazole synthesis, and the yield and optical purity of the product 102b recorded for each set 
of conditions (Table 4). The acidic reaction conditions of the traditional Hantzsch thiazole 
synthesis (entry 1) were not suitable for an acid-sensitive substrate and failed to yield the 
product. The Holzapfel and Meyers modifications afforded the desired thiazole albeit in low yield 
on a small scale (entries 2 and 3), or compromised enantiomeric purity on a larger scale (entry 
4). The failure of the Meyers-Hantzsch conditions to provide optically pure product in good yield 
on a large scale (>1 g) has been previously reported in a study by Pattenden etal., the problems 
being attributed to the decomposition of ethyl bromopyruvate under the reaction conditions.163 
Nicolaou’s conditions were also investigated and afforded A/-trifluoroacetamide 134 as the sole 
reaction product, which on treatment with sodium ethoxide gave thiazole 102b in 8 8% ee.
BocHN BocHN BocHN BocN
1 0 1 b  1 3 3  1 0 2 b  1 3 4
Table 4 Application of literature methodology to the synthesis of thiazole 102b
Method Quantity 
of 101b /g
Solvent
Step 1
Temp. /°C Temp. /°C
Step 2 
Reagents Yield
(%)
eea
(%)
1 Hantzsch EtOH reflux reflux - 0 b -
2 Holzapfel 0.05 DME 0 0 TFAA, 2,6-Lu 33 >98
3 Meyers 0.22 DME -40 —* -20 -40 —>-20 TFAA, 2,6-Lu 9 >98
4 Meyers 1.00 DME -40 —►-20 -40 —►-20 TFAA, 2,6-Lu 59c 88
5 Nicolaou 0.30 DME r.t. 0 TFAA, py, Et3N 85d
T30000
a The ee values were determined by HPLC on a chiral stationary phase, using a ChiralPac AD column; 
flow rate 1 mL min'1; /-PrOH:hexane, 5:95; detected at 269 nm.
b No product was isolated, probably as a result of HBr-catalysed Boc deprotection and subsequent loss of 
product during work-up and purification. 
c Recrystallisation furnished optically pure 102b (ee >98%)
d Only 134 was isolated; ee value was determined following subsequent solvolysis to 102b.
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3.3.2 -  Modification of literature procedures
As the established literature procedures failed to provide a satisfactory and reproducible route to 
thiazole 102b in terms of both yield and optical purity, further modifications to the reaction 
conditions were investigated (Table 5).
Table 5 Modified procedures for the synthesis of 102b
Solvent
Step 1
Temp. /°C Base Temp. /°C
Step 2 
Reagents Yield (%) eea (%)
1 DME r.t. NaHC03 0 TFAA, 2,6-Lu, Et3N 8 8b 91b
2 DME -18 KHCOa -18 TFAA, 2,6-Lu CO •"nI o >98
a The ee values were determined by HPLC on a chiral stationary phase, using a ChiralPac AD column; 
flow rate 1 mL min'1; /-PrOH: hexane, 5:95; detected at 269 nm.
b Isolated 102b (18% yield, 91% ee) and 134 (70% yield, 91% ee); the ee value for 134 was determined 
following subsequent solvolysis to 102b.
0 Only 134 was isolated; ee value was determined following subsequent solvolysis to 102b.
Modification of Nicolaou’s conditions by changing the base used for the elimination of 133 from 
pyridine to 2,6-lutidine led to the isolation of a 1:4 mixture of the desired product 102b and the N- 
trifluoroacetyl derivative 134 (entry 1), both in 91% ee, demonstrating that no racemisation 
occurred during the removal of the trifluoroacetyl group. The Meyers modification of the 
Hantzsch thiazole synthesis was then performed at -18 °C rather than -40 —► -20 °C and resulted 
in a dramatic increase in the yield from 59% to 97% but curiously delivered only the 
trifluoroacetamide 134 (entry 2). Treatment of 134 with sodium ethoxide in ethanol according to 
Nicolaou’s procedure led to the isolation of 102b as a single enantiomer.85 Despite the additional 
solvolysis step, this method has proved a high yielding and reliable route to optically pure valine- 
derived thiazole 1 0 2b.
3.3.3 -  Activation using methanesulfonyl chloride
With a method in hand for the synthesis of optically pure thiazoles, the reagents used to effect 
the dehydration of hydroxythiazoline 133 were varied in order to circumvent the formation of N- 
trifluoroacetyl thiazole 134 and thus remove the need for a subsequent solvolysis step. The use 
of methanesulfonyl chloride and triethylamine in the dehydration of alcohols is a well documented 
and reliable procedure, so these reagents were applied to the dehydration of hydroxythiazoline 
133 (Table 6 ).
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BocHN BocHN BocHN
K H C O 3, D M E , 
r.t., 2  h.
S e e  T ab le  6
1 0 1 b  1 3 3  1 0 2 b
Table 6 Reaction conditions for the methanesulfonyl chloride-triethylamine mediated elimination 
of hydroxythiazoline 133
MsCI (equiv.) Temp. /°C Time /h Aq. work-up Yield (%) eea (%)
1 1.1 r.t. 1 No 70 38
2 1.1 0  r.t. 2 No 33 >98
3 1.1 0 -> r.t. 2 Yes 15 >98
4 1.1 0 r.t. 48 No 21 >98
5 1.1 0 3.5 No 35 92
6 2 0 -> r.t. 60 No 28 >98
7 5 r.t. 2+1 No 36 38
8 10 r.t. 2+1 No 68 36
9b 10 -1 0.5 No 68 12
10c 10 -1 0.5 No 26 >98
a The ee values were determined by HPLC on a chiral stationary phase, using a ChiralPac AD column; 
flow rate 1 mL min'1; /-PrOH:hexane, 5:95; detected at 269 nm.
b Reaction conducted using a CEM Discover® CoolMate apparatus, with concurrent heating and cooling.
0 Reaction conducted under conductive heating conditions.
Reaction of thiovalinamide 101b with ethyl bromopyruvate at room temperature in the presence 
of solid potassium hydrogen carbonate afforded hydroxythiazoline 133, which was treated in situ 
with methanesulfonyl chloride and triethylamine as described in Table 6 . These findings 
demonstrate that it is possible to prepare thiazole 102b as a single enantiomer following 
dehydration, even when 133 is prepared at room temperature (entries 2-4 and 6 ). This would 
suggest that under basic reaction conditions, racemisation in the Hantzsch thiazole synthesis 
occurs in the elimination step of the procedure. This finding contradicts earlier results obtained 
by Meyers et al. which imply that racemisation occurs in the hydroxythiazoline formation step, 
further demonstrating the capricious nature of this reaction.138 Addition of methanesulfonyl 
chloride and triethylamine to 133 at room temperature and stirring for one hour furnished 102b in 
70% yield and 38% ee (entry 1). The probable cause of the observed racemisation was the 
exothermic reaction which occurred on addition of methanesulfonyl chloride and triethylamine
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and caused the reaction temperature to reach up to 90 °C. Repetition of the reaction with 
addition of the reagents at 0 °C prevented the exotherm and the reaction temperature increased 
by only 7 °C. The product was found to be optically pure by HPLC but the yield was drastically 
reduced (entry 2). Purification of the reaction mixture by aqueous work-up further reduced the 
yield (entry 3), and increasing the reaction time to 48 h also failed to improve the yield (entry 4).
Based on these findings it was concluded that the exotherm responsible for the racemisation was 
necessary to improve the yield of the reaction. Addition of two equivalents of methanesulfonyl 
chloride and prolonged reaction times (60 hours, entry 6 ) afforded a slight improvement in yield 
over entry 4 (28% vs. 21%). Addition of five equivalents of methanesulfonyl chloride, stirring for 
two hours, followed by addition of triethylamine resulted in a poor yield and low optical purity 
(entry 7); increasing to 10 equivalents of methanesulfonyl chloride gave a moderate yield of 102b 
(68%) albeit with low optical purity (36%, entry 8 ).
Following the limited success afforded by increasing the reaction time, the effect of low 
temperature microwave irradiation with concurrent heating and cooling was investigated, as this 
technique had been successfully applied to pyrazole synthesis within our laboratory.164 
Hydroxythiazoline 133 was prepared by irradiation of a mixture of thioamide 101b, ethyl 
bromopyruvate and solid potassium hydrogen carbonate in DME for 20 minutes at -20 °C with an 
initial power of 300 W, using a CEM Discover® CoolMate Sub-Ambient microwave synthesiser 
(Figure 14). The mixture was then treated as shown in Table 6 . Irradiation at -1 °C for 30 
minutes furnished the desired thiazole 102b in moderate yield, however the enantiomeric excess 
was only 12% (entry 9). Finally, the CoolMate elimination step was repeated under thermal 
conditions (entry 10) and afforded 102b as a single enantiomer albeit in poor yield (26%). This 
finding also supports the previous results in suggesting that racemisation occurs in the 
elimination step of the Hantzsch thiazole synthesis, rather than the hydroxythiazoline formation 
step.
Figure 14 The CEM Discover® CoolMate Sub-Ambient microwave synthesiser
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3.3.4 -  Activation using other reagents
As no suitable method for the synthesis of optically pure thiazoles in high yield had been 
discovered using methanesulfonyl chloride, other activating agents were investigated. No 
thiazole was formed on treatment of hydroxythiazoline 133 with either one or five equivalents of 
toluenesulfonyl chloride and triethylamine, even after prolonged reaction times (96 hours) at 
room temperature. Reactions using trifluoromethanesulfonic anhydride failed due to the 
polymerisation of the solvent. On the basis of these findings it was concluded that the most 
efficient route to enantiopure valine-derived thiazole 120b was via the trifluoroacetamide 
derivative 134 using the conditions shown in Table 5, entry 2.
3.3.5 -  Synthesis of threonine-derived thiazole 132
With a route to valine-derived thiazole building block 102b now in hand, the synthesis of 
threonine-derived thiazole 132 was investigated. Threonine-derived thioamide 138 was prepared 
as illustrated in Scheme 38.
Hi)
c o n h 2C02H c s n h 2c o 2hBocHN
1 3 5  1 36 1 37  1 38
Reagents and Conditions i) 2 ,2 -D M P , P P T S , T H F , reflux, 6  h, 100% ; ii) E tO C O C I, E t3N, T H F , 0  °C , 1 h, then 3 5 %  
aq. N H 3 , r.t., 2 4  h, 78% ; iii) Law esson 's  Reagent, P h M e, 8 0  °C , 1 .5  h, 24% ; iv) P O C I3, pyridine, 0  °C , 2  h, 8 6 %; v) 
(N H 4)2S, M e O H , r.t., 2 4  h, 100% .
Scheme 38 Synthesis of threonine-derived thioamide 138
A/-Boc-(2S,3R)-threonine was protected as oxazolidine 135 then converted to amide 136 via the 
mixed anhydride by treatment with ethyl chloroformate. The majority of literature procedures 
utilise Lawesson’s reagent or phosphorus pentasulfide to convert an amide to a thioamide 
directly.85 However, in this case, direct thionation of amide 136 with Lawesson’s reagent afforded 
thioamide 138 in only 24% yield following purification on silica. It was found to be more efficient 
to dehydrate the amide to give nitrile 137 by treatment with phosphorus oxychloride, followed by 
thionation with ammonium sulfide solution which afforded thioamide 138 in excellent yield with no 
need for purification.165 A range of conditions were investigated for the conversion of thioamide 
138 into thiazole 132 (Table 7).
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N CSNH2 
Boc s
138 132
Table 7 Synthesis of threonine-derived thiazole 132 from thioamide 138
Method Yield (%)
1 Meyers (Table 4, entries 2 and 3) 0
2 MsCI-Et3Na 21
3 Nicolaou (Table 4, entry 5) 87
a Reagents and conditions: Ethyl bromopyruvate, NaHC03, DME, r.t., 24 h; then MsCI (10 equiv., 
r.t., 16 h), Et3N (r.t., 4 h).
Meyers’ original conditions failed to give the desired product (entry 1); the methanesulfonyl 
chloride-triethylamine conditions afforded thiazole 132 in poor yield (entry 2). Nicolaou’s original 
conditions furnished 132 as a single diastereoisomer in very good yield (entry 3). The lack of a 
free NH in thiazole 132 eliminates the possibility of formation of an /V-trifluoroacetyl derivative, as 
observed in the valine example (Table 4, entry 5), thus making the Nicolaou modification of the 
Hantzsch thiazole synthesis particularly useful for such substrates.
3.4 -  Synthesis of the peptide backbone of MP1
Having successfully prepared thiazole building blocks 102b and 132, the synthesis of the 
backbone peptide fragment of micrococcin P1 (139) was undertaken. The disconnection of the 
natural product and of the peptide backbone is illustrated in Figure 15.
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Boc
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HN
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""O Hm icrococcin P1 (4)
1 0 2 b
Figure 15 Disconnection of the peptide backbone fragment of MP1
3.4.1 -  Synthesis of backbone pentapeptide 143
The synthesis of backbone pentapeptide 143 is illustrated in Scheme 39. Deprotection of 
thiazole 132 was effected in quantitative yield by stirring with five equivalents of lithium hydroxide 
for three hours. The resulting carboxylic acid 140 was converted to the ethyl chloroformate 
mixed anhydride and coupled with A/-deprotected valine-derived thiazole 141 to furnish 
tetrapeptide 142 in good yield. A/-Deprotection of peptide 142 was achieved using trifluoroacetic 
acid in dichloromethane, and the residue immediately neutralised and subjected to PyBOP®- 
mediated peptide coupling with protected threonine 135 to afford the peptide backbone 143 in 
93% yield. Use of HATU for this peptide coupling furnished pentapeptide 143 in 84% yield.
C02R
Reagents and Conditions i) L iO H , M e O H -H 20 ,  r.t., 3  h, 100% ; ii) 4  M HC I in dioxone, r.t., 2  h, 98% ; iii) 140, EtO C O C I, 
Et3N, T H F , 0 ° C ,  1 h; then 141, Et3N , T H F , r.t., 2  h, 82% ; iv) T FA , C H 2C I2, r.t., 1 h; v) 135, P yB O P® , Et3N, C H 2C I2, r.t., 
4  h, 93% .
Scheme 39 Synthesis of backbone pentapeptide 143
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3.4.2 -  Elimination to form protected backbone fragment 139
During the course of their total synthesis of the Bycroft-Gowland structure of micrococcin P1, 
Ciufolini et at. prepared backbone peptide 144, which differs from pentapeptide 143 only in the 
stereochemical configuration of the valine residue.132 Ciufolini’s peptide 144 was treated with 
methanesulfonyl chloride, then Boc-deprotected with trifluoroacetic acid. The remaining 
acetonide protecting group was cleaved using aqueous hydrochloric acid, prior to addition of 
DBU to effect elimination of the mesylate, furnishing peptide 94 in readiness for coupling to core 
domain 93 (Scheme 40, Scheme 14).
NBoc NBoc
Reagents and Conditions i) M sC I, Et3N, C H 2C I2, 0  °C , 10  m ins, 9 1% ; ii) T FA , C H 2C I2 , r.t., 10 mins; 
then 0 .2  M  H C I, T H F , r.t., 30  mins; iii) D B U , C H C I3, r.t., 30  m ins, 8 8 %
Scheme 40 Ciufolini’s modification of peptide backbone 144
In our hands, all attempts at reproducing these transformations failed, producing an intractable 
mixture of products. In the light of these problems it was decided to attempt the elimination of 
the central threonine residue whilst leaving all of the protecting groups intact. Previous reports 
by Bower and co-workers suggested that elimination cannot occur on such a substrate as the 
cyclic acetal protecting group forms a rigid scaffold, restricting the conformation and preventing 
E2 elimination.166 For the synthesis of thiostrepton binding fragment 145, Bower et al. employed 
Ciufolini’s mesylation-deprotection-elimination procedure after finding that O-mesylated peptide 
146 failed to undergo elimination to give 147 on treatment with DBU (Scheme 41). Gratifyingly, 
this was not the case for peptide 143 and the micrococcin peptide backbone 139 was prepared in 
98% yield (Scheme 42).
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NBoc
i) T F A
ii) HCI
>OMs
DBU
CO^ t
O
HO
Scheme 41 Bower’s attempted synthesis of dehydrodemethylvaline-containing peptide 147
Scheme 42 Mesylation and elimination of peptide 143 to form MP1 backbone peptide 139
3.5 -  Conclusion
A range of conditions have been investigated for the conversion of amino acid-derived 
thioamides into thiazoles without racemisation and previously reported conditions for this 
transformation have been found to be unreliable. Modifications to the reaction temperature and 
reagents used have provided evidence which suggests that racemisation in the Hantzsch 
thiazole synthesis occurs in the elimination step of the reaction. Valine-derived thiazole 102b 
has been prepared in excellent yield and with complete stereocontrol. The synthesis of 
threonine-derived thiazole 132 was also investigated and it was found that the Nicolaou- 
Hantzsch reaction conditions provided the optimum route to this thiazole building block. The 
pentapeptide backbone of the micrococcin thiopeptides (139) has been prepared from threonine 
in 10 steps and 44% overall yield.
NBoc NBoc
Reagents and Conditions i) M sC I, E t3N , C H 2CI2 , 0  °C , 16 h; then  D B U  CHCI3, r.t., 2  h, 98% .
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4 -  Synthesis of the Central Heterocyclic Domain of MP1
4.1 -  Introduction
Many biologically important molecules contain pyridine rings, and range from simple structures 
such as the B-vitamins depicted in Figure 16 to the complex molecular architecture of the series 
d and e thiopeptides (section 1.2, Table 1, Figure 1).
OH
nicotinic acid n icotinam ide
V V J
niacin, vitam in B3
OH
HOHO HO OH OHOH
pyridoxine pyridoxal pyridoxam ine
vitam in B6
Figure 16 Pyridine-containing vitamins B3 and B6
The coenzyme nicotinamide adenine dinucleotide (NAD+, 148) and its reduced form NADH (149) 
are components of oxidoreductase enzymes, enabling biological redox reactions to proceed with 
reversible transfer of hydrogen via the 4-positions of 148 and 149 (Figure 17).
= R
<j> HOHO OH
HO
HO OH
©v
R
148
n h 2 nh2
1 4 9
Figure 17 Nicotinamide adenine dinucleotide
Synthetic routes to pyridine-containing target molecules vary widely, as the core pyridine can be 
disconnected in several different ways (Figure 18). The most commonly used approaches are 
via cyclocondensation reactions (e.g. the Hantzsch pyridine synthesis, section 4.1.1 and the 
Bohlmann-Rahtz reaction, section 4.2.6) or cycloaddition reactions (e.g. the Wakatsuki- 
Yamazaki-Bonnemann reaction, section 4.1.2 and the Boger-Panek reaction, section 4.1.3). 
Specific routes towards thiopeptide pyridine domains will be discussed in detail in section 4.2.
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[4+ 2 ] cycloaddition
%
C o (l)-ca ta lysed  oligom erisation
M ichael Jl
h 2n
±>
= >  
o o
Figure 18 Retrosynthetic analysis of pyridine 
4.1.1 -  The Hantzsch pyridine synthesis
First reported in 1882 by Arthur Hantzsch, this pyridine synthesis involves the condensation of 
four components, two equivalents of a (3-dicarbonyl compound, an aldehyde and ammonia 
(Scheme 43) .167 The initial product of the Hantzsch reaction is a 1,4-dihydropyridine (150). This 
dihydropyridine can be readily oxidised to pentasubstituted pyridine 151. Hydrolysis and 
decarboxylation of the ester functionalities in the 3- and 5- positions affords 2,4,6-trisubstituted 
pyridines 152. The Hantzsch thiazole synthesis is a versatile and flexible route to pyridines and 
1,4-dihydropyridines, given the array of commercially available aldehyde starting materials, and 
the ease of synthesis of (3-ketoesters with a range of substituents in the R1 position.
EtQ2C
R
CO^ t
R' O O R 1
n h 3
Et02C C 0 2Et jq j  E t02C
R N R 
H
1 5 0
C 0 2Et
R N R
151
N R
1 5 2
Scheme 43 The Hantzsch pyridine synthesis
4.1.2 -  The Wakatsuki-Yamazaki-Bdnnemann reaction
The Wakatsuki-Yamazaki-Bonnemann reaction is a cobalt(l)-catalysed co-oligomerisation of a 
nitrile with alkynes (Scheme 44) .168,169 If two different symmetrically substituted alkynes are used,
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a mixture of products is obtained. 1,7-Diynes can be cyclised with nitriles to afford 5,6,7,8- 
tetrahydroisoquinolines using this methodology.
CpCo(CO)2
CpCo(CO)2
R
Scheme 44 The Wakatsuki-Yamazaki-Bdnnemann reaction
The proposed catalytic cycle for this reaction is illustrated in Scheme 45. The competing side 
reaction (co-trimerisation of the acetylene) can be suppressed by the use of an excess of the 
nitrile component.
CpCo- -
CpCo CpCo,
R
R
Scheme 45 Proposed catalytic cycle for the Wakatsuki-Yamazaki-Bdnnemann reaction
4.1.3 -  The Boger-Panek pyridine synthesis
The Boger-Panek pyridine synthesis is a [4+2] cycloaddition involving a 1,2,4-triazine and an 
enamine or enol ether (Scheme 46).170171 The initial steps is an inverse electron demand Diels- 
Alder reaction between the triazine diene and the electron-rich dienophile. The initial product 
153 loses nitrogen in a retro-Diels-Alder reaction to form 3,4-dihydropyridine 154 which 
subsequently eliminates amine or alcohol to form the pyridine product 155.
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Scheme 46 The Boger-Panek pyridine synthesis
4.2 -  Synthetic approaches to thiopeptide core domains
Each of the thiopeptide total syntheses successfully completed to date has utilised a different 
method for the synthesis of the central heterocyclic domain. These routes are outlined in the 
following section, together with the proposed biosynthetic pathway to the trisubstituted pyridine 
domain of micrococcin P1.
4.2.1 -  Proposed biosynthetic pathway to the pyridine and tetrahydropyridine cores of the 
thiopeptide antibiotics
In their 1978 paper reporting the structures of micrococcins P1 and P2, Bycroft and Gowland 
also proposed that the pyridine ring could be biosynthesised from a pair of dehydroalanine units, 
formed by the dehydration of two serine residues in the peptide precursor.130 This proposal was 
confirmed by Floss et al. fifteen years later following isotopic labelling studies.172 173 Floss and 
co-workers proposed a cycloaddition mechanism as shown in Scheme 47. Intramolecular aza- 
Diels-Alder reaction of 2-azadiene 156 affords hydroxytetrahydropyridine 157 which can undergo 
dehydration and 1,4-reduction to form the tetrahydropyridine core of thiostrepton (158). 
Alternatively, intermediate 157 can undergo aromatisation and loss of the -NHCOR unit to form 
the trisubstituted pyridine core of the micrococcin thiopeptides (159).
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aza -D ie ls -A ld e r
dehydration, loss of N -term inus dehydration , reduction
Scheme 47 The Bycroft-Gowland-Floss proposal for the biosynthesis of thiopeptide core 
domains
4.2.2 -  Aza-Diels-Alder approach
Moody et al. sought to directly mimic the Bycroft-Gowland-Floss mechanistic proposal in their 
total synthesis of amythiamicin D.74,75 1-Ethoxyazadiene 25 was reacted with N- 
acetyldehydroalanine 24 under microwave irradiation to yield the desired trisubstituted pyridine 
domain 26 in 33% yield (Scheme 48).
DMe
BnO
NH Boc
OMe
m icrow ave
BnO
2 4
NHBoc
Scheme 48 Biomimetic aza-Diels-Alder approach to the core domain of amythiamicin D
4.2.3 -  Diels-Alder dimerisation
Nicolaou and co-workers also employed the aza-Diels-Alder reaction in the total syntheses of 
thiostrepton, GE2270A and GE2270T. For all three thiopeptide antibiotics, the core domain was 
derived from building block 30, which underwent a Diels-Alder dimerisation (section 1.4.3,
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Scheme 5) to form intermediate 31. Subsequent hydrolysis of the imine functionality afforded the 
thiostrepton tetrahydropyridine domain 32 which could be converted to the corresponding 
pyridine by heating in the presence of DBU, or to a piperidine by treatment with sodium 
cyanoborohydride (Scheme 49).
NBoc
D ie ls -A lder dim erisation hydrolysis
o. NBoc O NBoc O. NBoc
3 2D B U
N aC N B H
NH
O- NBoc O NBoc
Scheme 49 Diels-Alder dimerisation approach to the core domains of thiostrepton and GE2270A
4.2.4 -  Coupling of an azomethine ylide and a chiral sulfinimine
Hashimoto et al. utilised a different and to date unique approach in the field of thiopeptide 
synthesis to prepare the dehydropiperidine domain of siomycin A (Scheme 50).107109 The 
azomethine ylide derived from 161 was coupled with chiral sulfinimine 160 to form imine 162. 
Removal of the sulfinyl group furnished an equilibrium mixture of five-membered imine 163 and 
six-membered imine 164, the six-membered imine being stereoselectively reduced with sodium 
cyanoborohydride to piperidine 165. The tetrasubstituted dehydropiperidine domain of siomycin 
A (166) was prepared in three further steps.
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Scheme 50 Preparation of the core domain of siomycin A
4.2.5 -  Synthesis via a 1,5-diketone
Ciufolini and Shen employed a cyclocondensation method for the synthesis of the central 
heterocyclic domain of the micrococcin thiopeptides.131 In this Hantzsch-like procedure, 1,5- 
diketone 87 was prepared (section 1.5.6, Scheme 13) and treated with ammonium acetate to 
form 1,4-dihydropyridine 167. Oxidation with DDQ afforded the trisubstituted pyridine core 
domain 88 (Scheme 51).
TBSO TBSO.
D D Q
87 167
NH ,NH
O O
Scheme 51 Ciufolini’s synthesis of the pyridine domain of the micrococcin thiopeptides
4.2.6 -  The Bohlmann-Rahtz pyridine synthesis
The total synthesis of promothiocin A by Moody and Bagley utilised the then little known 
Bohlmann-Rahtz pyridine synthesis to prepare the trisubstituted pyridine domain of the natural 
product (Scheme 52).66,67 While related to the Hantzsch pyridine synthesis, the Bohlmann-Rahtz
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reaction has the advantage that the pyridine is formed directly, without the need for an additional 
oxidation step as a result of employing an ynone rather than an enone to react with the
fi Qenamine.
OBn
A
OBnBocHN BocHN
1816
Scheme 52 The Bohlmann-Rahtz pyridine synthesis of the core domain of promothiocin A
The Bohlmann-Rahtz reaction has been studied extensively within our laboratory174 and has 
been successfully applied in the synthesis of several thiopeptide fragments and degradation 
products (Scheme 5 3 ).141143175
dim ethyl su lfom ycinam ate
fBuO
TMS fBuO
BocHNBocHN O
iii) N IS
HN,
cyclo thiazom ycin  y-lactam
TBSO
BocHN
am yth iam icin  dom ain
TBSO
BocHN
Scheme 53 Thiopeptide fragments synthesised using the Bohlmann-Rahtz reaction
76
Chapter 4 -  Synthesis of the Central Heterocyclic Domain of MP1
4.2.7 -  Retrosynthetic analysis of the central heterocyclic domain of MP1
With the backbone peptide sector of the micrococcin thiopeptides now in hand, a route to the 
central heterocyclic domain (168) was devised (Figure 19). Enamine 169 would be prepared 
from threonine-derived thiazole 132 and reacted with propargylic ketone 170 to furnish 
trisubstituted pyridine 171. Subsequent simultaneous elaboration of both ester moieties to the 
corresponding thiazole ethyl esters would yield the desired heterocyclic motif, completing the 
synthesis of 168.
BocN
tw o-directional th iazo le  
elaboration
C02MeB oh lm an n-R ah tz
-C02Me
BocN
Figure 19 Disconnection of the central heterocyclic domain of micrococcin P1
4.3 -  Synthesis of p-ketoester 172
4.3.1 -  Conversion of carboxylic acid 140 to p-ketoester 172
It was proposed that enamine building block 169 would be prepared from threonine-derived 
thiazole 132 as illustrated in Scheme 54. Central to this approach is the ability to prepare p- 
ketoester 172 in high yield. A range of different procedures were employed in order to effect the 
transformation of 132 or 140 into 172 (Table 8 ).
Scheme 54 Proposed synthesis of enamine 169
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Table 8 Synthesis of p-ketoester 172
Substrate Activating reagents Enolate source Time /h Yield (%)
1 132 - MeOAc / NaOMe 2 0a
2 140 EtOCOCI, Et3N EtOAc / LDA 0.5 0b
3 140 DCC, DMAP Meldrum’s acid, EtOH 4.5 0 b
4 140 EtOCOCI, Et3N Potassium ethyl malonate / 
MeMgBr
16 33
5 140 EtOCOCI, Et3N Potassium ethyl malonate / 
MeMgBr
2 72
a Only starting material 132 recovered.
b Only starting material 140 recovered.
Direct formation of p-ketoester 172 from threonine-derived thiazole ester 132 was attempted by 
the addition of sodium methoxide to a solution of 132 in methyl acetate (entry 1). Monitoring of 
the reaction by thin layer chromatography suggested the consumption of all of the starting 
material and formation of a single product, but on work up and NMR, only the starting ester was 
present, recovered in quantitative yield. Treatment of carboxylic acid 140 (activated as a mixed 
anhydride) with the lithium enolate of ethyl acetate failed to yield the desire product, again 
returning the starting material in quantitative yield (entry 2). Activation of 140 with 
dicyclohexylcarbodiimide and DMAP followed by reaction with Meldrum’s acid for 1.5 hours at 
room temperature then 3 hours at 65 °C again returned only starting material (entry 3). It was 
found that reaction of the mixed anhydride of 140 with a pre-mixed solution of potassium ethyl 
malonate and methyl magnesium bromide furnished the desired product in 33% yield if allowed 
to stir overnight at room temperature (entry 4). Encouraged by this result, the reaction was 
repeated, but stirred at room temperature for two hours (entry 5). This shortening of the reaction 
time led to the isolation of p-ketoester 172 in 72% yield after work up and purification by 
chromatography. It was possible to scale this reaction up with no decrease in yield, allowing 
access to multi-gram quantities of 172 in readiness for conversion to enamine 169.
4.4 -  Synthesis of enamine 169
The conversion of p-ketoester 172 into enamine 169 proved to be extremely challenging, failing 
under all but the harshest reaction conditions. The unexpected inertness of 172 to reaction with 
sources of ammonia is attributed in part to the steric bulk and conformational constraints 
imposed by the protecting groups used, and also to the stability of the enol tautomer of 172,
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which is clearly visible in the proton NMR spectrum, accounting for 22% of the material present 
by 1H-NMR integration in CDCI3.
4.4.1 -  Ammonia-saturated solvents
The reaction of 172 with ammonia-saturated solvents at room temperature or under microwave 
irradiation conditions (Table 9, entries 1-3) failed to yield enamine 169. Addition of a Lewis acid 
catalyst also failed to furnish the desired product (entry 4), unreacted starting material being 
returned in quantitative yield in all cases.
Table 9 Reaction of p-ketoester 172 with ammonia-saturated solvents
Solvent Temperature /°C Catalyst Time Yield (%)
1 NH3 in EtOH r.t. - 24 h 0
2 NH3 in CHCI3 r.t. - 96 h 0
3 NH3 in EtOH 100a - 30 min 0
4 NH3 in CH2CI2 100b Sc(OTf)3 10 min 0
CEM Discover single-mode microwave synthesiser, initial power 300 W. 
b CEM Discover® single-mode microwave synthesiser, initial power 100 W.
4.4.2 -  Ammonium acetate
Following the negative results obtained by treating 172 with ammonia-saturated solvents (Table 
9), a new ammonia source was employed. Enamine formation by the reaction of a p-ketoester 
with ammonium acetate in a mixture of benzene and acetic acid (5:1) is a well established 
procedure which has been utilised successfully in our laboratory in previous studies.176 
Unfortunately, p-ketoester 172 failed to react with ammonium acetate in toluene-acetic acid 
either at room temperature or at reflux (Table 10).
Table 10 Reaction of p-ketoester 172 with ammonium acetate under thermal conditions
Solvent NH4OAc (equiv) Temperature PC Time Yield (%)
1 PhMe-AcOH (5:1) 10 r.t. 6  days 0a
2 PhMe-AcOH (5:1) 10 reflux 24 h 0a
a Only starting material 172 recovered.
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4.4.3 -  Conductive heating vs. microwave conditions
The failure of the reaction of 172 with ammonium acetate in toluene-acetic acid when heated at 
reflux was partially attributed to the sublimation of ammonium acetate which occurs at 115 °C. 
This led to the build up of large quantities of solid ammonium acetate in the condenser, thus it 
was unable to act as an ammonia source in the reaction mixture. In order to circumvent this 
problem, the reaction was conducted in a sealed tube with microwave irradiation. It was hoped 
that the more efficient heating, coupled with the increased temperature and pressure would force 
172 to undergo the desired reaction (Table 11).
Table 11 Reaction of p-ketoester 172 with ammonium acetate under microwave irradiation
Solvent NH4OAc (equiv) Temperature
/°C
Time Heat source Yield (%)
1 PhMe-AcOH (5:1) 50 150 30 min MW, 300 W° 0a
2 PhMe-AcOH (5:1) 120 150 30 min MW, 300 W6 38
3 Mesitylene 120 150 2 h thermal 28
4 PhMe-AcOH (5:1) 120 150 15 min MW, 300 Wb 49
5 PhMe-AcOH (5:1) 120 150 10 min MW, 300 W* 69
6 PhMe-AcOH (5:1) 120 150 10 min MW, 300 W° 68
a Only starting material 172 recovered.
b CEM Discover® single-mode synthesiser. Power is moderated throughout the course of the experiment 
to maintain a constant reaction temperature. 100 mg of 172 used, 3 mL solvent.
c Milestone BatchSYNTH® multimode synthesiser. Power is moderated throughout the course of the 
experiment to maintain a constant reaction temperature. 1 g of 172 used, 30 mL solvent.
Microwave irradiation at 150 °C in the presence of 50 equivalents of ammonium acetate led to 
the recovery of the starting material (entry 1) but on increasing to 120  equivalents of ammonium 
acetate, the elusive enamine was finally obtained, albeit in 38% yield (entry 2). It was concluded 
that the high reaction temperature was necessary in order to provide a sufficiently high pressure 
of ammonia in the sealed microwave tube to force the reaction to occur. Evidence for this is 
provided by the observed pressure jump within the microwave vessel between 145 °C and 150 
°C (Figure 20). The reaction was then attempted under thermal conditions using mesitylene as 
the solvent in the hope of providing a method whereby the reaction could be scaled up (entry 3). 
Thermal reaction at 150 °C did furnish the desired product but the yield was poor, most likely as 
a result of the sublimation of large quantities of ammonium acetate out of the reaction mixture, or 
the evaporation of much of the ammonia generated. Faced with the poor yield of the thermal 
reaction (entry 3 ), the microwave methodology was optimised further, and it was found that
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reducing the reaction time increased the yield of 169 (entries 4 and 5). The optimum reaction 
time was found to be ten minutes, as shorter times led to the isolation of unreacted starting 
material which proved difficult to separate from the product.
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Figure 20 Reaction temperature, pressure and power profile under microwave irradiation 
conditions for the conversion of 172 to 169 using the Milestone BatchSYNTH® multimode 
synthesiser (Table 11, entry 6). Colour coding: Red = reaction temperature, yellow = power, light 
blue = pressure safety limit, dark blue = pressure inside reaction vessel.
4.4.4 -  Scale-up using a multimodal microwave
With a method for the formation of 169 now in hand, it was necessary to scale up the reaction in 
order to continue the synthesis of target domain 168 However, the need for such a vast excess 
of ammonium acetate meant that only 100 mg of 172 could be reacted at a time in the standard 
10 mL microwave vessels. Continuous flow systems could not be employed for the scale-up of 
this reaction due to the use of solid ammonium acetate. Fortunately, the use of a large capacity 
multimodal microwave synthesiser with a 60 mL reaction vessel provided the opportunity to scale 
up the reaction, using 1 gram of (3-ketoester 172 and 22 grams of ammonium acetate (Table 11, 
entry 6). This enabled the preparation of enamine 169 in 680 mg batches with a reproducible 
and almost identical yield (68%) to the small scale monomodal reaction (Table 11, entry 5, 69%).
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4.5 -  Alternative routes to enamine 169
In parallel with the development of the microwave-assisted route to enamine 169 discussed in 
the preceding section, alternative routes to 169 and related compounds were investigated due to 
the initial difficulties in obtaining the desired enamine, and in scaling up of the reaction.
4.5.1 -  Enamine formation via thiazole nitrile 174
Given the apparent inertness of p-ketoester 172 to ammonia, it was decided to prepare a 
substrate with the nitrogen atom already in place, obviating the need for reaction with an 
ammonia source in a later step. To this end, threonine-derived thiazole carboxylic acid 140 was 
converted to amide 173 and then dehydrated using phosphorus oxychloride to afford nitrile 174 
(Scheme 55). It was hoped that reaction of thiazole nitrile 174 with the lithium enolate derived 
from ethyl acetate and LDA would furnish enamine 169 but all attempts at this reaction failed, 
returning unreacted starting material. Subjecting nitrile 174 to the same reaction conditions 
successfully employed for the synthesis of p-ketoester 172 (potassium ethyl malonate -  
methylmagnesium bromide; Table 8 , entry 5) also failed to yield enamine 169.
140 1 73 174 1 69
Reagents and Conditions: i) EtOCOCI, Et3N, THF, 0 (t ,  1 h, then 35% aq. NH3, r.t., 3 h, 87%; ii) POCI3, pyridine, 0 °C ,
2 h, 48%.
Scheme 55 Proposed synthesis of enamine 169 via nitrile 174
The Bohlmann-Rahtz pyridine synthesis can be performed using an enamine with a nitrile group 
in place of the more common ester substituent (Scheme 56).69 It was hoped that nitrile 174 would 
react with the anion of acetonitrile to form 175 which could be used in the Bohlmann-Rahtz 
pyridine synthesis. Addition of sodium hydride to a solution of 174 in acetonitrile failed to yield 
the desired product, the starting material persisting even after 96 hours.
174 175
R2 = C 0 2Et, COMe, CN Reagents and Conditions: i) NaH, MeCN, reflux, 96 h.
Scheme 56 Attempted synthesis of enamine nitrile 175
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4.5.2 -  Enamine formation v ia  p-ketonitrile 176
Although the conversion of nitrile 174 into 175 failed, a different synthetic approach was 
investigated, this time accessing 175 via p-ketonitrile 176 (Scheme 57). Initially, the synthesis of 
176 directly from thiazole ester 132 was investigated, based on good literature precedent.177 
Addition of ester 132 to a mixture of sodium hydride and acetonitrile in THF failed to give the 
product, the starting material being recovered in quantitative yield, even after 5 days with heating 
at reflux. Addition of sodium hydride to a solution of ester 132 in acetonitrile also failed to yield 
the product instead producing a mixture of products.
132 140 1 76 175
Reagents and Conditions: i) LiOH, Me0 H -H 2 0 , r.t., 3  h, 100%; ii) E tO CO CI, E ^ N , M eC N , r.t., 2 h; then NaH , r.t., 2 h, 78% . 
Scheme 57 Synthetic approach to 175 via P-ketonitrile 176
The elusive p-ketonitrile 176 was finally obtained by preparing a solution of the mixed anhydride 
of carboxylic acid 140 in acetonitrile, then adding five equivalents of sodium hydride and stirring 
for a further two hours. Quenching of the reaction mixture and purification by chromatography 
led to the isolation of 176 in 78% yield. It was apparent from the proton NMR and infrared 
spectra of compound 176 that the p-ketonitrile existed entirely as the enol tautomer, and the lack 
of reactivity towards any sources of ammonia was attributed to this. Literature procedures for the 
conversion of p-ketonitriles to enamines by refluxing with ammonium acetate,178 or heating in 
ethanolic ammonia in a sealed vessel at 130 °c ,179 failed to afford the product, returning only 
starting material. Even the harsh conditions devised for the conversion of p-ketoester 172 to an 
enamine failed to force 176 to react, so the synthesis of nitrile 175 was not pursued further.
4.6 -  Synthesis of thiazole alkynone 170
With a reliable and reproducible route to enamine building block 169 now established, our 
attention was turned to the preparation of propargylic ketone 170. The ethyl ester homologue of 
170 had previously been synthesised within our laboratory (Scheme 53) 143175 and could have 
also been employed in this synthesis, but the methyl ester was required for the synthesis of 
another target (Chapter 6 ) so the same alkynone was used in the synthesis of 168.
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4.6.1 -  Synthesis of thiazole alkynone 170
Propargylic ketone 170 was prepared in six steps and 51% overall yield by the route shown in 
Scheme 58. Ammonium sulfide thionation of diethoxyacetonitrile afforded 2,2- 
diethoxythioacetamide 177, which underwent the Hantzsch thiazole synthesis in the presence of 
4 A molecular sieves in order to prevent concomitant acetal deprotection by trapping the 
equivalent of hydrogen bromide liberated in the course of the reaction. Thiazole acetal 178 was 
then trans-esterified to form 179 and acetal-deprotected using aqueous acid to liberate the 
aldehyde moiety. Treatment of aldehyde 180 with ethynylmagnesium bromide in tetrahydrofuran 
furnished propargylic alcohol 181, which was oxidised to the desired propargylic ketone 170 
using manganese dioxide.
Ey CN _ J u Ey ^  m
E,°  E1°  n h 2 RO N CO2R H N C 0 2Me
a -,-, i i r v i— 178 R = Et i a n
177 "i)L — 179 R = M e  1 8 0
Reagents and Conditions: i) (N H 4) 2S, M eO H , r.t., 2 4  h, 100% ; ii) Ethyl b rom opyruvate, 4  A m olecular sieves, E tO H , 
reflux, 1 h, 100% ; iii) P TS A , M eO H , reflux, 48  h, 9 6% ; iv) 2  M aq H C I, acetone, reflux, 2  h, 8 6 % ; v) 
E thynylm agnesium  bromide, T H F , 0 °C , 1 h, 81% ; vi) Activated M n 0 2, C H 2C I2, r.t., 2  h, 77% .
Scheme 58 Synthesis of propargylic ketone 170
Alkynone 170 was found to be extremely unstable, decomposing to a black tar-like substance 
overnight, even when stored at -18 °C under an inert atmosphere. For this reason, the 
propargylic alcohol precursor 181 was prepared in large quantities and only oxidised immediately 
prior to use in the subsequent Bohlmann-Rahtz reaction.
4.6.2 -  Scale-up limitations with the oxidation of propargylic alcohol 181
While the route depicted in Scheme 58 proved successful in furnishing multi-gram quantities of 
propargylic alcohol 181, subsequent oxidation to thiazole alkynone 170 consistently failed when 
undertaken using more than 800 mg of 181. The starting material was all consumed during the 
oxidation, and in most cases a single product spot was observed by thin layer chromatography. 
However, on filtration through Celite® the characteristic orange band of product could be seen to 
turn black, and TLC and 1H-NMR spectroscopic analysis of the filtrate revealed the absence of 
the previously observed alkynone (Figure 21).
VI)
170
C 02Me
181
84
Chapter 4 -  Synthesis of the Central Heterocyclic Domain of MP1
MnC>2 °vHO
181 170
170
181-
•  •  
•  •
filtration through C e lite *1
- h *  ■
reaction  
after 2  h
Figure 21 Observed decomposition of 170 when prepared on a large scale
Given the difficulties in storing alkynone 170, conducting the reaction in a number of small 
batches and combining the product was not a viable alternative to a single large scale reaction. 
Instead, a different oxidising agent was sought in order to circumvent the apparently problematic 
filtration step. A test reaction on 100 mg of 181 using IBX as the oxidising agent was found to be 
successful, furnishing the product in moderate yield (56%). On scale-up to 3.50 grams of 181, 
the yield fell to 34%, the probable cause being difficulty in removal of the product from 350 mL of 
DMSO during the work-up of the reaction. Despite the poor yield, IBX oxidation was the only 
method by which gram quantities of alkynone 170 could be reproducibly obtained.
4.7 -  Synthesis of protected core domain 168
4.7.1 -  The Bohlmann-Rahtz pyridine synthesis
With building blocks 169 and 170 now in hand, the assembly of pyridine core 171 was now 
attempted via the proposed Bohlmann-Rahtz methodology (Scheme 59). The success of the 
initial Michael addition of enamine 169 to propargylic ketone 170 was hampered by the instability 
of 170, the reaction yielding aminodienone 182 in 58% yield with 40% recovery of unreacted 
enamine 169 when 1.5 equivalents of alkynone 170 were used. Increasing to 2 equivalents of 
alkynone substantially improved the efficiency of the reaction, furnishing aminodienone 182 in 
81% yield with 12% recovery of enamine 169.
Y^^""C02Me
Me02C
Reagents and Conditions: i) 170, E tO H , r .t . , 18  h, 5 8 -8 1 % ; ii) l2. r.t., 2  h, 100% . 
Scheme 59 Bohlmann-Rahtz synthesis of pyridine 171
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Numerous methods for the cyclodehydration of aminodienones to pyridines have been 
developed within our laboratory, including the use of Bronsted acids,180 Lewis acids,181 N- 
halosuccinimides,182 and iodine.183 For the synthesis of pyridine 171, iodine was the 
cyclodehydration reagent of choice due to the extremely mild reaction conditions and high yield 
and purity of the product obtained, column chromatography being unnecessary following 
aqueous work up with sodium thiosulfate.
4.7.2 -  Two-directional thiazole elaboration
The final stage in our synthesis of the central heterocyclic domain of micrococcin P1 was the 
two-directional elaboration of pyridine 171, installing both of the remaining thiazoles 
simultaneously (Scheme 60).
183 r  = c o 2h
184 R = CONH2
185 R = CN
186 R = CSNH2
C02Me
Reagents and Conditions: i) L iO H , M e O H -H 20 ,  reflux, 7 2  h, 100% ; ii) E tO C O C I, E ^ N , T H F , 0  °C , 18 h, then  
3 5 %  aq. N H 3l r.t., 2 4  h, 6 2% ; iii) P O C I3, pyridine, 0  °C , 2  h, 8 7% ; iv) (N F U k S , M eO H , r.t., 18 h, 3 4 -7 0 % ; v) Ethyl 
brom opyruvate , K H C 0 3, D M E , r.t., 24  h, then pyridine, TFA A , 0  QC ->  r.t., 3  h, then  Et3N , r.t., 3  h, 9 6 % .
Scheme 60 Simultaneous elaboration of the 3- and 6 -position carboxylate groups of 171
Initial attempts to hydrolyse both esters using lithium hydroxide at room temperature failed, the 
ethyl ester remaining intact under all but the harshest hydrolysis conditions. The desired bis-acid 
183 was only formed on prolonged heating (72 hours or more) in the presence of 20 equivalents 
of lithium hydroxide. Bis-amide 184 was prepared in modest yield by the reaction of bis-acid 183 
with ethyl chloroformate followed by addition of 35% aqueous ammonia. As with the synthesis of 
threonine-derived thiazole 132 (section 3.3.5), direct thionation of the amide with Lawesson’s 
reagent was not used, as 184 failed to react with Lawesson’s reagent and recovery of the 
unreacted starting material proved difficult. Instead, bis-nitrile 185 was prepared and thionated 
using ammonium sulfide. This procedure proved to be uncharacteristically capricious when 
applied to nitrile 185, affording thioamide 186 in yields ranging from 34% to 70% after column 
chromatography. The final thiazole formation was successfully achieved using the Nicolaou 
modification of the Hantzsch thiazole synthesis (section 3.2.5), furnishing target molecule 168 in 
excellent yield.
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4.8 -  Synthetic approaches to micrococcinic acid
4.8.1 -  Degradation of micrococcin P1 to micrococcinic acid
Acidic hydrolysis of micrococcin by Walker et aC2Z led to the isolation of an acid-insoluble 
compound which contained many thiazoles,125 and was later named micrococcinic acid (80).126 
Walker’s degradation of ‘micrococcin P’ was performed by dissolving 5.4 grams of the natural 
product in 150 mL of 20% hydrochloric acid and heating the solution at reflux for 16 hours. 
Addition of the solution to water precipitated the ‘acid-insoluble fraction’ which was subsequently 
identified as micrococcinic acid (Scheme 61).
reflux
m icrococcin P1 (4) m icrococcinic acid (8 0 )
Scheme 61 Acidic hydrolysis of micrococcin P1 to micrococcinic acid
4.8.2 -  Kelly’s synthesis of micrococcinic acid
The first and indeed only synthesis of micrococcinic acid was reported by Kelly and co-workers in 
1991.184 Using a strategy similar to that recently employed by Bach et al. in their elegant total 
synthesis of GE2270A (section 1.4.4)," individually synthesised thiazole building blocks were 
appended to a pyridine core by means of palladium-catalysed coupling reactions (Scheme 62).
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Scheme 62 Kelly’s synthesis of micrococcinic acid
Bromothiazole 187 and 3-trimethylstannylpyridine 188 were coupled to form intermediate 
pyridine-thiazole 189. Subsequent conversion to 190 and coupling with bromo-bis-thiazole 191 
in the presence of Sn2Me6 and PdCI2(PPh3)2 afforded compound 192 which was converted to 
triflate 193 in readiness for the final biaryl coupling. The final coupling between pyridine triflate 
193 and 4-trimethylstannylthiazole 194 yielded micrococcinic acid precursor 195, which was 
successfully hydrolysed to furnish the target molecule with identical physical and spectroscopic 
properties to that isolated from the natural product.
4.8.3 -  Our synthetic approach to micrococcinic acid
Given the structural similarities between our protected micrococcin core domain 168 and 
micrococcinic acid 80, it was hoped that acidic hydrolysis of 168 using Walker’s original 
conditions would furnish the thiopeptide degradation product (Scheme 63). It was postulated that 
the harsh aqueous acidic conditions would cleave both A/-terminus protecting groups, hydrolyse 
the ethyl esters, and convert the remaining threonine residue into the ethyl ketone, as observed 
in the degradation of the natural product (section 2.5.2, Scheme 24).
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Scheme 63 Attempted conversion of 168 into micrococcinic acid
Micrococcin core domain 168 was dissolved in 6  M hydrochloric acid and heated at reflux for 2 
hours. On addition of the reaction mixture to water, a yellow acid-insoluble precipitate was 
observed, as described in the literature, but this was found to be deprotected core domain 196 
and not micrococcinic acid as hoped.
In order to effect the conversion of the still intact threonine residue into the ethyl ketone moiety of 
micrococcinic acid, the precipitate was heated in 6  M hydrochloric acid for a further 16 hours. 
This also failed to yield micrococcinic acid, instead returning a mixture of decomposition products 
unidentifiable by 1H-NMR spectroscopy due to the small scale of the reaction.
Undeterred, an alternative degradation method was employed, also used successfully by Walker 
et at. to hydrolyse micrococcin to micrococcinic acid.126 Accordingly, 168 was heated at reflux for 
6 hours in a 1:1 mixture of concentrated hydrochloric acid and 98% formic acid. Addition of the 
reaction mixture to water induced precipitation of a yellow solid, which was again unidentifiable 
by NMR spectroscopy, although it appeared to contain a monosubstituted pyridine. Following 
the lack of success with both sets of hydrolysis conditions, the synthesis of micrococcinic acid 
from 168 was not pursued further, as the central heterocyclic domain was required for the 
proposed total synthesis of micrococcin P1.
o
HO
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4.9 -  Conclusion
A range of conditions for the conversion of sterically hindered (3-ketoesters to enamines have 
been investigated, and a reproducible microwave-assisted method devised, which is suitable for 
both single- and multimode instruments, and for scale-up to produce multi-gram quantities of 
material. The central heterocyclic domain (168) of the micrococcin thiopeptides has been 
prepared from A/-Boc-(2S,3/:f)-threonine in 15 steps and 9% overall yield via a highly convergent 
strategy featuring an efficient two-directional thiazole elaboration.
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5 -  Assembly of the MP1 Macrocycle
5.1 -  Introduction
The amide bond is ubiquitous in nature, proteins and peptides being present and abundant within 
every living organism on Earth. Indeed, the importance of proteins is recognised in their name, 
derived from the Greek t t p o t e o o , meaning ranked first. In the synthesis of any peptide-based 
target, be it an enzyme containing perhaps hundreds of amino acid residues or a modified 
heterocyclic peptide such as those under investigation in this thesis, the ability to synthesise 
amide bonds in high yield and without racemisation/epimerisation is of paramount importance. 
What follows is a brief overview of peptide coupling reagents, and a discussion of the use of such 
reagents in the macrocyclisation steps of thiopeptide antibiotic syntheses.
5.1.1 -  Acid halogenating reagents
The activation of an amino acid by conversion to the corresponding acid chloride was introduced 
by Emil Fischer in 1903.185 Traditionally, acid chlorides are prepared using thionyl chloride, a 
reagent which is too vigorous for use with complex or sensitive substrates. While useful for the 
coupling of achiral or extremely hindered amino acids, activation as the acid chloride is prone to 
side reactions and racemisation, and thus unlikely to be the method of choice in the synthesis of 
a complex target molecule.
Acid fluorides, which are more tolerant of moisture and of acid-labile functionalities than their 
chloride counterparts, can be prepared using reagents such as cyanuric fluoride (197)186 and 
tetramethylfluoroformamidinium hexafluorophosphate (TFFH, 198).187
N N
fa  a
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Acid fluoride methodology has been successfully employed in macrolactamisation reactions 
(Scheme 64). In their synthetic approach to C3-epimauritine D, Han et al. generated the acid 
fluoride of 200 in situ using TFFH in the presence of HOAt, and formed the desired macrocyclic 
product 201 in 75% yield over two steps.188
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Scheme 64 TFFH-mediated macrolactamisation
5.1.2 -  Chloroformates
Chloroformates are widely used in peptide coupling reactions due to their low cost and the ease 
of purification of the product. For example, the by-products of an ethyl chlorofomate-mediated 
peptide coupling are ethanol, carbon dioxide and the hydrochloride salt of the tertiary amine base 
used (Scheme 65, path a). Disadvantages of chloroformate reactions include side reactions due 
to a lack of regioselectivity in the nucleophilic attack of the amine on the mixed anhydride 
intermediate 202, leading to acetylation of the amine (path b, 204).189 Also, it is necessary to 
protect any free alcohols present in the starting material, a step which may be omitted with the 
use of other peptide coupling reagents.
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Scheme 65 Possible side reactions in chloroformate-mediated peptide coupling reactions
5.1.3 -  Carbodiimide reagents
Carbodiimide reagents such as dicyclohexylcarbodiimide (DCC, 205) were first reported by 
Sheehan and Hess in 1955 and have been widely used in peptide synthesis ever since (Scheme 
6 6 ).190 The by-product of DCC coupling reactions is dicyclohexylurea, which is readily separated 
from the reaction product due to its poor solubility in most organic solvents. The intermediate O- 
acylisourea 206 is prone to side reactions (intramolecular acyl transfer) and racemisation, so an 
additional nucleophile is often added to react with 206 before any such reactions can occur. 
Common additives include 1-hydroxybenzotriazole (HOBt, 207), 1-hydroxy-7-azabenzotriazole 
(HOAt, 208) and ethyl-1-hydroxy-1 H-1 ,2,3-triazole-4-carboxylate (HOCt, 209).
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Scheme 66 DCC-mediated peptide coupling
5.1 .4 - Imidazolium reagents
Imidazolium reagents were first developed in the 1950s in the search for improved coupling 
reagents based on DCC (205).191 The parent reagent of this class of compounds is 1,1’- 
carbonyldiimidazole (CDI, 210). There are two possible routes to the active imidazolide species 
(212) in a CDI-mediated peptide coupling, namely rearrangement of the anhydride intermediate 
211 (Scheme 67, path a), or nucleophilic attack of the previously displaced imidazole (path b).
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Scheme 67 Formation of the active intermediate in CDI-mediated peptide coupling
More recent additions to the imidazolium family of reagents include 1,1’-carbonylbis(3- 
methylimidazolium) triflate (CBMIT, 213),192 which has proved useful in coupling sterically 
hindered amino acids, but suffers from considerable drawbacks regarding air and moisture 
sensitivity, and restricted choice of solvents as a result of its high polarity.193 Other imidazolium 
reagents such as 2-chloro-1,3-dimethylimidazolinium hexafluorophosphate (CIP, 214) and 2-
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(benzotriazol-1-yl)oxy-1,3-dimethylimidazolidinium tetrafluoroborate (BOI, 215) have found 
application as both peptide coupling reagents and esterification reagents.194189
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5.1.5 -  Organophosphorus reagents
The first reported use of an organophosphorus reagent as a peptide coupling reagent was by 
Yamada et at. in 1972.195 Yamada and co-workers prepared diphenylphosphoryl azide (DPPA, 
216) by treatment of diphenylphosphorochloridate with sodium azide. Reaction of a carboxylic 
acid with an organophosphorus reagent (e.g. DEPC, 217) generates a mixed carboxylic and 
phosphoric anhydride intermediate (219), which exhibits superior regioselectivity towards 
nucleophilic attack than the corresponding mixed anhydride 202 (Scheme 6 8 ).196 An alternative 
mechanism is that the displaced leaving group (azide, chloride or pentafluorophenoxide for 
reagents 216, 217 and 218 respectively) could attack intermediate 219, forming another 
activated species which is in turn attacked by the amine nucleophile to afford the product (as in 
Scheme 67).
\  OPh \  OEt X  X  X o E , 1t OH R O R NHR'
2 1 9
Scheme 68 Organophosphorus peptide coupling reagents
Both Ciufolini’s synthesis of Bycroft-Gowland micrococcin P1 and Moody’s synthesis of 
amythiamicin D utilised DPPA in their macrocyclisation steps. In Ciufolini’s synthesis of BG-MP1 
(83),132 DPPA-mediated macrolactamisation was the final step in the total synthesis, proceeding 
in 65% yield over 3 steps from precursor 95 (Scheme 69).
Macrolactamisation was also the final step in the synthesis of amythiamicin D (23d).75 N- and C- 
terminus deprotection of precursor 27 followed by treatment with DPPA and 
diisopropylethylamine furnished the natural product in excellent yield (73%) over two steps 
(Scheme 70).
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Scheme 69 Synthesis of the Bycroft-Gowland MP1 macrocycle
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Scheme 70 Synthesis of the amythiamicin D macrocycle
Pentafluorophenyl diphenylphosphinate (FDPP, 218) was developed in 1991 by Chen and Xu197 
and has found many applications to date, most notably in macrolactamisation reactions which 
are notoriously difficult to perform in high yield. Indeed, FDPP was used as the 
macrolactamisation reagent in the synthesis of the macrocyclic precursor (49) to GE2270A and 
GE2270T.98 Nicolaou et al. prepared macrocycle 49 from both 48a and 54a following Boc- 
deprotection and subsequent treatment of the linear peptides with FDPP at high dilution in DMF 
(Scheme 71).
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Scheme 71 Macrolactamisation approaches to GE2270A and GE2270T
5.1.6 -  Phosphonium reagents
Castro introduced the first phosphonium reagents (CloP, 220 and BroP, 221) in the early 
1970s.1981"  Amino acids coupled using CloP and BroP tended to exhibit significant degrees of 
racemisation and these reagents were soon superseded by the combined CloP-HOBt and CloP- 
HOAt reagents, BOP (222) and AOP (223). These reagents contain an inbuilt HOBt or HOAt 
nucleophile which reacts with intermediate 224 before racemisation can occur (Scheme 72; see 
also section 5.1.3).200
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Scheme 72 Early phosphonium reagents
All of the phosphonium reagents 220-223 possess one major drawback, namely the generation 
of extremely toxic and carcinogenic HMPA as a side product. For this reason, pyrrolidine 
analogues PyCloP (225), PyBroP (226), PyBOP® (227) and PyAOP (228) were introduced.201 
PyBOP® in particular is widely used in peptide synthesis due to ease of handling, few side
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reactions, the racemisation-suppressing capabilities of the HOBt nucleophile and formation of 
non-toxic by-products.
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5.1.7 -  Uronium reagents
The so-called uronium salts are amongst the most popular peptide coupling reagents in use 
today, functioning well in a wide range of applications including coupling of sterically hindered 
residues, macrolactamisation and even solid phase peptide synthesis.189202 The first uronium 
reagent was 0-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 229), 
introduced by Gross et al. in 1978.203 Since then, a range of analogues have been prepared, 
including the tetrafluoroborate anion analogue (TBTU, 230) and the HOAt analogues HATU (231) 
and TATU (232). It has since been demonstrated that the non-nucleophilic counterion has no 
effect on either reaction rate or degree of racemisation.204
2 2 9  n —  230  n —  231 2 3 2  n
O -H B T U  O -T B T U  O -H A T U  O -T A T U
Figure 22 Initially proposed uronium structures for HBTU and its analogues
The structure of HBTU was initially assigned as the uronium salt 229 by analogy with the 
phosphonium salts such as BOP (222). HATU was synthesised in 1993 and assigned the 
analogous structure (231 ).205 However, further studies indicated that the true structures in both 
the crystalline state206 and in solution were in fact guanidinium salts (N-HBTU, 233 and N-HATU, 
234, Figure 23).
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Figure 23 Guanidinium structures of HBTU and HATU
Preparation of the originally postulated uronium salts of HBTU and HATU (O-HBTU and O- 
HATU, Figure 22) revealed spectroscopic discrepancies with commercially available N-HBTU 
and N-HATU, as well as reactivity differences, confirming the true structures as being the those 
of the guanidinium species (Figure 23).207 Despite this revelation, the acronyms HBTU and 
HATU remain in use and these reagents are still frequently referred to as uronium salts.
HATU is widely regarded as the best peptide coupling reagent prepared to date, performing 
exceptionally well in macrolactamisation reactions.202208 This superiority is illustrated by the use 
of HATU to simultaneously form two peptide macrocycles in Danishefsky’s synthesis of 
hemastatin (Scheme 73).209
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Scheme 73 Use of HATU in the bis-macrocyclisation step of Danishefsky’s hemastatin synthesis
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Thiostrepton (1) possesses two macrocycles, the first of which was cyclised using HATU in 
Nicolaou’s total synthesis of 1.89 Staudinger reaction of 36 followed by treatment of the product 
with HATU, HOAt and diisopropylethylamine, furnished macrocycle 37 in 32% yield from 36 
(Scheme 74).
NH Alloc
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OH OH
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Scheme 74 Formation of the first thiostrepton macrocycle
The second thiostrepton macrocycle was closed using the Yamaguchi macrolactonisation 
protocol, affording advanced intermediate 41 (Scheme 75).210
SePh
DM AP, Et3N
OTBS OTBS
Scheme 75 Formation of the second thiostrepton macrocycle
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Both of the macrocycles of siomycin A (68a) were closed using HATU-mediated peptide 
couplings (Figure 24). The closure of the second macrocycle was conducted in the presence of 
dipeptide fragment 77 and an excess of HATU, enabling macrolactamisation and attachment of 
the side chain to occur in one pot (section 1.4.5, Scheme 12).107
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Figure 24 Positions of HATU-mediated macrolactamisations in the synthesis of siomycin A
5.1.8 -  Alternative macrocyclisation strategies used in thiopeptide synthesis
While the majority of the thiopeptide total syntheses completed to date make use of peptide 
coupling reagents discussed in the preceding sections to form the macrocycle(s), there are 
exceptions to this. The promothiocin A macrocycle was prepared using the Schmidt protocol, 
and Bach’s synthesis of GE2270A features an intramolecular Stille reaction.
5.1.8.1 -  The Schmidt protocol
Moody and Bagley’s total synthesis of promothiocin A (15a) employed the three-step Schmidt 
macrolactamisation protocol211 which had previously been used in their successful total synthesis 
of (+)-nostocyclamide.162 The first step in this method is conversion of the linear peptide 
precursor 235 into the activated pentafluorophenyl ester 236 by coupling with pentafluorophenol 
in the presence of EDCI (Scheme 76). Boc-deprotection of the resulting peptide 236 followed by 
neutralisation with potassium hydrogen carbonate and subsequent basification with triethylamine 
furnished macrocycle 20 in good yield (55%) from 236.66
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Scheme 76 Formation of the promothiocin A macrocycle
An alternative route to the promothiocin A macrocycle 20 was also successfully realised by 
Moody et at. utilising the same Schmidt protocol (Scheme 77).67 Cyclisation in this position 
proved more efficient, proceeding in excellent yield (71% overall from 238).
Scheme 77 Alternative promothiocin A macrolactamisation strategy
5.1.8.2 -  Intramolecular Stille coupling
In keeping with their unique approach to GE2270A via metal-catalysed coupling of thiazole 
moieties to a central pyridine core," Bach et al. made use of an elegant intramolecular Stille 
coupling reaction212 to form macrocycle 67 from linear precursor 66 in excellent yield (75%).
CH2OBn v\ // CH2OBn
aq . K H C 0 3
o o
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Scheme 78 Intramolecular Stille macrocyclisation in Bach’s synthesis of GE2270A
5.2 -  Deprotection of core domain 168
Our initial synthetic route to micrococcin P1 is outlined in Scheme 79. Based on the discovery 
that the ester in the 6 -position of pyridine 171 was readily hydrolysed, whereas the hydrolysis of 
the ester in the 3-position required harsh reaction conditions (section 4.7.2) it was hoped that 
despite the additional thiazoles in the core domain, selective ester hydrolysis would still be 
possible. This would permit coupling of the resulting core domain monoacid (241) with a side 
chain fragment (242), forming advanced intermediate 243, and permitting two possible 
macrolactamisation positions (a and b), depending on whether the backbone segment 139 was 
attached to the N- or C- terminus of 243.
BocN BocN
BocN
Scheme 79 Proposed route to MP1 via core-side chain coupling
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5.2.1 -  Ester hydrolysis with lithium hydroxide
Our initial attempt at the selective hydrolysis of the 6 -position ester of 168 used one equivalent of 
lithium hydroxide in methanol-water. It was hoped that the use of a single equivalent of base 
would minimise any hydrolysis of the more sterically hindered 3-ester. Monitoring of this reaction 
by TLC was straightforward due to the bright blue fluorescence exhibited by the core domain 
chromophore under ultraviolet irradiation at both 254 nm and 360 nm. The reaction appeared 
sluggish, starting material remaining after 18 hours. However, on changing to a more polar TLC 
solvent system, it became apparent that the remaining starting material was due to partial 
hydrolysis of both the 3- and 6 -esters, consuming all of the base added (Scheme 80). The two 
isomeric mono-acids formed (241 and 244) proved to be inseparable by chromatography, 
prohibiting the isolation of the desired product.
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Scheme 80 TLC analysis of the reaction between 168 and one equivalent of lithium hydroxide
The same result was also observed on conducting the reaction in THF-water, 168, 241, 244 and 
245 all present in the reaction mixture even after two weeks. Treatment of 168 with two or more 
equivalents of lithium hydroxide led to the formation of bis-acid 245 as the sole reaction product.
5.2.2 -  Ester hydrolysis with trimethyltin hydroxide
Following the lack of selectivity between the 3- and 6 -esters when lithium hydroxide was used to 
perform the hydrolysis, an alternative reagent was sought. In their syntheses of thiostrepton, 
GE2270A and GE2270E, Nicolaou et al. employed trimethyltin hydroxide to hydrolyse esters, 
finding it to be less harsh than the more traditional lithium hydroxide.213 In both the thiostrepton 
synthesis (Scheme 81), and the GE2270 syntheses (Scheme 82), an intermediate bis-esterwas 
formed which necessitated selective ester hydrolysis prior to macrocyclisation. In neither case 
was selective hydrolysis achieved, a mixture of mono-acids, starting material and bis-acid 
resulting in all cases. Ultimately, this lack of selectivity did not hamper the success of the
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syntheses, as only the desired macrocycles were formed, the unwanted mono-acids (246 and 
48b) failing to cyclise.
NHAIIoc
ITBS
OH
HNNH
OTES S HN//,.
HO'
OTBS
8  eq  M eaS nO H , 
50  °C , 4  h
168  R 1 = M e, R 2 = M e (28 % )
246  R 1 =  M e , R 2 =  H 1 „
36 R ’ = H ,  R2 = M e l ( 5 2 / ")
2 47  R 1 = H , R2 =  H (14 % )
Scheme 81 Attempted selective ester hydrolysis during Nicolaou’s thiostrepton synthesis
NHBoc
Scheme 82 Attempted selective ester hydrolysis during Nicolaou’s GE2270A and E syntheses
Trimethyltin hydroxide also failed to discriminate between the 3- and 6 -esters in 168, returning a 
mixture of compounds similar to that observed by Nicolaou and co-workers (Scheme 83). 
Addition of two equivalents of trimethyltin hydroxide to a solution of 168 at 50 °C at hourly 
intervals (method A) resulted in 51% recovery of 168, a 27% yield of the mixed mono-acids 241 
and 244, and 22% conversion to bis-acid 245. Prolonged reaction with 2 equivalents of 
trimethyltin hydroxide at 50 °C (method B) afforded a mixture of 241 and 244 in 34% yield with 
11% bis-acid 245, the remainder of the material isolated being starting bis-ester 168. Repetition 
of method B using 1.2 equivalents of trimethyltin hydroxide afforded a similar mixture of 
components.
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Scheme 83 Ester hydrolysis using trimethyltin hydroxide
All attempts at coupling either the mixture of esters (241 and 244) or bis-acid 245 with various 
side chain fragments (section 5.5) failed to yield the desired product (243). Separation of the 
numerous products by chromatography proved impossible, and analysis of the crude reaction 
mixtures by mass spectrometry confirmed that no coupling had occurred. Faced with a lack of 
selectivity between the esters and our inability to couple even the bis-acid with side chain 
fragments (242), the proposed synthetic route to micrococcin P1 had to be revised.
5.2.3 -  AFterminus deprotection of 168
Our alternative approach to MP1 is illustrated in Figure 25. This route begins with coupling of N- 
deprotected central heterocyclic domain 248 and C-deprotected backbone pentapeptide 249 to 
furnish intermediate peptide 250. Due to the aforementioned issues with selective ester 
hydrolysis, both the 3-and 6 -esters would then be cleaved, followed by A/-terminus deprotection. 
Based on the literature precedent established by Nicolaou’s syntheses of thiostrepton and the 
GE2270 thiopeptides, it was postulated that the linear peptide would cyclise to form only the 
desired macrocycle 251 which could then be elaborated to the natural product.
/V-deprotection of 168 proved to be unusually facile, furnishing 248 in good yield (Scheme 84).
EtC
O
Reagents and Condtions: i) T F A , C H 2C I2, r.t., 1 h, 7 5 %
Scheme 84 A/-deprotection of 168
106
Chapter 5  -  Assembly of the M P1 Macrocycle
X  E,0!C\
NBoc )
•C02H
Figure 25 Revised disconnection of micrococcin P1
5.3 -  Deprotection of backbone peptide 139
5.3.1 -  Literature methods for AZ-deprotection
Had the initial synthetic approach to the core-side chain fragment of micrococcin (243, Scheme 
79) proved successful, then coupling with backbone pentapeptide 139 could have taken place at 
two possible sites (Scheme 79), requiring either or C- or A/-deprotection of 139.
The difficulties in A/-deprotection of backbone precursor 143 using Ciufolini’s method132 have 
already been discussed (section 3.4.2). It was hoped that eliminated peptide 139 would undergo 
deprotection more readily (Scheme 85). Use of aqueous hydrochloric acid failed to effect 
deprotection, as did treatment with aqueous hydrochloric acid followed by TFA, both methods 
resulting in the disappearance of most of the material, likely due to the formation of water-soluble 
fragments which were lost during aqueous work up. Following the facile A/-deprotection of core 
domain 168 using a 1:1 solution of TFA and dichloromethane, it was hoped that these conditions 
would be applicable to substrate 139, but as with all other attempts, an intractable mixture of 
products was formed.
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Scheme 85 Failed N-deprotection of pentapeptide 139
Fortunately, due to the failure of the selective ester hydrolysis of core domain 168, N- 
deprotection of 139 was no longer necessary, and C-deprotection was investigated instead.
5.3.2 -  C-terminus deprotection
Gratifyingly, C-terminus deprotection of pentapeptide 139 proved to be both facile and reliable, 
with carboxylic acid 249 formed in excellent yield (Scheme 8 6 ) in readiness for coupling with core 
domain 248.
N
H
NBoc
139
9  \ \  N.
j  s ' v «H S
S
u \  ^  N Boc
/ V  249
^ - C 0 2 H
Reagents and Conditions i) L iOH, M e O H -H 20 ,  r.t., 16 h, 8 9 % . 
Scheme 86 C-terminus deprotection of backbone peptide 139
5.4 -  Construction of macrocycle 251
With both the central heterocyclic domain and the peptide backbone segment successfully 
deprotected, the stage was set for the assembly of the micrococcin thiopeptide macrocycle (251).
5.4.1 -  Coupling of core domain 248 and backbone peptide 249
The preliminary attempt at coupling fragments 248 and 249 was made using PyBOP® (227) as 
this reagent had already been used successfully in the synthesis of peptide 143 (section 3.4.1, 
Scheme 39). Addition of a solution of 248 and triethylamine in dichloromethane to a solution of 
249 and PyBOP® in dichloromethane, followed by stirring overnight at room temperature afforded 
the desired product 250 in 33% yield (Scheme 87).
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©
CF3CO2 H
HO
BocN
BocN
o
o
Reagents and Conditions i) 249, PyBO P® , C H 2C I2 , 0  °C , 5  min; then  248, EtsN, C H 2C I2 , r.t., 16 h, 33% ; 
ii) 249, D IP E A , H A TU , C H 2CI2, r.t., 1 h; then 248, D IP E A , C H 2C I2, r.t., 3 .5  h, 77 %
Scheme 87 Synthesis of intermediate 250
Repetition of this reaction on the same scale (~40 mg of 249) using HATU as the coupling 
reagent increased the yield dramatically to 77%. Although consistently more efficient than 
PyBOP®, the yield of the HATU-mediated coupling ranged between 50-77% when scaled up to 
between 40 mg and 130 mg of 249. However, on two occasions, coupling failed completely, 
returning an inseparable mixture of compounds, probably containing both starting materials, 
HATU, the tetramethylguanidinium derivative of 248, HOAt, and numerous other species, none of 
which were the reaction product.
5.4.2 -  Deprotection of fragment 250
Despite the occasional failure of the coupling of 248 and 249, sufficient quantities of advanced 
intermediate 250 were obtained to continue with the synthesis of macrocycle 251 (Scheme 8 8 ). 
It was known from the earlier investigation into ester hydrolysis (sections 5.2.1 and 5.2.2) that 
both the 3- and 6 -positions could be readily deprotected, and lithium hydroxide was the reagent 
of choice owing to the high toxicity of trimethyltin hydroxide. Accordingly, 250 was stirred at 
room temperature with 10 equivalents of lithium hydroxide for 14 hours. Isolation of the product 
proved difficult, and it was decided that on completion of the hydrolysis, the reaction mixture 
would be evaporated and not purified prior to A/-deprotection in the next step, the lithium salt 
being protonated to form the acid under the A/-deprotection conditions.
Following the difficulties in A/-deprotection of peptides 143 and 139, it was with some trepidation 
that the next step was approached. Fortunately, deprotection was effected using HCI-saturated
109
Chapter 5  -  Assembly of the M P1 Macrocycle
ethyl acetate (see section 5.5.4), although the success of the reaction was difficult to verify. Bis- 
acid 253 was insoluble in ethyl acetate, but on sonication formed a fine, pale yellow precipitate. 
Addition of HCI-ethyl acetate resulted in a colour change to give a bright yellow solid, which was 
insoluble in all solvents with the exception of DMF and DMSO. This prevented analysis of 
compound 254 by mass spectrometry, and due to the scarcity of material, NMR analysis in d6- 
DMSO was not undertaken.
Reagents and Conditions i) L iO H , M eO H -hfeO , r.t., 14  h; ii) H C I-E tO A c , EtO A c, r.t., 1 h.
Scheme 88 Deprotection of fragment 250
5.4.3 -  Macrolactamisation
Based on literature precedent, it was hoped that precursor 254 would cyclise to form macrocycle 
251, and not 255 (Scheme 89). In their synthesis of the GE2270 macrocycle, Nicolaou et al. 
used FDPP to effect cyclisation, and obtained only the correct macrocycle. For this reason, 
cyclisation of 254 with FDPP was investigated. Monitoring of the reaction proved difficult due to 
the extremely polar nature of the starting material. Proton NMR analysis of the crude mixture 
following evaporation of the solvent revealed only FDPP. As no product was observed, it was 
decided that HATU would be used as the macrolactamisation reagent, based on its successful 
use in the syntheses of thiostrepton and siomycin A, and also in the coupling of fragments 248 
and 249. A solution of 254, diisopropylethylamine and HATU in DMF at high dilution (1 mM) 
was stirred at room temperature for 45 hours, then evaporated in vacuo. Analysis of the reaction 
mixture by mass spectrometry showed a peak at m/z 1004 (Appendix 1), corresponding to the 
[M+H]+ of macrocycle 251. The residue was triturated with ethyl acetate, leaving an off-white 
solid. In order to remove the HATU and base, the solid was partitioned between chloroform and 
5% acetic acid solution. A pale brown solid remained between the organic and aqueous layers,
>
BocN BocN
o
o o o
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which was subsequently found to be the macrocycle, formed in excellent yield (85% over three 
steps, Scheme 90). Unfortunately, the macrocycle was insoluble in all solvents except DMSO, 
DMF and pyridine, making characterisation and verification of its identity as either 251 or 255 
impossible. It was hoped, as found in the syntheses of thiostrepton and siomycin A, that the 
identity of the macrocycle would be confirmed following elaboration to the natural product and 
spectroscopic comparison with natural material.
i©e
n h 3c i
Scheme 89 Possible macrocycles formed from linear precursor 254
BocN
HN
EtO
'"OH
254
EtO,
O
HN p H
HN
OH
251
HO.
o
Reagents and Conditions i) L iO H , M e O H -H 20 ,  r.t., 14  h; ii) H C I-E tO A c, EtO A c, r.t., 1 h; iii) H A T U , 
D IP E A , D M F , r.t., 2 4  h, 8 5 %  (3  steps)
Scheme 90 Synthesis of macrocycle 251
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5.5 -  Synthesis of the MP1 side chain
The dipeptide side chain of micrococcin P1 was synthesised adorned with different combinations 
of protecting groups in order to allow greater flexibility once attached to macrocycle 251 for 
elaboration to the natural product.
QTBS
BocHN
O O O
256 257 258
5.5.1 -  Synthesis of side chain fragment 256
Protected dipeptide 256 was synthesised from A/-Boc-(2S,3/:?)-threonine in three steps and 98% 
overall yield (Scheme 91).
BocHN
O O O O
135 259 256
Reagents and Conditions: i) 2 ,2 -D M P , P P TS , T H F , reflux, 6  h, 1 00% ; ii) (f? )-1 -am ino -2-propano l, P yB O P ® ,
E t3N, C H 2CI2, r.t., 18 h, 100% ; iii) A c20 ,  pyridine, r.t., 48  h, 9 8 % .
Scheme 91 Synthesis of side chain fragment 256
5.5.2 -  Synthesis of side chain fragment 257
Protected dipeptide 257 was synthesised from A/-Boc-(2S,3/:?)-threonine in three steps and 55% 
overall yield (Scheme 92). TBDMS-protection of threonine was achieved using TBDMS-triflate in 
dichloromethane, followed by treatment with aqueous base to hydrolyse the intermediate silyl 
ester to the desired carboxylic acid 260.
BocHNBocHN BocHNBocHN
O O O O
260 261 257
Reagents and Conditions: i) T B D M S O T f, Et3N, C H 2C I2, r.t., 2  h; then  K2C 0 3, M e O H -H 20 ,  r.t., 2  h, 100% ; 
ii) (fl)-1 -a m in o -2 -p ro p a n o l, P yB O P ® , Et3N , C H 2C I2, r.t., 18  h, 6 5 % ; iii) A c20 ,  pyridine, r.t., 48  h, 8 4 % .
Scheme 92 Synthesis of side chain fragment 257
112
Chapter 5  -  Assembly of the M P1 Macrocycle
5.5.3 -  Synthesis of side chain fragment 258
Side chain peptide 258 was synthesised in three steps and 98% overall yield from A/-Boc- 
(2S,3fl)-threonine (Scheme 93), via intermediate 259 which had previously been used to prepare 
fragment 256.
OTBS
BocHN
O O O  O
135 259 258
Reagents and Conditions: i) 2 ,2 -D M P , P P T S , T H F , reflux, 6  h, 100% ; ii) ( /^ -1 -a m in o -2 -p ro p a n o l, P yB O P ® ,
E t3N, C H 2C I2, r.t., 18 h, 100% ; iii) Im idazole, D M A P , T B D M S C I, D M F , 3 6  h, 9 8 % .
Scheme 93 Synthesis of side chain fragment 258
5.5.4 -  Selective removal of Boc in the presence of TBDMS
Side chain fragments 257 and 258 contain ferf-butoxycarbonyl and fe/t-butyldimethylsilyl 
protecting groups, both of which are acid-labile. Prior to coupling with the micrococcin 
macrocycle, Boc-deprotection is necessary, but this must be conducted in such a way that the 
TBDMS group remains intact. Failure to do so would result in a fragment containing two 
unprotected secondary alcohols (262), thereby preventing selective elimination of the threonine 
residue to the dehydrodemethylvaline unit present in the natural product.
coupling elim ination
O O O  o
258 262
Scheme 94 Problems caused by accidental TBDMS deprotection.
Fortunately, a detailed investigation into the selective A/-Boc deprotection in peptides containing 
TBDMS-protected alcohols had been undertaken by Cavelier and Enjalbal, in which a wide range 
of reagents and conditions were screened.214 The most effective reagent was found to be a 
saturated solution of HCI in ethyl acetate. This reagent was prepared and used in the Boc- 
deprotection of side chain fragment 257; analysis of the reaction mixture by mass spectrometry 
indicated that after 30 minutes at room temperature, the major component of the reaction mixture 
was the desired product 263 (Appendix Two). This reagent was also successful in A/-terminus 
deprotection of macrocycle precursor 253.
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o
263
5.6 -  Elaboration of macrocycle 251 to MP1
With both the micrococcin P1 side chain and the macrocycle in hand, the final approach towards 
the natural product was undertaken. It was hoped that coupling of macrocycle 251 and fragment 
263 (derived from dipeptide 257) would afford the carbon framework of the natural product (264) 
and that this intermediate could be readily elaborated to micrococcin P1 in four further steps 
(Scheme 95).
HN OH
HN
HN,
OH
251
N —
HO.
HN PH
QAc HN
S\ ^ N AC2O, pyridine  
| ii) H F -p yrid in e263
iii) M sC I, Et3N
iv) LiOH
H A T U , D IP E A , D M F
OH
264
N —
AcO
TBSO'
Scheme 95 Initial proposal for the elaboration of 251 to micrococcin P1
Following coupling of the side chain dipeptide, acetate protection of the two free alcohols and 
removal of the TBDMS group using a fluoride source would afford the substrate for mesylation 
and elimination. This would install the final dehydrodemethylvaline residue, and subsequent 
global deprotection of the three remaining acetate groups would furnish the natural product.
5.6.1 -  One-pot macrolactamisation and side chain coupling
The first attempt at preparation of intermediate 264 was via a one-pot cyclisation-side chain 
elongation strategy as used by Hashimoto and co-workers in the final stages of their total 
synthesis of siomycin A .107 To this end, a solution of macrocycle precursor 254, side chain 
fragment 263, HATU and DIPEA in DMF was stirred at room temperature and the reaction 
monitored by TLC. The only identifiable product from this reaction was macrocycle 251, isolated
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in 35% yield. Treatment of 251 with HATU, DIPEA and a solution of side chain fragment 265 
afforded a mixture of unidentifiable products, which appeared to possess a TBDMS protecting 
group. It was therefore decided that the products should be subjected to acetate protection using 
acetic anhydride in pyridine (Scheme 96), in an attempt to improve the solubility and thus aid 
purification and identification. By 1H-NMR it was determined that these reaction conditions had 
cleaved the TBDMS protecting group, which would leave all four secondary alcohols protected 
identically (267), preventing successful completion of the total synthesis (Appendix Three).
HN HN
TBSO". OH HN HN
265 HN,
251
OH OAc
266 267
N — N = -
HO AcO
TBSO' AcO'
Reagents and Conditions: i) 251 , H A T U , D IP E A , D M F , r.t., 1 h; then  265, D IP E A , D M F , r.t., 7 2  h; ii) AC2O, 
pyridine, r.t., 62  h.
Scheme 96 Attempted acetate protection of intermediate 266
5.6.2 -  Acetate protection of macrocycle 251
Armed with the knowledge that the conditions used for acetate protection could cleave a TBDMS 
protecting group, it was decided that macrocycle 251 would be protected prior to coupling with 
side chain peptide 269 (derived from 256), the resulting product 270 then requiring only 
mesylation-elimination and acetate removal to furnish the natural product (Scheme 97). Due to 
the poor solubility and scarcity of material, verification of the success of acetate protection of 251 
by 1H-NMR was not possible. It was hoped that submitting the material to the remaining steps in 
the synthesis would afford the natural product, thus confirming the identities of all intermediate 
species. Analysis of the reaction mixture by thin layer chromatography prior to the final 
deprotection step indicated that there was a single compound present, which exhibited 
characteristic blue fluorescence under UV irradiation (Figure 26). Encouragingly, this compound 
had a higher Rf than micrococcin P1, as predicted due to the three hydroxyl groups being 
protected in proposed structure 271. Unfortunately, the natural product remained elusive and
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was not identified among the mixture of compounds produced on treatment with lithium 
hydroxide.
HNHN PAc PA c
HO OAc HN
269 iii - iv)HN,HN,
251
OAcOAc
270268
N —
AcO
HO’
Reagents and Conditions: i) 251, AC2 0 , pyridine, r.t., 2 4  h; ii) 268, H A T U , D IP E A , D M F , r.t., 1 h; then 269, D IP E A , 
D M F , r.t., 2 4  h; iii) M sC I, Et3N , C H 2C I2, r.t., 1 h; then D B U , C H C I3, r.t., 2  h; iv) L i0 H .H 20 ,  M e 0 H -H 20 ,  r.t., 12  h.
Scheme 97 Acetate protection of 251 and attempted elaboration to the natural product
HN
HN
HN,
OH
after
reaction
N = r
HO
HN OAc
HN
27 1 — -
OAc
271
b efo re
reaction
N —
AcO
Figure 26 Attempted deprotection of 271 to form micrococcin P1 
5.6.3 -  TBDMS-protection of macrocycle 251
Following the failure of the acetate-protected macrocycle route (Scheme 97), TBDMS-protection 
of the alcohols in 251 was investigated. The proposed synthetic route is outlined in Scheme 98.
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HNHN P  TBS
QTBS HN
273HN, HN,
251 MP1 (4)
HATU, DIPEA, DMF
OTBSOTBS
274272
HO.
TBSO
HO'
Reagents and Conditions: i) TBDMSOTf, Et3N, DMF, r.t., 18 h; or TBDMSOTf, imidazole, DMF, 50 °C, 24 h.
Scheme 98 Proposed synthesis of MP1 via TBDMS-protected macrocycle 272
Treatment of macrocycle 251 with fert-butyldimethylsilyl triflate and triethylamine in DMF at room 
temperature failed to yield 272, the starting material being recovered in 67% yield. Repetition of 
the reaction using imidazole in place of triethylamine, and heating the mixture at 50 °C resulted in 
the apparent decomposition of the macrocycle.
5.7 - Conclusion
The micrococcin thiopeptide macrocycle has been synthesised in 20 steps and 4% overall yield 
from A/-Boc-(2S,3H)-threonine. Three micrococcin P1 side chain dipeptides have been prepared, 
each bearing different protecting groups, allowing for a range of synthetic strategies in the final 
stages of the total synthesis.
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6 -  Reinvestigation of the Stereochemistry of Cyclothiazomycin
6.1 -  Introduction
Cyclothiazomycin (275) is an unusual series d thiopeptide that possesses a number of unique 
structural features. First isolated from the fermentation broth of Streptomyces sp. NR0516 from 
a soil sample collected at Kanagawa, Japan,215 initial work towards structure determination used 
high-resolution FAB mass spectrometry, elemental analysis and 13C and 1H NMR spectroscopy. 
The spectroscopic data was supported by chemical degradation studies, acidic hydrolysis 
generating an unusual pyridine-containing y-amino acid as lactam 276 and saramycetic acid 
(277).216 NOESY experimental data was used in the elucidation of both the structure and 
stereochemistry of cyclothiazomycin, the latter supported by amino acid analyses, and showed 
this unique series d thiazolyl peptide lacked the characteristic 2- and 3-azole substituents on the 
central domain. Cyclothiazomycin was found to possess an alanine-derived heterocyclic residue, 
reportedly of (/^-configuration, quaternary sulfide and two macrocyclic peptide loops (Figure
Figure 27 Proposed structure of cyclothiazomycin and its degradation products
Although no antibacterial data has been associated with cyclothiazomycin, which also lacks the 
characteristic polydehydroalanine side chain implicated in tipA promoter activity, this thiopeptide 
is biologically active, functioning as an inhibitor of human plasma renin, with an IC5o of 1.7 pM.
6.1.1 -  Chemical degradation of cyclothiazomycin
Acidic hydrolysis of cyclothiazomycin was conducted by heating 275 in 6  M hydrochloric acid at 
110 °C for 18 hours. In addition to isolating 276 and 277, one equivalent each of glycine, L-
27).217
c o 2hy-lactam 276
.co2h
c o 2h
o
cyclothiazomycin (275) saramycetic acid (277)
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threonine, L-proline and L-aspartic acid were isolated, along with four equivalents of L-cysteine, 
determined by HPLC.216217 The optical rotation of y-lactam 276 was not reported, and the 
configuration of its alanine-derived stereogenic centre assigned purely on the basis of NOE data.
6.1.2 -  Isolation of new cyclothiazomycins
In 2006, Hashimoto and co-workers reported the isolation of two new cyclothiazomycin 
thiopeptides, named cyclothiazomycin B1 (278) and cyclothiazomycin B2 (279), from 
Streptomyces sp. A307.218 Both of these thiopeptides were reported to exhibit antifungal activity, 
with cyclothiazomycin B1 also acting as a bacterial RNA polymerase inhibitor.
c ycb th iazo m yc in  (275 ) R
DHAA-i = (Z)
cycb th ia zo m y c in  B1 (278 ) R
DHAA-i = (£)
DHHAi
cycb th ia zo m y c in  B2 (279 ) R
CO2H
DHAA-i = (Z)
Figure 28 Cyclothiazomycins B1 and B2
Hashimoto et at. determined the structures of 278 and 279 using 1H- and 13C-NMR, COSY, 
NOESY, ROESY and HMBC data in conjunction with tandem MS-MS (MALDI-TOF/TOF) studies. 
The absolute stereochemical configurations of the amino acids were determined by acidic 
hydrolysis of the natural products followed by treatment with Marfey’s reagent (109, section 2.3) 
and HPLC analysis. Acidic hydrolysis of 278 and 279 under the same conditions employed by 
Aoki et al. in their degradation of cyclothiazomycin 275 afforded saramycetic acid (277) and 
pyridine domain 280 which surprisingly failed to cyclise to lactam 276. In order to facilitate study 
by NMR spectroscopy, pyridine bis-acid 280 was esterified to give the dimethyl derivative 281.
c o 2h
2 7 7 2 8 0
MeO'
281 C 02M e
Figure 29 Degradation products from the acidic hydrolysis of cyclothiazomycins B1 and B2
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The stereochemistry of the alanine-derived stereogenic centre was not assigned, although it was 
proposed that the centre should be of (S)-configuration, i.e. derived from natural L-alanine. This 
is at variance with the presently accepted structure of cyclothiazomycin (275), and based on our 
previous findings relating to the valine stereochemistry in the micrococcin thiopeptides, it was 
deemed worthy of further investigation.
6.2 -  Reinvestigation of the stereochemistry of cyclothiazomycin
The synthesis of cyclothiazomycin lactam 276 had previously been completed within our 
laboratory using the Bohlmann-Rahtz pyridine synthesis (Scheme 99) .143
N H 4O A c
BocHNBocHN
BocHN
> 9 9 %  ee
HN,
a ) 6  M  HCI, then  U O H , then P S -D M A P
b) 6  M  HCI
EtO
BocHN
9 2 %  ee
M eth o d  a): R  = H (2 7 6 ), 8 8 %  e e  
M eth o d  b): R  = E t (2 8 3 ), 9 4 %  ee
Scheme 99 Synthesis of cyclothiazomycin y-lactam 276
Discussions with Prof. Hashimoto revealed that treatment of pyridine methyl ester 281, derived 
from material isolated from the degradation of cyclothiazomycin B1 with sodium hydrogen 
carbonate in methanol resulted in the formation of lactam 284 (Scheme 100). It was therefore 
decided that lactam methyl ester 284 would be synthesised via the same synthetic route as 
lactam 276, using thiazole alkynone 170 (section 4.6.1) in place of 282 (Scheme 99). 
Deprotection route b) would be employed in order to cleave the A/-Boc group and form the 
lactam, leaving the methyl ester intact. Comparison of the material isolated from the natural 
product with that prepared via the route outlined above would permit the determination of the 
absolute configuration of the alanine residue in the central domain of the cyclothiazomycin 
thiopeptides.
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MeO
MeOH
281
HN,
284
Scheme 100 Conversion of pyridine 281 into lactam 284
6.2.1 -  Synthesis of lactam 284
Our first synthesis of lactam 284 was achieved by the esterification of a 4 milligram sample of 
lactam 276 previously prepared in our laboratory (Scheme 101 ).,v Lactam 276 was heated at 
reflux in methanol with a trace of 6 M hydrochloric acid for three hours. The product was 
identical to that obtained by Hashimoto et al. by 1H-NMR (Appendix Four), but the enantiomeric 
excess found to be only 6% by HPLC on a chiral stationary phase (Figure 30).v
HN,
284
HN,
2 7 6
Scheme 101 Preparation of 284 by esterification of 276
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Figure 30 HPLC analysis of lactam 284 prepared by esterification of 276
lv Lactam 276 prepared by Dr. Xin Xiong; for experimental details, see ref. 143
v Chiralcel OD column, eluting with /-PrOH:hexane (10:90), 1.00 ml min'1, detected at 314 nm, retention 
times: (S)-enantiomer = 32 min, (ft)-enantiomer = 64 min.
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In the light of the poor enantiomeric excess of the lactam obtained via esterification of 276, it was 
decided that 284 would be prepared from A/-Boc-(/^-alanine (Scheme 102).
rBocHN v. x N s
I °
BocHN
«) EtO
BocHN
2 8 5 2 88
iii)
C02Me 2 8 4 C02Me
BocHN C02Me C 0 2Me
BocHN
Reagents and Conditions: i) EtOCOCI, EtaN, THF, -10 °C, 30 mins; then LDA, EtOAc, -78 °C, 1 h, 30%; ii) NH 4OAC, 
EtOH, 50 °C, 20 h; then 170 , r.t., 2.5 h; then NIS, 0 °C, 30 min, 36%; iii) 6  M  aq. HCI, r.t., 6  h.
Scheme 102 Synthesis of lactam 284 from A/-Boc-(/7)-alanine
Despite its similarity to the route used in the successful synthesis of 276, the preparation of 284 
proved extremely challenging. (3-Ketoester 286 was prepared as a single enantiomer from N- 
Boc-(/?)-alanine in 30% yield by treatment of the mixed anhydride with the lithium enolate of ethyl 
acetate.^ The conversion of 285 to enamine 286 was found to be sluggish and prone to 
racemisation. At room temperature, the reaction was complete by TLC analysis after 20 hours, 
but the enantiomeric excess of the product was only 61% (Figure 31 ).vn Pyridine 288 was 
prepared from (3-ketoester 285 by sequential treatment with ammonium acetate, thiazole 
alkynone 170 (to form aminodienone intermediate 287) and finally NIS to furnish the desired 
pyridine. The poor yield of this reaction is likely due to the decomposition of unstable alkynone 
170 (section 4.6.1) throughout the course of the reaction. Due to the poor yields of the preceding 
steps, pyridine 288 was obtained in extremely small quantities. Final Boc-deprotection and 
spontaneous cyclisation afforded the desired lactam 284 with an enantiomeric excess of 47% 
(Figure 32).Vl" While the material obtained was not enantiomerically pure, comparison with the 
HPLC trace obtained for the sample of 284 prepared from 276 (Figure 30) confirmed the
Vl ChiralPak AD column, eluting with /-PrOH:hexane (1:99), 1.00 ml min'1, detected at 244 nm, retention 
times: (F7)-enantiomer = 39 min.
v" ChiralPak AD column, eluting with /-PrOH:hexane (5:95), 1.00 ml min'1, detected at 273 nm, retention 
times: (fl)-enantiomer = 16 min, (S)-enantiomer = 23 min.
Vl" Chiralcel OD column, eluting with /-PrOH:hexane (10:90), 1.00 ml min'1, detected at 314 nm.
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retention times of (S)- and (R)-284 as 32 and 64 minutes respectively, paving the way for HPLC 
analysis of the lactam isolated from the natural product.
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Figure 31 HPLC analysis of enamine 286
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Figure 32 HPLC analysis of lactam 284 prepared from A/-Boc-(F?)-alanine
6.2.2 -  HPLC analysis of lactam 284
A sample of lactam 284 was provided by Prof. Hashimoto for HPLC analysis and comparison 
with our synthetic material, in order to verify the stereochemistry of the alanine residue in the 
core domain of the cyclothiazomycin thiopeptides. HPLC analysis of two synthetic samples of 
284 derived from (R)-alanine confirmed the retention times of (S)- and (R)-284 as 32 and 64
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minutes (Figures 30 and 32). The sample derived from the natural product was then analysed 
under the same conditions (Figure 33).IX
VWD1 A. Wave*ength=314 nm (MCB\EAMJAP2 D)
mAU
0 8
0.6 -
0 4
0.2
V->
0
-0.2
-0.4 -
Figure 33 HPLC analysis of lactam 284 derived from cyclothiazomycin B1
The sample was found to have undergone partial racemisation under the degradation conditions 
used, which is unsurprising given the observed propensity for racemisation encountered during 
the syntheses of 284, particularly when employing acidic reagents (Scheme 101, Figure 30). 
Despite this, the enantiomeric of the lactam was found to be 61%, with the (S)-enantiomer 
(retention time 32 minutes) predominating. This result implies that the absolute stereochemistry 
of the alanine residue in the core domain of the cyclothiazomycin thiopeptides is S, and that the 
initial assignment as R based on nOe data is erroneous.216,217
6.3 -  Conclusion
HPLC analysis of degradation products from newly isolated cyclothiazomycin thiopeptides and 
comparison with synthetic material has provided evidence that the stereochemistry of the 
alanine-derived heterocyclic residue in the cyclothiazomycin core domain has been incorrectly 
assigned as R. On the basis of these findings, it is proposed that the absolute stereochemistry 
should be revised to S.
IX Chiralcel OD column, eluting with /-PrOH:hexane (10:90), 1.00 ml min'1, detected at 314 nm.
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7.1 -  Reinvestigation of MP1 stereochemistry by chemical degradation studies
Chemical degradation studies on micrococcin P1 have established that the stereochemistry of 
the valine residue in the natural product is S and not R as previously assigned in the literature. 
This confirms Ciufolini’s hypothesis that the Bycroft-Gowland structure of MP1 differs from the 
natural product on stereochemical grounds.
7.2 -  Modification of the Hantzsch thiazole synthesis
A range of conditions for the synthesis of amino acid-derived thiazoles have been investigated 
and previously reported conditions found to be unreliable. Evidence has been provided to 
suggest that racemisation in the Hantzsch thiazole synthesis occurs in the elimination step of the 
reaction. The peptide backbone of micrococcin P1 has been prepared in 10 steps and 44% 
overall yield, incorporating S-valine based on the results of our degradation studies.
7.3 -  Synthesis of the central heterocyclic domain of MP1
A microwave-assisted method for the conversion of sterically hindered |3-ketoesters to enamines 
has been devised, which is suitable for single- and multimode instruments, and for scale-up to 
produce multigram quantities of material. The central heterocyclic domain of the micrococcin 
thiopeptides has been prepared in 15 steps and 9% overall yield via a highly convergent strategy 
incorporating the Bohlmann-Rahtz pyridine synthesis and featuring an efficient two-directional 
thiazole elaboration.
7.4 -  Assembly of the MP1 macrocycle
The micrococcin thiopeptide macrocycle has been synthesised in 20 steps and 4% overall yield. 
Three micrococcin P1 side chain dipeptides have been prepared, each incorporating different 
protecting groups, enabling a range of different approaches to the natural product to be 
investigated.
7.5 -  Reinvestigation of the stereochemistry of cyclothiazomycin
HPLC analysis of degradation products from newly isolated cyclothiazomycin thiopeptides and 
comparison with synthetic material has provided evidence that the alanine-derived residue in the 
cyclothiazomycin core domain is of S stereochemistry, and not R as previously assigned in the 
literature.
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8.1 -  Experimental techniques
Commercially available reagents were used without further purification; solvents were dried by 
standard procedures. Petroleum ether refers to the fraction with bp 40-60 °C, ether (Et20 ) refers 
to diethyl ether and EtOAc refers to ethyl acetate. Column chromatography was carried out 
using Merck Kieselgel 60 H silica or Matrex silica 60. Analytical thin layer chromatography was 
carried out using aluminium-backed plates coated with Merck Kieselgel 60 GF254 that were 
visualised under UV light (at 254 and/or 360 nm). Melting points (mp) were determined on a 
Kofler hot stage apparatus and are uncorrected. Infra-red (IR) spectra were recorded in the 
range 4000-650 cm-1 on a Perkin-Elmer 1600 series FTIR spectrometer using KBr disks, as a 
nujol mull between NaCI plates, or in CH2CI2 for solid samples, or as a thin film between NaCI 
plates for liquid samples and are reported in cm-1. Nuclear magnetic resonance (NMR) spectra 
were recorded in CDCI3 at 25 °C unless stated otherwise using a Bruker DPX 400, Bruker 
Avance 250 or Bruker DRX 500 instrument operating at the frequency stated and are reported in 
ppm; J values are reported in Hz and multiplicities are expressed by the usual conventions (s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad, app = apparent, m = multiplet). Low- 
resolution mass spectra (LRMS) were recorded using a Fisons VG Platform II Quadrupole 
instrument using the ionisation method stated. APCI refers to atmospheric pressure chemical 
ionisation, ES refers to electrospray ionisation, Cl refers to chemical ionisation (ammonia) and El 
refers to electron impact ionisation. High-resolution mass spectra were obtained courtesy of the 
EPSRC Mass Spectrometry Service at Swansea, UK using the ionisation methods specified. 
Microanalyses were recorded courtesy of Warwick Analytical Services Ltd. at University of 
Warwick Science Park, UK using an Exeter 440 Elemental Analyser. Specific rotations were 
measured at the indicated temperature using an AA-1000 (Optical Activity Ltd) polarimeter at the 
sodium D line and are given in deg cm3 g~1 dm-1 with concentration c in 1CT2 g cm-3. HPLC was 
carried out using a HP-1100 HPLC machine equipped with a variable wavelength UV detector 
and variable flow pump. In vacuo refers to evaporation at reduced pressure using a rotary 
evaporator and diaphragm pump, followed by the removal of trace volatiles using a vacuum (oil) 
pump.
8.2 -  General experimental methods
8.2.1 -  General method for the derivatisation of amino acids with Marfey’s reagent
Amino acid (125 pmol) was dissolved in water (2.5 mL) and a solution of Marfey’s reagent (1% in 
acetone, 47.6 mg, 175 pmol, 1.4 equiv, in 4.76 mL acetone) added. Aqueous sodium hydrogen 
carbonate (1 M, 1 mL, 1 mmol) was added and the solution stirred at 35 °C for 1 h. The reaction
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mixture was allowed to cool to room temperature, aqueous hydrochloric acid (2 M, 0.5 mL, 1 
mmol) was added and the solution extracted with ethyl acetate ( 3 x 2  mL). The combined 
organic extracts were dried (Na2S 0 4) and the solvent removed in vacuo to afford the product.
8.3 - Experimental
(S)-2-(5-Fluoro-2,4-dinitrophenylamino)propanamide (Marfey’s reagent, 109)
(S)-Alaninamide hydrochloride (472 mg, 3.79 mmol) was dissolved in aqueous sodium hydroxide 
solution (1 M, 3.90 mL, 3.90 mmol) and acetone (60 mL) added. Anhydrous magnesium 
sulphate (10 g) was added and the solution stirred at room temperature for 3 hours. The solution 
was filtered and added dropwise to a stirred solution of 1,5-difluoro-2,4-dinitrobenzene (668  mg, 
3.27 mmol) in acetone (15 mL). The reaction mixture was stirred at room temperature for 30 
minutes, water (75 mL) added and the acetone removed in vacuo. Filtration of the resulting 
aqueous solution afforded the title compound (596 mg, 67%) as a bright yellow solid, mp 235- 
237 °C (acetone) (Found: [M+H]+, 273.0627. Calc, for C9I-L0N4O5F: 273.0630); [a]D25 +60.4 (c 
0.50, acetone); vmax(CH2CI2)/cm-1 3440, 3339, 3167, 2925, 1687, 1668, 1643, 1632, 1582, 1500, 
1423, 1365, 1333, 1287, 1172, 1117, 1057, 1037, 925, 837, 739; 5H(400 MHz; d6-DMSO) 9.05 (1 
H, d, J 6.4, NHCHCH3), 8.84 (1 H, d, J 8.2, 6 -H), 7.68 (1 H, s, NH2), 7.46 (1 H, s, NH2), 6.90 (1 H, 
d, J 14.4, 3-H), 4.33 (1 H, app. quin, J 6 .8 , NHCHCH3), 1.38 (3 H, d, J 6 .8 , CHCH3); 5C(67 MHz; 
DMSO) 172.3 (C), 147.7 (C), 147.5 (C), 127.4 (CH), 102.1 (CH, d, J 29), 51.6 (CH), 18.3 (CH3), 
doublets for CF and FCCN02 not observed; m/z(ES+) 311 ([M+K]+, 100%), 295 ([M+Na]+, 50%), 
228(19), 140 (12).
(S)-2-(5-(( S)-1 -Amino-1 -oxopropan-2-y lamino)-2,4-dinitropheny lamino)-3-methy Ibutanoic 
acid (110a)
c o 2h
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The title compound was prepared according to general method 8.2.1 using (S)-valine. Isolated 
as a bright yellow solid, mp 165-168 °C (acetone) (Found: [M+Na]+, 392.1174. Calc, for 
Ci4H19N50 7 Na: 392.1177); [a]D25 -76.0 (c 0.25, acetone); vmax(CH2CI2)/crn'1 3100-2000 br, 2915, 
1674, 1659, 1614, 1559, 1524, 1469, 1398, 1383, 1343, 1248, 1192, 1127, 1087, 1032, 926; UV 
(MeCN-TEAP [25 mM, pH 3], 1:1)/nm Amax 338 (e 25902.5 mol'1 dm3 cm'1); 6H(250 MHz; d6- 
DMSO) 9.00 (1 H, s, f), 8.92 (1 H, br d, J 7 .0, h), 8.63 (1 H, brd, J 6.5, e), 7.81 (1 H, s, a), 7.41 
(1 H, s, b), 5.73 (1 H, s, g), 4.28 (1 H, br app. quin, J 6.5, c), 4.07 (1 H, br m, i), 2.22 (1 H, br m, 
j), 1.44 (3 H, d, J 6.7, d), 1.06 (3 H, d, J 6.7, k), 0.93 (3 H, d, J 6.7, I); m/z (ES+) 408 ([M+K]+, 
25%), 392 ([M+Na]+, 100%), 324 (50), 280 (7).
(2S,3/=?)-2-(5-((S)-1-Amino-1-oxopropan-2-ylamino)-2,4-dinitrophenylamino)-3- 
hydroxybutanoic acid (110c)
109
Ha
Hb
110ch HN OH
The title compound was prepared according to general method 8.2.1 using (2S,3R)-threonine. 
Isolated as a bright yellow solid, mp 141-144 °C (acetone) (Found: [M+H]+, 372.1165. Calc, for 
Ci3H18N50 8: 372.1155); [a]D25 -25.6 (c 0.25, acetone); vmax(CH2CI2)/crn'1 3100-2000 br, 2915, 
2845, 1609, 1564, 1529, 1479, 1408, 1383, 1343, 1248, 1192, 1032, 911, 796; UV (MeCN-TEAP 
[25 mM, pH 3], 1:1)/nm Amax 342 (e  27579.5 mol'1 dm3 cm'1); 6H(250 MHz; d6-DMSO) 9.02 (1 H, s, 
f), 8.86 (1 H, brd, J6.6, h), 8.83 (1 H, brd, J6.6, e), 7.77 (1 H, s, a), 7.47 (1 H, s, b), 5.75 (1 H, 
s, g), 4.40-4.18 (3 H, m, c, i, j), 1.40 (3 H, d, J 6.7, d), 1.16 (3 H, d, ^ 6.1, k); m/z (ES+) 394 
([M+Na]+, 100%), 305 (37), 217 (18), 140 (11).
(S)-2-(5-((S)-2-Hydroxypropylamino)-2,4-dinitrophenylammo)propanamide (110d)
(S)-(+)-1-Amino-2-propanol (9.4 mg, 125 pmol) was dissolved in water (2.5 mL) and a solution of 
Marfey’s reagent (1% in acetone, 47.6 mg, 175 pmol, 1.4 equiv, in 4.76 mL acetone) added.
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Aqueous sodium hydrogen carbonate (1 M, 1 mL, 1 mmol) was added and the solution stirred at 
35 °C for 1 h. The reaction mixture was allowed to cool to room temperature, aqueous 
hydrochloric acid (2 M, 0.5 mL, 1 mmol) added and the resulting solution analysed by reverse- 
phase HPLC.
(S)-2-(5-((fi)-2-Hydroxypropylamino)-2,4-dinitrophenylamino)propanamide (HOe)
(H)-(-)-1-Amino-2-propanol (9.4 mg, 125 pmol) was dissolved in water (2.5 mL) and a solution of 
Marfey’s reagent (1% in acetone, 47.6 mg, 175 pmol, 1.4 equiv, in 4.76 mL acetone) added. 
Aqueous sodium hydrogen carbonate (1 M, 1 mL, 1 mmol) was added and the solution stirred at 
35 °C for 1 h. The reaction mixture was allowed to cool to room temperature, aqueous 
hydrochloric acid (2 M, 0.5 mL, 1 mmol) added and the resulting solution analysed by reverse- 
phase HPLC.
(S)-A/-ferf-(Butoxycarbonyl)valine (116)
Sodium hydroxide (0.75 g, 18.78 mmol, 1.1 equiv) and di-terf-butyldicarbonate (4.10 g, 18.78 
mmol, 1.1 equiv) were added to an ice-cold solution of (S)-valine (2.00 g, 17.07 mmol, 1.0 equiv) 
in water-tert-butanol (1:1, 40 mL), and the mixture stirred at 0 °C for 1 hour, warmed to room 
temperature and stirred for a further 14 hours. The mixture was concentrated to half-volume and 
extracted with light petroleum (20 mL) and the aqueous layer was acidified to pH 1-2 with ice- 
cold 1 M H2S 0 4. The resulting solution was extracted with ethyl acetate ( 3 x 1 5  mL) and the 
combined organic extracts were dried (Na2S 0 4), filtered and evaporated in vacuo to give a 
colourless viscous oil (4.05 g). After drying in vacuo for 48 h, the title compound (3.96 g, 98%) 
was obtained as a colourless solid, mp 78-80 °C (EtOAc) (Found: [M+H]+ 218.1388. Calc, for 
Ci0H20NO4: 218.1387); [a]D17 -6.4 (c 1.0, AcOH); vmax(CH2CI2)/cm-1 3309, 2924, 2854, 1706, 
1648, 1458, 1370, 1276, 1161, 1096, 1012, 982, 858, 782; 5H(400 MHz; CDCI3) 10.46 (1 H, br s, 
NH), 6.00 (0.37 H, br s, NH), 4.95 (0.63 H, d, J 8.9, NH), 4.20 (0.63 H, dd, J 8.9, 4.5, a-CH), 3.98
o o116
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(0.37 H, br s, a-CH), 2.15 (1 H, m, Me2CH), 1.38 (9 H, s, CMe3), 0.94 (3 H, d, J 6.8, MeCHMe), 
0.87 (3 H, d, J 6.8, MeCHMe); 6C(100 MHz; CDCI3) 177.4 (C), 177.0 (C), 157.1 (C), 155.9 (C),
81.6 (C), 80.1 (C), 60.0 (CH), 58.4 (CH), 31.1 (CH), 30.9 (CH) 28.3 (CH3), 28.2 (CH3), 19.1 
(CH3), 19.0 (CH3) 17.5 (CH3), 17.4 (CH3); m/z (APCI) 218 ([M+H]+, 80%), 162 (100), 160 (15), 
144 (5).
(S)-A/-?erf-(Butoxycarbonyl)valinamide
To a stirred solution of A/-Boc-(S)-valine (3.00 g, 13.81 mmol) and triethylamine (1.94 mL, 1.41 g, 
13.94 mmol, 1.01 equiv) in anhydrous tetrahydrofuran (120 mL) at 0 °C was added ethyl 
chloroformate (1.33 mL, 1.51 g, 13.94 mmol, 1.01 equiv) and the mixture stirred for 1 h. 
Aqueous ammonia (35%, 10 mL) was added and the solution was allowed to warm to room 
temperature and stirred for 1 hour. The organic solvent was removed in vacuo and the resulting 
aqueous solution diluted with water (10 mL) and extracted with ethyl acetate (3 x 50 mL). The 
combined organic extracts were washed sequentially with saturated aqueous sodium hydrogen 
carbonate solution (50 mL), citric acid (1 M, 50 mL), brine (50 mL), dried (Na2S 04) and 
evaporated in vacuo to yield the title compound (2.83 g, 95%) as a colourless solid, mp 159-161 
°C (EtOAc) (lit.,219 160-161 °C) (Found: [M+H]+217.1546. Calc, for C10H21N2O3: 217.1547); [ct]D20 
17.0 (c 1.00, MeOH) {lit.,220 17.7 (c 1.33, DMF)}; vmax(CH2CI2)/crTV1 3385, 3342, 3191, 2921, 
1681, 1657, 1519, 1461, 1377, 1245, 1170, 1044, 1019, 899, 878, 775, 722; 5H(250 MHz; CDCI3)
6.05 (1 H, br s, exch. D20 , NH), 5.72 (1 H, br s, exch. D20 , NH), 5.05 (1 H, br d, exch. D20 , NH), 
3.90 (1 H, dd, J 7.9, 7.9, a-CH), 2.08 (1 H, m, Me2Chi), 1.38 (9 H, s, CMe3), 0.92 (3H, d, J6.8, 
MeCHMe), 0.88 (3 H, d, J 6.8, MeCHMe); 6C(100 MHz; CDCI3) 175.0 (C), 156.1 (C), 80.1 (C),
59.4 (CH), 30.8 (CH), 28.3 (CH3), 19.3 (CH3), 17.8 (CH3); m/z (APCI) 217 ([M+H]+, 90%), 161 
(100), 151 (15), 149 (57), 139 (10), 129 (22).
(S)-AFferf-(Butoxycarbonyl)thiovalinamide (101b)
• n h 2 --------- ►
t-BuO N' t-BuO
(S)-A/-te/t-(Butoxycarbonyl)valinamide (2.00 g, 9.25 mmol, 1 equiv) was dissolved in dry 
dichloromethane (120 mL). Lawesson’s reagent (1.87 g, 4.62 mmol, 0.5 equiv) was added and
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the resulting solution heated at reflux for 16 h. The solvent was evaporated in vacuo and the 
residue dissolved in ethyl acetate (100 mL) and washed with saturated aqueous sodium 
hydrogen carbonate solution (100 mL). The organic layer was dried (Na2S 0 4) and evaporated in 
vacuo. Purification on silica eluting with petroleum ether-diethyl ether (3:7), gave the title 
compound (1.33 g, 62%) as a yellow foam, mp 84-85 °C (light petroleum-diethyl ether) (lit.,96 
112-113 °C) (Found: [M+H]+ 233.1319. Calc, for C10H21N2O2S: 233.1318); [a]D26 -46.7 (c 0.3, 
chloroform) {lit.,96 -43.5 (c 0.7, chloroform)}; R, 0.30 (petroleum ether-diethyl ether 3:7); 
Vmax(CH2CI2)/cm'1 3317, 3146, 2923, 2853, 1684, 1509, 1456, 1366, 1298, 1237, 1164, 1045, 
1011, 870, 763, 718; 6H(400 MHz; CDCI3) 8.20 (1 H, br s, exch. D20 , NH), 7.70 (1 H, br s, exch. 
D20, NH), 5.24 (1 H, d, J8.9, exch. D20 , NH), 4.13 (1 H, m, a-CH), 2.10 (1 H, m, Me2CH), 1.37 
(9 H, s, CMe3), 0.92 (6 H, app. d, J5.9, CHMe2)\ 6C(100 MHz; CDCI3) 209.5 (C), 156.0 (C), 80.3 
(C), 65.2 (CH), 33.3 (CH), 28.4 (CH3), 19.6 (CH3), 18.3 (CH3); m/z (APCI) 233 ([M+H]+, 18%), 
177(100), 133 (75).
(S)-Ethyl 2-(1-(tert-butoxycarbonylamino)-2-methylpropyl)thiazole-4-carboxylate (102b) 
[Meyers, Table 4, entry 4]
Potassium hydrogen carbonate (1.72 g, 17.2 mmol, 4 equiv) was added to a solution of (S)-A/- 
te/t-(butoxycarbonyl)thiovalinamide (1.00 g, 4.3 mmol) in anhydrous 1,2-dimethoxyethane (10 
mL) at -40 °C. Ethyl bromopyruvate (2.32 mL, 3.61 g, 18.5 mmol, 3 equiv) was added and the 
solution was stirred for 16 h at -20  °C. The mixture was allowed to warm to room temperature, 
filtered through a pad of Celite®and the pad washed with diethyl ether (10 mL). The filtrate was 
evaporated in vacuo and the residue dissolved in anhydrous DME (10 mL). The solution was 
cooled to -4 0  °C and a solution of trifluoroacetic anhydride (2.01 mL, 2.98 g, 14.2 mmol, 3.3 
equiv) and 2,6-lutidine (3.46 mL, 3.18 g, 29.7 mmol, 6.9 equiv) in anhydrous DME (5 mL) was 
added. The reaction mixture was stirred at -20  °C for 30 minutes then evaporated in vacuo. The 
residue was dissolved in chloroform (100 mL) and washed with water (100 mL). The aqueous 
layer was further extracted with chloroform (50 mL) and the combined organic extracts washed 
with water (100 mL) and brine (100 mL), dried (Na2S 0 4) and evaporated in vacuo. Purification of 
the residue by column chromatography on silica eluting with petroleum ether-ethyl acetate (3:1) 
afforded the title compound (0.83 g, 59%) as a colourless solid, mp 114-116 °C (ethyl acetate- 
petroleum ether) (lit.,162 114-115 °C) (Found: [M+H]+ 329.1532. Calc, for Ci5H25N20 4S: 
329.1530); [a]D23 -36.2 (c 1.00, chloroform) {lit.,162 (/?)-enantiomer; +41.6 (c 1.06, chloroform)}; 
ee 88%; 0.28 (petroleum ether-ethyl acetate 3:1); vmax(CH2CI2)/cm'1 3300, 3094, 2922, 2853,
BocHN
S
BocHN
102b
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1713, 1699, 1456, 1379, 1339, 1305, 1232, 1174, 1104, 1084, 1031, 999, 878, 777, 718; 5H(400 
MHz; CDCI3) 8.01 (1 H, s, 5-H), 5.25 (1 H, d, J 7.7, exch. D20, NH), 4.85 (1 H, dd, J l .  7, 7.7, a- 
CH), 4.35 (2 H, q, J7.1, OCH^Hs), 2.41 (1 H, m, Me2CH), 1.38 (9 H, s, CMe3), 1.34 (3 H, t, J 
7.1, OCH2CH3), 0.92 (3 H, d, J 6.7, MeCHMe), 0.83 (3 H, d, J 6.7, MeCHMe); 6C(100 MHz; 
CDCI3) 173.3 (C), 161.4 (C), 155.5 (C), 147.4 (C), 126.8 (CH), 80.1 (C), 61.4 (CH2), 58.0 (CH),
33.3 (CH), 28.3 (CH3), 19.5 (CH3), 17.3 (CH3), 14.4 (CH3); m/z (APCI) 329 ([M+H]+, 100%).
(S)-2-[1-(A/-terf-Butoxycarbonylamino)-2-methylpropyl]thiazole-4-carboxylic acid
BocHNBocHN
To a stirred solution of (S)-ethyl-2-[1-(A/-tert-butoxycarbonylamino)-2-methylpropyl]thiazole-4- 
carboxylate (328 mg, 1.00 mmol) in methanol-water (5:1, 20 mL) was added lithium hydroxide 
monohydrate (210 mg, 5.00 mmol, 5 equiv) and the mixture stirred at room temperature for 16 h. 
The methanol was evaporated in vacuo and the solution partitioned between water (20 mL) and 
diethyl ether (20 mL). The organic layer was further extracted with water (20 mL) and the 
combined aqueous extracts acidified to pH 3 using citric acid (10% w/v). The acidified aqueous 
solution was extracted with ethyl acetate (3 x 20 mL) and the combined organic extracts were 
washed with water (20 mL) and brine (20 mL), dried (Na2S 04) and evaporated in vacuo to afford 
the title compound (270 mg, 90%) as a colourless solid, mp 300 °C (lit.,162 300-302 °C) (Found: 
[M+H]+ 301.1219. Calc, for C i3H21N20 4S: 301.1217); [a ]D21 -41.0 (c 1.00, chloroform) {lit.,162 (R)- 
enantiomer; +42.0 (c 2.60, chloroform)}; vmax(CH2CI2)/crn‘1 3400-3000 br, 2922, 2853, 1712, 
1461, 1377, 1340, 1229, 1167, 1105, 1001, 722; 6H(400 MHz; CDCI3) 8.12 (1 H, s, 5-H), 6.20 
(0.25 H, br s, exch. D20 , NH), 5.31 (0.75 H, br s, NH), 4.83 (0.75 H, app br m, a-CH), 4.69 (0.25 
H, app br s, a-CH), 2.34 (1 H, m, Me2CH), 1.38 (9 H, s, CMe3), 0.90 (3 H, d, J 6 .6 , MeCHMe), 
0.86 (3 H, d, J 6 .6 , MeCHMe); 6C(100 MHz; CDCI3) 173.8 (C), 164.4 (C), 155.5 (C), 146.7 (C),
128.3 (CH), 80.3 (C), 58.0 (CH), 33.2 (CH), 28.3 (CH3), 19.4 (CH3), 17.4 (CH3); m/z (APCI) 301 
([M+H]+, 100%), 175 (5), 153 (10), 149 (22), 139 (24), 130 (7).
(S)-2-(1-Amino-2-methylpropyl)thiazole-4-carboxylic acid hydrochloride (100)
BocHN C 0 2HCO2 H
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A solution of hydrogen chloride in dioxane (4 M, 2 mL) was added to (S)-2-[1-(N-te/t- 
butoxycarbonylamino)-2-methylpropyl]thiazole-4-carboxylic acid (200 mg, 0.67 mmol) the mixture 
stirred at room temperature under an atmosphere of nitrogen for 2 hours. The solvent was 
removed in vacuo and toluene (2 mL) added. The solvent was removed in vacuo and the 
residue purified by trituration with diethyl ether ( 2 x 5  mL) to furnish the title compound (152 mg, 
96%) as a colourless solid, mp 258-259 °C dec. (lit.,136 259-261 °C dec.) (Found: [M+H]+ 
201.0692. Calc, for C8H13N2 0 2S: 201.0692); [a]D23 -7 .2  (c 0.5, water); vmax(CH2Cl2)/cm-1 3408, 
3316, 2922, 1702, 1589, 1509, 1465, 1377, 1244; 5H(400 MHz; D20 ) 8.39 (1 H, s, 5-H), 4.55 (1 
H, d, J 7.5 a-CH), 2.31 (1 H, app qd, J 6.7, 7.5, Me2CH), 1.00 (3 H, d, J 6.7, MeCHMe), 0.85 (3 
H, d, J 6.7, MeCHMe)\ 6C(100 MHz; D20 ) 166.1 (C), 164.2 (C), 146.4 (C), 131.1 (CH), 57.8 (CH),
32.6 (CH), 17.9 (CH3), 17.8 (CH3); n?/z(ES+) 201 ([M+H]\ 15%), 184 (85), 166 (100).
Cyclic hexapeptide 115
To a suspension of (S)-2-(1-amino-2-methylpropyl)thiazole-4-carboxylic acid hydrochloride (100 
mg, 0.42 mmol) in acetonitrile (8.8  mL) under an inert atmosphere was added 
diisopropylethylamine (0.219 mL, 163 mg, 1.26 mmol, 3 equiv), followed by FDPP (242 mg, 0.63 
mmol, 1.5 equiv) and the mixture stirred at room temperature for 18 h. The solvent was removed 
in vacuo and the resiude dissolved in ethyl acetate (25 mL) and washed with hydrochloric acid (2 
M, 2 x 25 mL). The combined aqueous layers were extracted with ethyl acetate (25 mL) and the 
combined organic extracts washed sequentially with aqueous sodium hydroxide (1 M, 2 x 25 
mL), water (25 mL) and brine (25 mL), dried (Na2S 0 4) and evaporated in vacuo. Purification of 
the residue by chromatography on silica eluting with petroleum ether-ethyl acetate (3:7) furnished 
the title compound as a colourless solid, mp 256-259 °C (Et20 ) (lit.,140 258-260 °C) (Found: 
[M+H]+ 547.1618. Calc, for C24H31N60 3S3: 547.1614); [a ]D25 -110.4 (c 0.25, chloroform) {lit.,140 
(F7)-enantiomer; +126.8 (c 0.53, chloroform)}; R, 0.25 (petroleum ether-ethyl acetate 3:7); 5H(400 
MHz; CDCI3) 8.39 (3 H, d, J 9.3 NH), 8.02 (3 H, s, 5-H), 5.37 (3 H, dd, J 9.3, 6.7 a-CH), 2.21 (3 
H, app qd, J 6.7, 6.7, Me2CH), 1.03 (9 H, d, J 6.7, MeCHMe), 0.98 (9 H, d, J 6.7, MeCHMe)\
5C(100 MHz; CDCI3) 168.6 (C), 159.8 (C), 149.2 (C), 123.5 (CH), 55.5 (CH), 35.4 (CH), 18.9 
(CH3), 18.4 (CH3); m/z (APCI) 547 ([M+H]+, 65%), 385 (100), 279 (26), 247 (40), 233 (15), 221 
(23), 219(8), 130 (10).
c o 2h
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Degradation of hexapeptide 115
s
Cyclic hexapeptide 115 (1 mg, 1.8 pmol) was dissolved in dichloromethane (10 mL) and a stream 
of ozone bubbled through the resulting solution at room temperature for 3 h. The solvent was 
evaporated under a stream of nitrogen and the residue dissolved in hydrochloric acid (6 M, 0.3 
mL) and heated at 110 °C for 24 h. The solvent was removed in vacuo and water (0.1 mL) 
added. A solution of Marfey’s reagent (1 mg, 3.7 pmol) in acetone (0.2 mL) was added, followed 
by sodium hydrogen carbonate solution (1 M, 40 pL, 40 pmol), and the mixture heated at 45 °C 
for 1 hour. The solution was allowed to cool to room temperature and hydrochloric acid (2 M, 20 
pL, 40 pmol) added. The products were identified by reverse-phase HPLC using a chiral 
Hypersil 5p reverse phase column, gradient eluting with 10% - 50% acetonitrile in 50 mM TEAP 
buffer (pH 3), flow rate 0.25 ml min'1, detected at 340 nm.
Degradation of MP1
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Micrococcin P1 (1 mg, 0.87 pmol) was dissolved in dichloromethane (5 mL) and a stream of 
ozone bubbled through the resulting solution at room temperature for 3 h. The solvent was 
evaporated under a stream of nitrogen and the residue dissolved in hydrochloric acid (6 M, 0.5 
mL) and heated at 110 °C for 24 h. The solvent was removed in vacuo and water (0.1 mL) 
added. A solution of Marfey’s reagent (2 mg, 7.4 pmol) in acetone (0.2 mL) was added, followed 
by sodium hydrogen carbonate solution (1 M, 50 pL, 50 pmol), and the mixture heated at 45 °C 
for 1 hour. The solution was allowed to cool to room temperature and hydrochloric acid (2 M, 25 
pL, 50 pmol) added. The products were identified by reverse-phase HPLC using a chiral 
Hypersil 5p reverse phase column, gradient eluting with 10% - 50% acetonitrile in 50 mM TEAP 
buffer (pH 3), flow rate 0.25 ml min'1, detected at 340 nm.
(S)-Ethyl 2-(1-(terM>utoxycarbonylamino)-2-methylpropyl)thiazole-4-carboxylate (102b) 
[Holzapfel, Table 4, entry 2]
BocHN BocHN
102b
Potassium hydrogen carbonate (0.176 g, 1.76 mmol, 8 equiv) was added to a solution of (S)-N- 
te/f-(butoxycarbonyl)thiovalinamide (50 mg, 0.22 mmol) in DME (2 mL) and the mixture stirred 
vigorously for 5 minutes. Ethyl bromopyruvate (83 pL 0.66 mmol, 3 equiv) was added and the 
solution was stirred for 1 minute then cooled to 0 °C. A solution of trifluoroacetic anhydride (125 
pL, 0.89 mmol, 4 equiv) and 2,6-lutidine (0.22 mL, 1.87 mmol, 8.5 equiv) in DME (1 mL) was 
added and the reaction mixture was allowed to reach ambient temperature before evaporation in 
vacuo. The residue was partitioned between chloroform (10 mL) and water (10 mL), and the 
organic layer dried (Na2S 0 4) and evaporated in vacuo. Purification on silica eluting with light 
petroleum-diethyl ether (2:1) afforded the title compound (24 mg, 33%) as a pale yellow solid, ee 
>98%.
(S)-Ethyl 2-(1-(/V-(terf-butoxycarbonyl)-2,2>2-trifluoroacetamido)-2-methylpropyl)thiazole-4- 
carboxylate (134) [Table 5, entry 2]
BocHN
134
Potassium hydrogen carbonate (2.36 g, 23.6 mmol, 8 equiv) was added to a solution of (S)-N- 
te/?-(butoxycarbonyl)thiovalinamide (684 mg, 2.94 mmol) in anhydrous 1,2-dimethoxyethane (7
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mL) and the solution cooled to -1 8  °C. Ethyl bromopyruvate (1.11 mL, 1.72 g, 8.83 mmol, 3 
equiv) was filtered through a pad of Celite®, the pad washed with diethyl ether (7 mL) and the 
combined filtrates evaporated in vacuo. The residue was dissolved in anhydrous DME (7 mL) 
and the solution cooled to -18  °C. A solution of trifluoroacetic anhydride (1.67 mL, 2.48 g, 11.78 
mmol, 4 equiv) and 2,6-lutidine (3.09 mL, 2.84 g, 26.50 mmol, 9 equiv) in anhydrous DME (4 mL) 
was added. The reaction mixture was stirred at -18  °C for 30 minutes then evaporated in vacuo. 
The residue was dissolved in chloroform (20 mL) and washed with water (20 mL). The aqueous 
layer was further extracted with chloroform (20 mL) and the combined organic extracts washed 
with water (20 mL) and brine (20 mL), dried (Na2S 0 4) and evaporated in vacuo. Purification of 
the residue by column chromatography on silica eluting with petroleum ether-ethyl acetate (3:1) 
afforded the title compound (1.21 g, 97%) as a yellow oil; (Found: [M+H]+ 425.1361. Calc, for 
C17H24N2O5F3S: 425.1358); R /0.30 (petroleum ether-ethyl acetate 3:1); vmax(CH2Cl2)/cm'1 2970, 
2925, 1713, 1649, 1508, 1369, 1237, 1202, 1168, 1097, 1017; 6H(500 MHz; CDCI3) 8.12 (1 H, s, 
5-H), 5.39 (1 H, d, J10.9, a-CH), 4.34 (2 H, q, J7.1, O C H £H 3), 2.78 (1 H, m, Me2CH), 1.43 (9 
H, s, CMe3), 1.31 (3 H, t, J7.1, OCH2CH3), 0.95 (3 H, d, J 6 .6 , MeCHMe), 0.92 (3 H, d, J 6 .6 , 
MeCH/We); 6C(125 MHz; CDCI3) 173.2 (C), 161.4 (C), 155.2 (C), 147.4 (C), 126.8 (CH), 86.9 (C),
61.4 (CH2), 58.0 (CH), 33.3 (CH), 28.3 (CH3), 27.4 (CH3), 19.4 (CH3), 14.4 (CH3) {signals for 
F3CCO and F3CCO not observed}; m/z (ES+) 425 ([M+H]+, 3%), 325 (58), 273 (100), 196 (30), 
180 (8 ).
(S)-Ethyl 2-(1-(tert-butoxycarbonylamino)-2-methylpropyl)thiazole-4-carboxylate (102b) 
[from Table 5, entry 2]
carboxylate (700 mg, 1.65 mmol) was dissolved in ethanol (16.5 mL) and sodium ethoxide (0.336 
mg, 4.95 mmol, 3 equiv) added. The solution was stirred at room temperature for 4 hours then 
evaporated in vacuo. The residue was partitioned between ethyl acetate (20 mL) and water (20 
mL). The aqueous layer ws further extracted with ethyl acetate ( 2 x 1 0  mL) and the combined 
organic extracts dried (Na2S 0 4) and evaporated in vacuo. Trituration of the residue with 
petroleum ether afforded the product (440 mg, 81%) as a colourless solid, ee >98%.
BocHN
102b
(S)-Ethyl 2-(1-(A/-(ferf-butoxycarbonyl)-2,2,2-trifluoroacetamido)-2-methylpropyl)thiazole-4-
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(S)-Ethyl 2-(1-(/V-(terf-butoxycarbonyl)-2,2,2-trifluoroacetamido)-2-methylpropyl)thiazole-4- 
carboxylate (134) [Nicolaou, Table 4, entry 5]
BocHN
134
Sodium hydrogen carbonate (868  mg, 10.33 mmol, 8 equiv) was added to a solution of (S)-N- 
terF(butoxycarbonyl)thiovalinamide (300 mg, 1.29 mmol) in anhydrous 1,2-dimethoxyethane (15 
mL). Ethyl bromopyruvate (0.49 mL, 755 mg, 3.87 mmol, 3 equiv) was added and the solution 
stirred for 16 h at room temperature. The mixture was evaporated in vacuo and the residue 
partitioned between water (30 mL) and diethyl ether (15 mL). The aqueous layer was further 
extracted with diethyl ether (15 mL) and the combined organic extracts washed with brine (15 
mL), dried (Na2S 0 4) and evaporated in vacuo. The residue was dissolved in anhydrous DME (15 
mL) and the solution cooled to 0 °C. Pyridine (0.94 mL, 919 mg, 11.61 mmol, 9 equiv) was 
added slowly followed by dropwise addition of trifluoroacetic anyhdride (0.73 mL, 1.09 g, 5.16 
mmol, 4 equiv) and the solution was stirred at 0 °C for 2 h. Triethylamine (0.36 mL, 261 mg, 2.58 
mmol, 2 equiv) was added and the reaction mixture was warmed to room temperature and 
evaporated in vacuo. The residue was dissolved in chloroform (20 mL), washed with water (20 
mL) and brine (10 mL), dried (Na2S 0 4) and evaporated in vacuo. Purification of the residue by 
column chromatography on silica eluting with petroleum ether-ethyl acetate (3:1) afforded the title 
compound (467 mg, 85%) as a yellow oil. [ee 8 8 % after conversion to (S)-ethyl 2-(1 -(tert- 
butoxycarbonylamino)-2-methylpropyl)thiazole-4-carboxylate (102b) by the method outlined 
above.]
(4S,5F?)-3-(terM3utoxycarbonyl)-2l2>5-trimethyloxazolidine-4-carboxylic acid (135)85
HO'-. — - '°X
BocH N * ^ ^ C 0 2H N C 0 2h
d OC
135
A/-Boc-L-threonine (7.50 g, 34.2 mmol) was dissolved in tetrahydrofuran (200 mL) and 2,2- 
dimethoxypropane (42.07 mL, 35.64 g, 342.2 mmol, 10 equiv) and PPTS (2.58 g, 10.3 mmol, 0.3 
equiv) added. The solution was heated at reflux for 16 hours, allowed to cool and evaporated in 
vacuo. The residue was partitioned between ethyl acetate (200 mL) and water (200 mL) and the 
aqueous layer further extracted with EtOAc (2 x 100 mL). The combined organic extracts were 
washed with brine (100 mL), dried (Na2S 0 4) and evaporated in vacuo to furnish the title 
compound (8.81 g, 99%) as an off-white solid, mp 91-92 °C (chloroform) (Found: [M+H]+
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260.1491. Calc, for C12H22NO5: 260.1492); [ct]D22 -60.0 (c 1.00, chloroform); vmax(CH2Cl2)/cm-1 
3468, 3067, 2923, 1754, 1666, 1459, 1367, 1133, 988, 949, 856, 783, 722; 6H(400 MHz; CDCI3) 
10.47 (1 H, br s, exch. D20, OH), 4.16 (1 H, dq, J 8.0, 6.0, 5-H), 3.93 (0.38 H, d, J 8.0, 4-H), 
3.86 (0.62 H, d, J 8.0, 4-H), 1.59 (1.86 H, s, 2-Me), 1.53 (1.14 H, s, 2-Me), 1.51 (1.86 H, s, 2 -  
Me), 1.48 (1.14 H, s, 2-Me), 1.42 (3.43 H, s, CMe3), 1.37 (3 H, d, J 6.0, 5-Me), 1.34 (5.57 H, s, 
CMe3); 6C(100 MHz; CDCI3) 177.1 (C), 175.9 (C), 152.2 (C), 150.9 (C), 95.3 (C), 94.7 (C), 81.3 
(C), 80.9 (C), 73.9 (CH), 73.5 (CH), 66.0 (CH), 65.9 (CH), 28.3 (CH3), 28.2 (CH3), 27.7 (CH3),
26.5 (CH3), 24.8 (CH3), 23.9 (CH3), 18.9 (CH3); m/z (APCI) 260 ([M+H]+, 5%), 204 (42), 160 
(100), 146 (32).
(4S,5fi)-tert-Butyl 4-carbamoyl-2,2,5-trimethyloxazolidine-3-carboxylate (136)85
x ° r  —  > c ~N ^ ^ C 0 2 H  n  c o n h 2
Boc Boc
136
To a stirred solution of (4S,5f?)-3-(te/t-butoxycarbonyl)-2,2,5-trimethyloxazolidine-4-carboxylic 
acid (8.80 g, 33.9 mmol) and triethylamine (4.97 mL, 3.61 g, 35.63 mmol, 1.05 equiv) in 
anhydrous tetrahydrofuran (200 mL) at 0 °C was added ethyl chloroformate (3.41 mL, 3.87 g, 
35.63 mmol, 1.05 equiv.) and the mixture stirred for 1 h. Aqueous ammonia (35%, 100 mL) was 
added and the solution was allowed to warm to room temperature and stirred for 24 hours. The 
organic solvent was removed in vacuo and the resulting aqueous solution extracted with ethyl 
acetate (3 x 100 mL). The combined organic extracts were washed sequentially with water (100 
mL) and brine (100 mL), dried (Na2S 0 4) and evaporated in vacuo to yield the title compound 
(6.77 g, 77%) as a colourless solid, mp 148-150 °C (chloroform) (Found: [M+H]+ 259.1654. Calc, 
for C12H23N20 4 : 259.1652); [<x]D22 -45.4 (c 1.00, chloroform); vmax(CH2CI2)/cm-1 3412, 3217, 2922, 
1694, 1634, 1456, 1377, 1268, 1221, 1173, 1135, 1089, 987, 942, 861, 784; 6H(400 MHz; CDCI3) 
6.60-5.80 (2 H, br s, exch. D20, 2 NH), 4.16 (1 H, app. br s, 5-H), 3.70 (1 H, app. br s, 4-H),
1.55 (3 H, s, 2-Me), 1.52 (3 H, s, 2-Me), 1.39 (9 H, s, CMe3), 1.33 (3 H, d, J6.1, 5-Me); 5C(100 
MHz; CDCI3) 172.7 (C), 94.8 (C), 81.1 (C), 74.2 (CH), 67.4 (CH), 28.3 (CH3), 25.3 (CH3), 18.9 
(CH3); m/z (APCI) 259 ([M+H]+, 25%), 221 (17), 204 (22), 203 (70), 159 (100), 145 (5).
(4f?,5fi)-ferf-Butyl 4-cyano-2,2,5-trimethyloxazolidine-3-carboxylate (137)
c o n h 2
Boc Boc
137
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(4S,5fl)-tert-Butyl 4-carbamoyl-2,2,5-trimethyloxazolidine-3-carboxylate (6.70 g, 25.9 mmol) was 
dissolved in pyridine (150 mL) and the solution cooled to 0 °C. Phosphorus oxychloride (6.04 
mL, 9.94 g, 64.9 mmol, 2.5 equiv) was added and the solution stirred at 0 °C for 3 hours. The 
mixture was poured over ice then diluted with water (150 mL) and extracted with diethyl ether (3 
x 100 mL). The combined organic extracts were washed sequentially with hydrochloric acid (2M, 
150 mL), water (3 x 150 mL), brine (100 mL), dried (Na2S 04) and evaporated in vacuo to afford 
the title compound (4.88 g, 78%) as a colourless solid, mp 44-47 °C (Et20 ) (Found: [M+H]+ 
241.1547. Calc, for Ci2H2iN20 3: 241.1547); [o t]D22 -69.4 (c 1.00, chloroform); vmax(CH2CI2)/cm'1 
3058, 2982, 2936, 2245, 1713, 1477, 1458, 1367, 1318, 1266, 1216, 1167, 1132, 1096, 993, 
961, 936, 857, 776; 5H(400 MHz; CDCI3) 4.37 (1 H, m, 5-H), 4.04 (0.3 H, br d, J6.1, 4-H), 3.96 
(0.7 H, d, J 7.3, 4-H), 1.61 (3 H, s, 2-Me), 1.56 (3 H, s, 2-Me), 1.45 (9 H, s, CMe3), 1.38 (3 H, d, 
J 6.1, 5-Me); 6C(100 MHz; CDCI3) 150.5 (C), 117.2 (C), 95.8 (C), 95.2 (C), 82.2 (C), 74.1 (CH),
73.9 (CH), 53.0 (CH), 30.3 (CH3), 29.7 (CH3), 28.3 (CH3), 27.8 (CH3), 26.5 (CH3), 25.4 (CH3),
24.5 (CH3), 18.3 (CH3); m/z(CI+) 259 ([M+NH4]+, 100%), 241 ([M+H]+, 40%), 202 (12), 125 (10), 
114(50), 58 (20).
(4S,5F?)-terf-Butyl 4-carbamothioyl-2,2,5-trimethyloxazolidine-3-carboxylate (138)85
csnh2
(4R,5R)-tert-Buly\ 4-cyano-2,2,5-trimethyloxazolidine-3-carboxylate (4.80 g, 20.0 mmol) was 
dissolved in methanol (100 mL) and ammonium sulfide (50 wt% in H20 , 5.44 mL, 40.0 mmol, 2 
equiv) added. The solution was stirred at room temperature for 24 hours then evaporated in 
vacuo. The residue was partitioned between ethyl acetate (100 mL) and water (100 mL) and the 
aqueous layer further extracted with ethyl acetate (2 x 50 mL). The combined organic extracts 
were dried (Na2S 0 4) and evaporated in vacuo to yield the title compound (5.40 g, 99%) as a pale 
yellow solid, mp 106-108 °C (Et20 ) (Found: [M+H]+ 275.1424. Calc, for C i2H23N20 3S: 275.1424); 
[oc]d 22 -8 .2  (c 1.00, chloroform) {lit.,85 -9 .8  (c 0.19, chloroform)}; vmax(CH2CI2)/cm'1 3307, 3196, 
2925, 1672, 1619, 1443, 1368, 1265, 1139, 1090, 978, 940, 855, 736; 5H(400 MHz; CDCI3) 7.86 
(2 H, br s, exch. D20, 2 NH), 4.21 (1H, d, J 7.7, 5-H), 4.06 (1 H, br s, 4-H), 1.57 (6 H, s, both 2 -  
Me), 1.36 (12 H, app. s, CMe3 and 5-Me); 6C(100 MHz; CDCI3) 205.6 (C), 152.2 (C), 125.5 (CH),
94.8 (C), 81.6 (C), 73.9 (CH), 30.3 (CH3), 28.3 (CH3), 26.2 (CH3), 19.2 (CH3); m/z (ES+) 297 
([M+Na]\ 7%), 219 (12), 161 (100), 133 (27), 116 (40).
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(4S,5/=0-terf-Butyl 4-carbamothioyl-2,2,5-trimethyloxazolidine-3-carboxylate (138)
n * ’ ^ c o n h 2
Boc
N’^ '" C S N H 2
Boc
138
To a stirred solution of (4S,5fl)-te/t-butyl 4-carbamoyl-2)2,5-trimethyloxazolidine-3-carboxylate 
(12.90 g, 49.94 mmol) in toluene (500 mL) at 80 °C, Lawesson’s reagent (10.50 g, 25.97 mmol, 
0.52 eq) was added and the mixture stirred at 80 °C for 1.5 hours. The solvent was removed in 
vacuo and the residue purified by chromatography on silica, furnishing the title compound (3.26 
g, 24% as a pale yellow solid (R, 0.28, petroleum ether-diethyl ether 3:7).
(4S,5fl)-terf-Butyl 4-(4-(ethoxycarbonyl)thiazol-2-yl)-2,2,5-trimethyloxazolidine-3-
carboxylate (132) [Nicolaou, Table 7, entry 3]
Sodium hydrogen carbonate (20.82 g, 247.81 mmol, 8 equiv) was added to a solution of (4S,5R)~ 
tert-butyl 4-carbamothioyl-2,2,5-trimethyloxazolidine-3-carboxylate (8.50 g, 30.98 mmol) in 
anhydrous 1,2-dimethoxyethane (150 mL). Ethyl bromopyruvate (11.66 mL, 18.12 g, 92.93 
mmol, 3 equiv) was added and the solution was stirred for 16 h at room temperature. The 
mixture was evaporated in vacuo and the residue partitioned between water (150 mL) and diethyl 
ether (150 mL). The aqueous layer was further extracted with diethyl ether (75 mL) and the 
combined organic extracts washed with brine (150 mL), dried (Na2S 0 4) and evaporated in vacuo. 
The residue was dissolved in anhydrous DME (150 mL) and the solution cooled to 0 °C. Pyridine 
(22.55 mL, 22.05 g, 278.79 mmol, 9 equiv) was added slowly followed by dropwise addition of 
trifluoroacetic anyhdride (17.53 mL, 26.06 g, 123.91 mmol, 4 equiv) and the solution was stirred 
at 0 °C for 2 h. Triethylamine (8.64 mL, 6.27 g, 61.95 mmol, 2 equiv) was added and the 
reaction mixture warmed to room temperature and evaporated in vacuo. The residue was 
dissolved in chloroform (200 mL), washed with water (200 mL) and brine (100 mL), dried 
(Na2S 0 4) and evaporated in vacuo. Purification of the residue by column chromatography on 
silica eluting with petroleum ether-ethyl acetate (3:1) afforded the title compound (9.97 g, 87%) 
as an off-white solid, mp 97-100 °C (petroleum ether-ethyl acetate) (Found: [M+H]+ 371.1633. 
Calc, for C17H27N2O5S: 371.1635); [a]D22 -59.6 (c 1.00, chloroform) {lit.,85 -51.0 (c 0.33, 
chloroform)}; R, 0.25 (petroleum ether-ethyl acetate 3;1); vmax(CH2Cl2)/crn'1 3400, 2982, 1720, 
1699, 1476, 1369, 1302, 1261, 1240, 1214, 1136, 1096, 1 0 2 0 , 942, 784; 6H(400 MHz; CDCI3)
c s n h 2
132
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8.09 (1 H, s, 5’-H ), 4.73 (1 H, brd, J 6.0, 4-H), 4.36 (2 H, q, J 6.7, OCH^CH^, 4.09 (1 H, br s, 5 -  
H), 1.63 (6 H, s, both 2-Me), 1.36 (3 H, d, J 6.0, 4-Me), 1.33 (3 H, t, J 6.7, OCH2CH3), 1.12 (9 H, 
br s, CMe3); 6C(100 MHz; CDCI3) 173.4 (C), 161.2 (C), 151.3 (C), 146.7 (C), 127.3 (CH), 95.3 
(C), 80.7 (C), 77.9 (CH), 65.9 (CH), 61.5 (CH2), 28.1 (CH3), 26.5 (CH3), 25.9 (CH3), 17.9 (CH3),
14.4 (CH3); m/z (ES+) 393 ([M+Na]+, 45%), 371 ([M+H]+, 20%), 271 (100), 257 (75), 213 (52), 
167 (30).
2-((4S,5/=7)-3-(te/t-Butoxycarbonyl)-2,2,5-trimethyloxazolidin-4-yl)thiazole-4-carboxylic acid 
(140)
1 4 0
To a stirred solution of (4S,5f7)-tert-butyl 4-(4-(ethoxycarbonyl)thiazol-2-yl)-2,2,5- 
trimethyloxazolidine-3-carboxylate (3.00 g, 8.10 mmol) in methanol-water (5:1, 150 mL) was 
added lithium hydroxide monohydrate (1.70 g, 40.50 mmol, 5 equiv) and the mixture stirred at 
room temperature for 3 h. The methanol was evaporated in vacuo and the resulting aqueous 
solution extracted with diethyl ether (2 x 50 mL). The aqueous layer was acidified to pH 3 using 
citric acid (10% w/v) and extracted with ethyl acetate (3 x 100 mL). The combined organic 
extracts were washed with water (100 mL) and brine (100 mL), dried (Na2S 0 4) and evaporated in 
vacuo to afford the title compound (2.77 g, 100%) as a colourless solid, mp 159-160 °C 
(chloroform) (Found: [M+H]+ 343.1324. Calc, for C15H23N20 5S: 343.1322); [a]D22 -63.00 (c 1.00, 
chloroform); vmax(CH2CI2)/crTV1 3400-2500 br, 3116, 3054, 2984, 1704, 1368, 1281, 1136, 1091, 
984, 934, 895, 856; 6H(400 MHz; CDCI3) 10.48 (1 H, br s, OH), 8.23 (1H, s, 5-H), 4.73 (1 H, d, J
7.0, 4’-H), 4.12 (1 H, m, 5’-H ), 1.63 (6 H, s, both 2’-Me), 1.37 (3 H, d, J 6.0, 5’-Me), 1.13 (9 H, s, 
CMe3); 5C(100 MHz; CDCI3) 173.9 (C), 164.7 (C), 151.3 (C), 145.7 (C), 128.9 (CH), 95.4 (C),
80.9 (C), 77.8 (CH), 65.9 (CH), 28.1 (CH3), 26.5 (CH3), 25.9 (CH3), 17.8 (CH3); m/z (ES+) 365 
([M+Na]+, 32%), 343 ([M+H]+, 7%), 309 (25), 265 (19), 243 (96), 229 (100), 211 (42), 185 (8 8 ), 
167 (89).
(S)-Ethyl 2-(1-amino-2-methylpropyl)thiazole-4-carboxylate hydrochloride (141)
BocHN
141
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A solution of hydrogen chloride in dioxane (4 M, 1 mL) was added to (S)-ethyl-2-[1-(A/-te/t- 
butoxycarbonylamino)-2-methylpropyl]thiazole-4-carboxylate (70 mg, 0.21 mmol) and the 
solution stirred at room temperature for 2 hours. Toluene (1 mL) was added and the solvent 
removed in vacuo. Purification of the residue by trituration with diethyl ether ( 2x1  mL) afforded 
the title compound as an off-white solid, mp 110 °C (H20  evolution), 159-162 ° (ether); 6H(400 
MHz; CD3OD) 8.41 (1 H, s, 5-H), 4.56 (1 H, d, J 6 .6 , a-H), 4.30 (2 H, q, J 7.1, O C H £H 3), 2.28 (1 
H, m, Me2CH), 1.29 (3 H, t, J 7.1, OCH2CH3), 1.02 (3 H, d, J 6 .8 , MeCHMe), 0.90 (3 H, d, J 6 .8 ); 
6C(100 MHz; CD3OD) 163.7 (C), 159.5 (C), 145.1 (C), 127.7 (CH), 59.7 (CH2), 55.6 (CH), 30.9 
(CH), 15.6 (CH3), 11.6 (CH3); m/z (APCI) 229 ([M+H]+, 100%), 212 (78), 158 (22), 72 (26).
(4S,5F?)-te/?-Butyl 4-(4-((S)-1 -(4-(ethoxycarbonyl)thiazol-2-yl)-2-
methylpropylcarbamoyl)thiazol-2-yl)-2,2,5-trimethyloxazolidine-3-carboxylate (142)
o
N
HBococ
1 4 2
To a stirred solution of carboxylic acid 140 (71 mg, 208 pmol) and triethylamine (29 pL, 208 
pmol, 1 equiv) in dry THF (2 mL) at 0 °C, ethyl chloroformate (20 pL, 208 pmol) was added and 
the mixture stirred for 1 hour. A solution of amine 141 (55 mg, 208 pmol) and triethylamine (29 
pL) in dry THF (I mL) was added to the reaction mixture and the resulting solution stirred at room 
temperature for 2 hours then evaporated in vacuo. Purification of the residue on silica eluting 
with petroleum ether-ethyl acetate (1:1) furnished the title compound (94 mg, 82%) as a pale 
yellow solid, mp 106-108 °C (chloroform) (Found: [M+NH4]+, 570.2414. Calc, for C25H4oN50 6 S2: 
570.2415); [a]D25 -46.4 (c  0.25, acetone); Rf 0.42 (petroleum ether-ethyl acetate 1:1); 
Vmax(CH2CI2)/cm -1 3399, 3121, 2977, 2935, 2874, 1711, 1538, 1480, 1367, 1320, 1238, 1211, 
1172, 1135, 1091, 1022, 921, 856; 6H(400 MHz; C D C I3) 8.05 (1 H, br s, Thr-thz H), 8.01 (1 H, s, 
Val-thz H) 7.89 (1 H, br d, exch. D20, J 9.3, NH), 5.27 (1 H, dd, J9.3, 6.7, Val a-H), 4.70 (0.33 H, 
br s, Thr 4-H), 4.60 (0.67 H, brd, J 7 .5, Thr4-H), 4.35 (2 H, q, J7.1, OCH^Hs), 4.12 (1 H, dq, J 
7.5, 6.3, Thr 5-H), 2.58 (1 H, m, Me2CH), 1.65 (6 H, br s, both Thr 2-Me), 1.38 (3 H, d, J6.3, Thr
5-Me), 1.33 (3 H, t, J7.1, OCH2CH3), 1.11 (9 H, s, CMe3), 0.92 (6  H, d, J 6 .8 , MeCHMe)\ 6C(125 
MHz; CDCI3) 161.3 (C), 147.6 (C), 126.9 (CH), 123,8 (CH), 77.8 (CH), 65.9 (CH), 61.4 (CH2),
56.5 (CH), 33.0 (CH), 28.1 (CH3), 25.5 (CH3), 19.7 (CH3), 17.1 (CH3), 14.4 (CH3); m/z(ES+) 575 
([M+Na]\ 18%), 553 ([M+H]+, 18%), 453 (100), 395 (5), 212 (5).
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(4S,5/:?)-terf-Butyl 4-((1S,2F7)-1-(4-((S)-1-(4-(ethoxycarbonyl)thiazol-2-yl)-2-
methylpropylcarbamoyl)thiazol-2-yl)-2-hydroxypropylcarbamoyl)-2,2,5- 
trimethyloxazolidine-3-carboxylate (143)
PyBOP®-mediated coupling
Peptide 142 (399 mg, 0.72 mmol) was dissolved in dichloromethane (2.5 mL) and trifluoroacetic 
acid (2.5 mL) added. The solution was stirred at room temperature for 1 hour then evaporated in 
vacuo. The residue was dissolved in dichloromethane (5 mL) and triethylamine (1.50 mL, 1.09 g, 
10.76 mmol, 14.9 equiv) added. The resulting solution was added dropwise to a stirred solution 
of (4S,5f?)-3-(tert-butoxycarbonyl)-2,2,5-trimethyloxazolidine-4-carboxylic acid (187 mg, 0.72 
mmol, 1 equiv) and PyBOP® (413 mg, 0.79 mmol, 1.1 equiv) in dichoromethane (10 mL) at 0 °C. 
The reaction mixture was allowed to warm to room temperature and stirred for 4 hours. 
Evaporation in vacuo and purification by chromatography on silica, eluting with ethyl acetate 
furnished the title compound (440 mg, 93%) as a yellow solid, mp 123-124 °C (chloroform) 
(Found: [M+NH4]+, 671.2892. Calc, for C29H47N60 8S2: 671.2891); [a]D25 -64.0 (c0.20, acetone); R, 
0.40 (EtOAc); vmax(CH2Cl2)/cm-1 3376, 3082, 2978, 2935, 1722, 1682, 1538, 1484, 1392, 1368, 
1216, 1175, 1142, 1094, 1020, 917, 874; 5H(400 MHz; d6-acetone) 8.23 (1 H, s, I), 8.12 (1 H, br 
s, exch. D20 , g) 8.05 (1 H, s, r), 7.76 (1 H, d, J 8.0, exch. D20, m), 5.16 (1 H, dd, J9.0, 7.4, h),
5.12 (1 H, dd, J 8.0, 6.7, n), 4.34 (1 H, app. br m, f), 4.22 (2 H, q, J 7.1, s), 4.04 (2 H, app. br m, 
e, i), 2.41 (1 H, m, o), 1.45 (6 H, s, b, c), 1.42 (9 H, s, a), 1.29 (3 H, brd, J5.3, d), 1.24 (3 H, t, J
7.1, t), 1.14 (3 H, br d, J 4.6, j), 0.92 (3 H, d, J 6.7, p), 0.86 (3 H, d, J 6.7, q); 6C(125 MHz; 
CDCI3) 161.3 (C), 147.3 (C), 127.0 (CH), 125.3 (CH), 77.8 (CH), 67.5 (CH), 61.5 (CH), 56.6 (CH),
33.8 (CH), 28.3 (CH3), 25.6 (CH3), 19.7 (CH3), 18.2 (CH3), 14.3 (CH3); m/z (ES-) 652 ([M-H]+, 
25%), 608 (58), 534 (18), 476 (12), 312 (10), 183 (11), 145 (100), 77 (12).
HATU-mediated coupling
(4S,5H)-3-(terf-Butoxycarbonyl)-2,2,5-trimethyloxazolidine-4-carboxylic acid (199 mg, 0.77 
mmol, 1.25 equiv) was dissolved in dichloromethane (10 mL) and diisopropylethylamine (0.54 
mL, 398 mg, 3.08 mmol, 5 equiv) added. HATU (292 mg, 0.77 mmol, 1.25 equiv) was added and 
the solution stirred at room temperature for 1 hour before the dropwise addition of a solution of 
A/-deprotected 142 (324 mg, 0.62 mmol, 1 equiv) and diisopropylethylamine (0.54 mL, 398 mg,
3.08 mmol, 5 equiv) in dichloromethane (5 mL). The reaction mixture was stirred at room
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temperature for 4 hours, evaporated in vacuo and the residue purified by chromatography on 
silica, eluting with ethyl acetate to give the title compound (338 mg, 84%) as a yellow solid.
methylpropylcarbamoyl)thiazol-2-yl)prop-1-enylcarbamoyl)-2,2,5-trimethyloxazolidine-3- 
carboxylate (139)
Peptide 143 (323 mg, 0.49 mmol) was dissolved in dichloromethane (15 mL) and the solution 
cooled to 0 °C. Triethylamine (1.03 mL, 750 mg, 7.41 mmol, 15 equiv) was added, followed by 
dropwise addition of methanesulfonyl chloride (0.38 mL, 566 mg, 4.94 mmol, 10 equiv). The 
solution was stirred at room temperature for 16 hours, evaporated in vacuo and partitioned 
between chloroform (20 mL) and water (10 mL). The organic layer was washed with saturated 
aqueous sodium hydrogen carbonate (10 mL), brine (10 mL) and dried (Na2S 04). DBU (0.22 
mL, 226 mg, 1.48 mmol, 3 equiv) was added and the solution stirred at room temperature for 2 
hours. Evaporation in vacuo and purification on silica eluting with ethyl acetate furnished the title 
compound (307 mg, 98%) as a pale yellow solid, mp 79-80 °C (chloroform) (Found: [M+Na]+, 
658.2334. Calc, for C29H4iN50 7 S2Na: 658.2340); [o]D25 +71.2 (c0.25, acetone); R,0.60 (EtOAc); 
Vmax(CH2CI2)/cm-1 3450, 3294, 2978, 2935, 1720, 1692, 1537, 1481, 1392, 1368, 1321, 1214, 
1173, 1133, 1095, 1021, 918, 857; 5H(400 MHz; CDCI3) 8.02 (1 H, s, j), 7.95 (1 H, s, p) 7.84 (1 
H, d, J9.1, exch. D20, k), 7.66 (1 H, s, exch. D20 , g), 6.60 (1 H, app br m, h), 5.23 (1 H, dd, J
9.1, 7.2, I), 4.35 (1 H, app. br m, e), 4.35 (2 H, q, J7.1, q), 3.99 (1 H, d, J 7.2, f), 2.58 (1 H, m, 
m), 1.53 (6 H, s, b, c), 1.41 (3 H, app brm, i), 1.40 (9 H, s, a), 1.38 (3 H, t, J 7.1, r), 1.32 (3 H, d, 
J 6.9, d), 0.97 (3 H, d, J 6.7, n), 0.93 (3 H, d, J 6.7, o); 6C(125 MHz; CDCI3) 168.4 (C), 161.3 (C),
128.0 (CH), 127.0 (CH), 81.4 (C), 77.3 (CH), 76.6 (CH), 61.4 (CH), 56.7 (CH), 33.0 (CH), 31.5 
(CH3), 30.9 (CH3), 28.4 (CH3), 28.3 (CH3), 26.2 (CH3), 26.0 (CH3), 19.7 (CH3), 19.5 (CH3), 18.4 
(CH3), 14.4 (CH3); m/z (ES+) 658 ([M+Na]+, 28%), 636 ([M+H}+, 10), 580 (11), 536 (100), 261 (9).
(4 S, 5 F?)-tert-B uty I 4-((Z)-1 -(4-((S)-1 -(4-(ethoxycarbonyl)thiazol-2-yl)-2-
NBoc
a
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(4”S,5” /=2)-feAt-Butyl 4-(4-(3-ethoxy-3-oxopropanoyl)thiazol-2-yl)-2,2,5-trimethyloxazolidine-
3-carboxylate (172)
i) Methyl magnesium bromide in diethyl ether (3 M, 6.02 mL, 18.05 mmol, 2.06 equiv) was 
added to a stirred suspension of potassium ethyl malonate (3.07 g, 18.05 mmol, 2.06 equiv), in 
dry THF (50 mL) at 0 °C. The mixture was stirred at 0 °C for 30 minutes then warmed to room 
temperature and stirred for a further 1.5 hours.
ii) Ethyl chloroformate (0.89 mL, 1.01 g, 9.29 mmol, 1.06 equiv) was added dropwise to a stirred 
solution of carboxylic acid 140 (3.00 g, 8.76 mmol) and triethylamine (1.29 mL, 0.94 g, 9.29 
mmol, 1.06 equiv) in dry THF (100 mL) at 0 °C and stirred for 1 hour. The solution prepared in 
part i) was added and the resulting mixture stirred at room temperature for 2 h. The reaction was 
quenched with saturated aqueous NH4CI (100 mL) and the organic solvent evaporated in vacuo. 
The resulting solution was diluted with water (50 mL) and extracted with chloroform (3 x 75 mL) 
and the combined organic extracts washed sequentially with acetic acid (5% w/v; 100 mL), water 
(100 mL), saturated aqueous NaHC03 (100 mL) and brine (100 mL), dried (Na2S 04) and 
evaporated in vacuo. Purification by column chromatography on silica, eluting with light 
petroleum-EtOAc (1:1) gave the title compound as a pale yellow oil (2.61 g, 72%) (Found: 
[M+H]*, 413.1738. Calc, for C 19H29N20 6S: 413.1741); [a]D22 -42.6 (c 1.00, chloroform); R, 0.70 
(EtOAc); Vmax(film)/cm-1 3438, 2986, 2925, 1735, 1694, 1639, 1479, 1366, 1258, 1217, 1167, 
1137, 1092, 1027; 6H(500 MHz; CDCI3) 12.01 (0.22 H, s, exch. D20 , OH), 8.12 (0.78 H, s, 5’-H ), 
7.70 (0.22 H, s, 5 ’-H ), 5.99 (0.22 H, s, 2-H), 4.69 (0.22 H, brs, 4”-H ), 4.59 (1 H, m, 5”-H ), 4.18 
(0.4 H, q, J 7.1, OCH2Me), 4.11 (1.6 H, q, J 7.1, OCH2Me), 4.10 (0.78 H, br s, 4”-H ), 4.05 (0.78 
H, d, J 18.1, 2-HH), 3.98 (0.78 H, d, J18.1, 2-HH), 1.7-1.0 (18H, 2'’,2'’,5”-M e  and CMe3), 1.28 
(0.7 H, t, J7.1, CH2Me), 1.20 (2.3 H, t, J7.1, CH2/We); 5C(125 MHz; CDCI3) 187.5 (C), 173.4 (C), 
172.4 (C), 171.2 (C), 167.5 (C), 166.6 (C), 164.8 (C), 153.4 (C), 152.3 (C), 151.3 (C), 149.6 (C),
125.9 (CH), 120.1 (CH), 95.4 (C), 95.2 (C), 94.8 (C), 89.6 (CH), 81.2 (C), 80.7 (C), 80.5 (C), 65.9 
(CH), 65.7 (CH), 61.5 (CH2), 61.2 (CH2), 60.4 (CH2), 49.0 (C), 46.9 (CH2), 41.7 (CH2), 29.1 (C), 
28.1 (C), 26.5 (CH3), 26.2 (CH3), 26.1 (CH3), 25.5 (CH3), 17.7 (CH3), 14.3 (CH3), 14.1 (CH3); m/z 
(CI+) 413 «M+H]+, 100%), 357 (12), 297 (10), 158 (8 ), 58 (18).
CO2 H
172
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(4 S, 5 R)-tert-Buty I 4-(4-(1 -amino-3-ethoxy-3-oxoprop-1 -enyl)thiazol-2-yl)-2,2,5-
trimethyloxazolidine-3-carboxylate (169)
s
X
s
1 6 9
CEM Discover® (Table 11, entry 5)
|3-Ketoester 172 (100 mg, 0.24 mmol) was dissolved in toluene-acetic acid (5:1, 3 mL) and 
ammonium acetate (2.24 g, 29.09 mmol, 120 equiv) added. The mixture was irradiated in a 
sealed tube at 150 °C with continuous cooling for 10 minutes using a CEM Discover® single 
mode microwave synthesiser (initial power 300 W). The mixture was cooled to room 
temperature, evaporated in vacuo and partitioned between water (20 mL) and ethyl acetate (10 
mL). The aqueous layer was further extracted with ethyl acetate ( 2 x 1 0  mL) and the combined 
organic extracts washed sequentially with saturated aqueous sodium hydrogen carbonate (15 
mL) and brine (15 mL), dried (Na2S0 4) and evaporated in vacuo. Purification by column 
chromatography on silica, eluting with petroleum ether-ethyl acetate (3:1) gave the title 
compound (69 mg, 69%) as a viscous yellow oil (Found: [M+H]+, 412.1899. Calc, for 
C19H29N3O5S: 412.1901); [a]D25 -52.5 (c 1.50, acetone); 0.34 (petroleum ether-ethyl acetate 
3:1); vmax(film)/cm'1 3488, 3407, 3146, 2975, 1694, 1478, 1368, 1258, 1217, 1167, 1132, 1087; 
6H(500 MHz; CDCI3) 7.54 (1 H, br s, thz), 7.10-6.60 (2 H, br s, exch. D20 , NH) 5.12 (1 H, br s, 
C=C-H), 4.68 (0.4 H, br s, Thr 4-H), 4.57 (0.6 H, br d, J 4.2, Thr 4-H), 4.14 (1 H, m, Thr 5-H),
4.12 (2 H, q, J 7.0, OCH^CH3), 1.64 (7 H, br s), 1.40 (3 H, br s), 1.34 (3 H, br d, J 6.2, Thr 5-Me),
1.24 (3 H, t, J 7.0, OCH2C H3), 1.10 (6  H, br s); 6C(125 MHz; CDCI3) 171.9 (C), 170.4 (C), 151.8 
(C), 151.2 (C), 150.6 (C), 124.9 (CH), 116.9 (CH), 95.2 (C), 81.4 (CH), 80.6 (C), 65.9 (CH), 58.9 
(CH2), 28.1 (CH3), 26.5 (CH3), 25.5 (CH3), 17.7 (CH3), 14.6 (CH3); m/z (APCI) 412 ([M+H]+, 7%), 
356 (17), 312 (30), 285 (10), 241 (30), 227 (25), 183 (14), 134 (100).
Milestone BatchSYNTH® (Table 11, entry 6)
p-Ketoester 172 (1.00 g, 2.43 mmol) was dissolved in toluene-acetic acid (5:1, 30 mL) and 
ammonium acetate (22.44 g, 291.12 mmol, 120 equiv) added. The mixture was irradiated in a 
sealed 60 mL Teflon reaction vessel at 150 °C for 10 minutes using a Milestone BatchSYNTH® 
Dave multimodal microwave synthesiser (initial power 300 W). The mixture was cooled to room 
temperature, evaporated in vacuo and partitioned between water (200 mL) and ethyl acetate (50 
mL). The aqueous layer was further extracted with ethyl acetate (2 x 25 mL) and the combined 
organic extracts washed sequentially with saturated aqueous sodium hydrogen carbonate (150 
mL) and brine (100 mL), dried (Na2S 0 4) and evaporated in vacuo. Purification by column 
chromatography on silica, eluting with petroleum ether-ethyl acetate (3:1) gave the title 
compound (680 mg, 6 8 %) as a viscous yellow oil.
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(4S,5ft)-fe/?-Butyl 4-(4-carbamoylthiazol-2-yl)-2,2,5-trimethyloxazolidine-3-carboxylate 
(173)
Carboxylic acid 140 (753 mg, 2.20 mmol) was dissolved in THF (50 mL) and triethylamine (0.32 
mL, 234 mg, 2.31 mmol, 1.05 equiv) added. Ethyl chloroformate (0.221 mL, 251 mg, 2.31 mmol,
1.05 equiv) was added and the solution stirred at room temperature for 1 hour. Aqueous 
ammonia (35%, 50 mL) was added and the solution stirred vigorously at room temperature for 3 
hours. The organic solvent was removed in vacuo and the resulting aqueous solution diluted 
with water (20 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic extracts 
were washed with brine (25 mL), dried (Na2S 0 4) and evaporated in vacuo to furnish the title 
compound (652 mg, 87%) as a colourless solid, mp 65 °C (EtOAc) (Found: [M+H]+, 342.1485. 
Calc, for C15H24N3O4S: 342.1482); [a]D24 -49.0 (c 1.02, chloroform); vmax(KBr)/cm'1 3465, 2979, 
2925, 1701, 1591, 1458, 1367, 1308, 1261, 1173, 1135, 1089, 984, 946, 857, 757; 5H(500 MHz; 
CDCI3) 8.06 (1 H, s, 5-H), 7.08 (1 H, br s, exch D20 , NF/H) 6.39 (0.6 H, br s, exch D20, NHH), 
6.26 (0.4 H, br s, exch D20 , NHH), 4.65 (0.4 H, brs, 4 ’-H ), 4.57 (0.6 H, d, J 7.3, 4 ’-H ), 4.13 (1 H, 
m, 5 -H ), 1.62 (6 H, s, both 2’-Me), 1.36 (3 H, d, J 5.0, 5’-Me), 1.12 (9 H, s, CMe3); 5C(125 MHz; 
CDCI3) 172.1 (C), 171.2 (C), 163.1 (C), 149.1 (C), 124.0 (CH), 95.3 (C), 81.3 (C), 77.6 (CH), 65.8 
(CH), 28.3 (CH3), 26.5 (CH3), 25.5 (CH3), 21.1 (CH3) ; m/z (ES+) 364 ([M+Na]\ 36%), 308 (30), 
286 (28), 242 (100), 228 (52), 184 (23), 166 (10).
(4S,5F?)-te/t-Butyl 4-(4-cyanothiazol-2-yl)-2,2,5-trimethyloxazolidine-3-carboxylate (174)
Amide 173 (600 mg, 1.76 mmol) was dissolved in pyridine (25 mL) and phosphorus oxychloride 
(0.41 mL, 674 mg, 4.39 mmol, 2.5 equiv) added. The solution was stirred at 0 °C for 2 hours 
then poured over ice. Water (50 mL) was added and the aqueous solution extracted with diethyl 
ether (3 x 20 mL). The combined organic extracts were washed with hydrochloric acid (2 M, 100 
mL), water (100 mL) and brine (50 mL), dried (Na2S 0 4) and evaporated in vacuo to afford the 
title compound (271 mg, 48%) as a yellow oil (Found: [M+H]\ 324.1376. Calc, for C15H22N30 3S: 
342.1376); [a]D23 -66.38 (c0.93, chloroform); vmax(film)/crTV1 3020, 2250, 1703, 1369, 1215, 1135,
c o n h 2
173
c o n h 2
174
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932, 760, 6 6 8 ; 5H(400 MHz; CDCI3) 7.95 (1 H, br s, 5-H), 4.72 (0.5 H, m, 4 ’-H), 4.65 (0.5 H, m, 
4’-H ), 4.13 (0.5 H, m, 5’-H ), 4.10 (0.5 H, m, 5 -H ), 1.65 (6 H, s, both 2’-Me), 1.40 (3 H, d, J6.0, 
5’-M e), 1.36 (9 H, s, CMe3); 6C(100 MHz; CDCI3) 174.5 (C), 173.1 (C), 152.3 (C), 151.1 (C),
130.3 (CH), 126.3 (C), 113.8 (C), 95.5 (C), 95.0 (C), 81.5 (C), 81.0 (C), 77.4 (CH), 76.7 (CH),
65.8 (CH), 65.4 CH), 28.1 (CH3), 26.5 (CH3), 26.2 (CH3), 25.8 (CH3), 17.9 (CH3), 17.7 (CH3); m/z 
(CI+) 324 ([M+H+], 70%), 285 (35), 268 (30), 114 (15), 58 (100).
(4S,5R)-tert-Buty\ 4-(4-((2)-2-cyano-1-hydroxyvinyl)thiazol-2-yl)-2,2,5-trimethyloxazolidine-
3-carboxylate (176)
C02H
176
Carboxylic acid 140 (175 mg, 0.51 mmol) was dissolved in dry acetonitrile (20 mL) and 
triethylamine (75 pL, 54 mg, 0.54 mmol, 1.05 equiv) added. Ethyl chloroformate (51 pL, 58 mg, 
0.54 mmol, 1.05 equiv) was added and the solution stirred at room temperature for 2 hours. 
Sodium hydride (60% in mineral oil, 102 mg, 61 mg NaH, 2.56 mmol, 5 equiv) was added under 
an umbrella of nitrogen and the solution stirred at room temperature for a further 2 h then 
quenched with saturated aqueous ammonium chloride solution (10 mL) and evaporated in vacuo. 
The resulting aqueous solution was diluted with water (10 mL) and extracted with ethyl acetate (3 
x 15 mL). The combined organic extracts were washed with brine (15 mL), dried (Na2S 0 4) and 
evaporated in vacuo. Purification of the residue on silica eluting with diethyl ether furnished the 
title compound (145 mg, 78%) as a beige solid, mp 63-65 °C (ether); [a]D25 -48.3 (c 1.20, 
acetone); vmax(KBr)/crn'1 3518, 3468, 3397, 2976, 2252, 1683, 1574, 1368, 1258, 1132; 5H(400 
MHz; CDCI3) 8.03 (1 H, s, 5-H), 7.08 (1 H, br s, exch D20 , OH) 6.00 (1 H, br s, CHCN), 4.65 (0.3
H, br s, 4 ’-H ), 4.56 (0.7 H, br d, J6.3, 4 ’-H ), 4.13 (1 H, br m, 5’-H ), 1.62 (6 H, s, both 2’-Me),
I.36 (3 H, d, J 5.0, 5’-Me), 1.12 (9 H, s, CMe3); 5C(125 MHz; CDCI3) 162.8 (C), 149.1 (C), 124.0 
(CH), 95.3 (C), 77.6 (CH), 65.8 (CH), 28.1 (CH3), 26.5 (CH3), 25.5 (CH3), 17.7 (CH3).
2,2-Diethoxythioacetamide (177)
EtO EtO NH2
1 7 7
2,2-Diethoxyacetonitrile (5.00 mL, 36.0 mmol) was dissolved in methanol (200 mL) and 
ammonium sulfide (50 wt. % in H20; 9.80 mL, 71.9 mmol) added. The solution was stirred at
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room temperature for 18 h then evaporated in vacuo to give the title compound (5.87 g, 100%) as 
a pale yellow solid, mp 94-95 °C (Et20 ) {(lit.143 mp 93-94 °C)} (Found: [M+Na]+, 186.0560. Calc, 
for C6H13N 0 2SNa: 186.0559); vmax(CH2CI2)/cm-1 3371, 3250, 2971, 2884, 1603, 1423, 1245, 
1121, 1057, 1011, 960, 912, 823, 730; 6H(500 MHz; CDCI3) 7.81 (1 H, br s, exch D20 , NH), 7.56 
(1 H, br s, exch D20 , NH), 4.98 (1 H, s, CH), 3.67 (2 H, dq, J 9.5, 7.0, 2 OCHHMe), 3.58 (2 H, dq, 
J 9.5, 7, 2 OCHHMe), 1.19 (6 H, t, J 7.0, 2 OCH2Me)\ 6C(125 MHz; CDCI3) 202.4 (C), 103.2 (CH),
63.0 (CH2), 15.1 (CH3); m/z (CI+) 181 ([M+NH4]+, 20%), 164 ([M+H]+, 65%), 132 (10), 103 (100), 
88(18), 74 (12).
Ethyl 2-(diethoxymethyl)thiazole-4-carboxylate (178)
178
Ethyl bromopyruvate (5.44 ml, 8.45 g, 43.3 mmol, 1.2 equiv) was added to a stirred solution of
2 ,2-diethoxythioacetamide (5.89 g, 36.1 mmol) in ethanol (100  ml) over 4A molecular sieves (25 
g) and the mixture heated at reflux for 1 h. The solution was allowed to cool, filtered through 
Celite® and evaporated in vacuo. The residue was dissolved in dichloromethane (200 mL) and 
the solution washed with saturated aqueous sodium hydrogen carbonate (200 mL), brine (200 
mL), dried (Na2S 04) and evaporated in vacuo to furnish the title compound (9.36 g, 100%) as a 
brown oil, (Found: [M+Na]+, 282.0769. Calc, for CnH17N 04SNa: 282.0770); vmax(filrn)/crrf1 3113, 
2979, 1735, 1484, 1369, 1312, 1241, 1205, 1061, 948, 905, 759; 5H(400 MHz; CDCI3) 8.14 (1 H, 
s, 5-H), 5.64 (1 H, s, CH), 4.36 (2 H, q, J 7.2, OCHHMe), 3.69 (2 H, dq, J9.6, 7.2, 2 OCHH), 3.59 
(2 H, dq, J 9.6, 7.2, 2 OCHH), 1.34 (3 H, t, J 7.2, OCH2Me), 1.19 (6 H, app t, J 7.2, 2 OCH2/We); 
6C(100 MHz; CDCI3) 170.2 (C), 161.4 (C), 147.1 (C), 128.5 (CH), 98.8 (CH), 62.8 (CH2), 61.5 
(CH2), 15.1 (CH3), 14.4 (CH3); m/z (ES+) 282 ([M+Na}\ 32%), 214 (72), 186 (93), 157 (41), 139 
(100 ).
Ethyl 2-(dimethoxymethyl)thiazole-4-carboxylate (179)
1 7 9
Ethyl 2-(diethoxymethyl)thiazole-4-carboxylate (9.36 g, 36.1 mmol) was dissolved in methanol 
(250 mL) and p-toluenesulfonic acid (1.37 g, 7.22 mmol, 20 mol%). The solution was heated at 
reflux for 48 h, cooled to room temperature and evaporated in vacuo. The residue was dissolved
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in ethyl acetate (100 mL) and the solution washed with saturated aqueous sodium hydrogen 
carbonate solution. The aqueous layer was extracted with ethyl acetate (2 x 100 mL) and the 
combined organic extracts washed with water (100 mL) and brine (100 mL), dried (Na2S 04) and 
evaporated in vacuo to give the title compound (7.51 g, 96%) as a red-brown oil (Found: [M+H]+, 
218.0480. Calc, for C8H12N 04S: 218.0482); vmax(film)/cm'1 3118, 2954, 2835, 1729, 1488, 1435, 
1327, 1247, 1216, 1068, 974, 919, 864, 754; 6H(250 MHz; CDCI3) 8.18 (1 H, s, 5-H), 5.54 (1 H, 
s, CH), 3.89 (3 H, s, OMe), 3.39 (6  H, s, 2 OMe); 6C(125 MHz; CDCI3) 169.0 (C), 161.8 (C),
147.0 (C), 128.7 (CH), 100.4 (CH), 54.0 (CH3), 52.5 (CH3); m/z (ES+) 218 ([M+H}+, 58%), 186 
( 100).
Methyl 2-formylthiazole-4-carboxylate (180)
Methyl 2-(dimethoxymethyl)thiazole-4-carboxylate (7.50 g, 34.53 mmol) was dissolved in acetone 
(150 mL) and aqueous hydrochloric acid (2 M, 150 mL) added. The solution was heated at reflux 
for 1 hour, allowed to cool to room temperature and the acetone removed in vacuo. The 
remaining aqueous solution was extracted with chloroform (3 x 100 mL) and the combined 
organic extracts washed with brine (100 mL), dried (Na2S 04) and evaporated in vacuo to yield 
the title compound (5.19 g, 8 8 %) as a yellow-brown solid, mp 111-114 °C (CH2CI2) (Found: 
[M+H]+, 172.0066. Calc, for C6H6N 0 3S: 172.0063); vmax(CH2CI2)/cnT1 3120, 2956, 2865, 1735, 
1699, 1492, 1463, 1429, 1336, 1256, 1217, 1103, 989, 865, 790; 6 H (400 MHz; CDCI3) 10.00 (1 
H, s, CHO), 8.72 (1 H, s, 5-H), 3.96 (3 H, s, C 0 2Me); 6C(100 MHz; CDCI3) 183.6 (CH), 166.2 (C),
161.0 (C), 149.1 (C), 133.3 (CH), 53.0 (CH3); m/z(ES+) 172 ([M+H+], 13%), 158 (40), 140 (100).
Methyl 2-[1-(1 -hydroxyprop-2-ynyl)]thiazole-4-carboxylate (181)
To a stirred solution of methyl 2-formylthiazole-4-carboxylate (4.50 g, 26.3 mmol) in anhydrous 
THF (125 mL) at 0 °C, ethynylmagnesium bromide (0.5 M in THF, 55.2 mL, 27.6 mmol, 1.05 
equiv) was added and the mixture stirred at 0 °C for 1 hour. Saturated aqueous ammonium 
chloride (125 mL) was added and the THF removed in vacuo. The resulting aqueous solution 
was partitioned between chloroform (150 mL) and water (50 mL) and the aqueous layer was
COjjMe C 0 2Me
180
C 0 2Me C 0 2Me
181
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further extracted with chloroform (2 x 75 mL). The combined organic extracts were washed with 
brine (100 mL), dried (Na2S 0 4) and evaporated in vacuo. The residue was purified by 
recrystallisation (CH2CI2-Et20 ) to afford the title compound (4.19 g, 81%) as a pale brown solid, 
mp 109-110 °C (CHCI3) (Found: [M+H]+, 198.0217. Calc, for C8H8N 0 3S: 198.0219); R, 0.30 
(petroleum ether-ethyl acetate 1:1); vmax(CH2CI2)/cm'1 3428, 3307, 3016, 2393, 2112, 1725, 
1503, 1479, 1428, 1328, 1248, 1212, 1092, 1032, 992, 926; 5H(400 MHz; CDCI3) 8.13 (1 H, s, 5- 
H), 5.82 (1 H, s, 1’-H), 4.14 (1 H, s, OH), 3.88 (3 H, s, C 0 2Me), 2.65 (1 H, d, J 2.4, 3’-H); 5C(125 
MHz; CDCI3) 171.2 (C), 161.6 (C), 146.7 (C), 128.7 (CH), 80.9 (C), 75.8 (CH), 61.6 (CH), 52.6 
(CH3); m/z (APCI) 220 ([M+Na+], 50%), 198 ([M+H+], 23), 180 (95), 166 (100), 122 (8 ).
Methyl 2-(propynoyl)thiazole-4-carboxylate (170)
Mn02 oxidation
To a stirred solution of methyl 2-[1-(1-hydroxyprop-2-ynyl)]thiazole-4-carboxylate (882 mg, 4.47 
mmol) in dichloromethane (50 mL), activated manganese(IV) oxide (1.94 g, 22.36 mmol, 5 equiv) 
was added and the mixture stirred at room temperature for 30 minutes. A further portion of 
activated manganese(IV) oxide (1.94 g, 22.36 mmol, 5 equiv) was added and the solution stirred 
at room temperature for 2 hours then filtered through a pad of Celite® and the pad washed with 
dichloromethane (25 mL). The solvent was evaporated under a stream of nitrogen and the 
residue (672 mg, 77%) used immediately without further purification. Recrystallisation afforded 
the title compound as a yellow solid, mp 152 °C (dec.) (CHCI3) (Found: [M+H]+, 196.0068. Calc, 
for C8H6N 0 3S: 196.0059); R, 0.40 (petroleum ether-ethyl acetate 1:1); vmax(CH2CI2)/crn'1 3209, 
3128, 2360, 1742, 1641, 1480, 1461, 1427, 1341, 1265, 1240, 1109, 993, 960, 911, 827; 6H(250 
MHz; CDCI3) 8.46 (1 H, s, 5-H), 3.93 (3 H, s, C 0 2Me), 3.66 (1 H, s, 3’-H); 6C(125 MHz; CDCI3)
169.0 (C), 166.2 (C), 161.1 (C), 149.2 (C), 133.8 (CH), 84.9 (CH), 78.9 (C), 52.8 (CH3); m/z 
(ES+) 196 ([M+H+], 100%), 156 (15).
IBX oxidation
Methyl 2-[1-(1-hydroxyprop-2-ynyl)]thiazole-4-carboxylate (3.50 g, 17.75 mmol) was dissolved in 
DMSO (35 mL) and the solution added to a homogenous solution of IBX (12.43 g, 44.37 mmol,
2.5 equiv) in DMSO (315 mL) and the mixture stirred at room temperature for 16 hours. Water 
(350 mL) was added and the mixture stirred at 0 °C for 10 minutes then partitioned between 
water (200 mL) and ether (200 mL). The aqueous layer was extracted with ether (4 x 200 mL) 
and the combined organic extracts washed with water (3 x 200 mL), saturated aqueous sodium 
hydrogen carbonate (200 mL) and brine (200 mL), dried (Na2SQ4) and evaporated in vacuo to
C02Me C02Me
170
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furnish the title compound (1.19 g, 34%) as a yellow-orange solid which was used immediately 
without further purification.
(4S,5fi)-te/t-Butyl 4-(4-((3£)-1-amino-2-(ethoxycarbonyl)-5-(4-(methoxycarbonyl)thiazol-2- 
yl)-5-oxopenta-1,3-dienyl)thiazol-2-yl)-2,2,5-trimethyloxazolidine-3-carboxylate (182)
To a stirred suspension of methyl 2-(propynoyl)thiazole-4-carboxylate (670 mg, 3.43 mmol, 1.5 
equiv) in ethanol (75 mL) was added a solution of enamine 169 (920 mg, 2.24 mmol, 1 equiv) in 
ethanol (25 mL) and the mixture stirred at room temperature for 24 h. The solvent was 
evaporated in vacuo. Purification by column chromatography on silica, eluting with petroleum 
ether-ethyl acetate (1:1) afforded the title compound (800 mg, 58%) as a bright yellow-orange 
foam, mp 70-72 °C (EtOAc-petrol); (Found: [M+H]+, 607.1898. Calc, for C27H35N4O8S2. 
607.1891); [a]D25 -45.2 (c 1.00, CHCI3); Rf 0.45 (petroleum ether-ethyl acetate 1:1); 
vmax(CH2CI2)/cm-1 3488, 3406, 3128, 2976, 1695, 1641, 1478, 1461, 1368, 1265, 1218, 1167, 
1132, 1087; 6 H (400 MHz; CDCI3) 9.71 (1 H, br s, exch D20, i), 8.31 (1 H, s, n), 8.22 (1 H, d, J 
15.3, I), 7.82 (1 H, d, J 15.3, m), 7.72 (0.5 H, br s, g), 7.64 (0.5 H, br s, g), 6 .66  (1 H, br s, exch 
D20, h), 4.70 (0.4 H, br s, f), 4.60 (0.6 H, br d, J 7.5, f), 4.34 (2 H, q, J7.1, j), 4.16 (1 H, m, e), 
3.91 (3 H, s, o), 1.64 (6 H, app br s, b, c), 1.48 (3 H, t, J7.1, k), 1.41 (3 H, br s), 1.36 (4 H, br s) 
1.12(5 H, brs); 5C(100 MHz; CDCI3) 181.8 (C), 170.7 (C), 169.7 (C), 161.7 (C), 151.1 (C), 148.0 
(CH), 147.8 (CH), 144.6 (C), 144.2 (C), 132.5 (CH), 125.6 (CH), 115.3 (CH), 114.6 (CH), 97.0 
(C), 95.4 (C), 94.9 (C), 81.4 (C), 80.8 (C), 76.8 (CH), 65.9 (CH), 60.8 (CH2), 52.7 (CH3), 52.5 
(CH3), 28.1 (CH3), 26.5 (CH3), 26.2 (CH3), 25.6 (CH3), 18.0 (CH3), 17.7 (CH3), 14.2 (CH3); m/z 
(ES+) 629 ([M+Na+], 70%), 607 ([M+H+], 100%), 407 (8 ), 385 (20), 363 (40), 341 (50), 285 (30), 
263(13), 241 (45).
C02Me
O
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(4S,5fl)-test-Butyl 4-(4-(3-(ethoxycarbonyl)-6-(4-(methoxycarbonyl)thiazol-2-yl)pyridin-2- 
y l)thiazol-2-yl)-2,2,5-trimethyloxazolidine-3-carboxylate (171)
C 0 2Me
M e02C
Aminodienone 182 (650 mg, 1.07 mmol) was dissolved in ethanol (100 mL) and iodine (136 mg, 
0.54 mmol, 0.5 equiv) added. The solution was stirred at room temperature for 2 hours, 
evaporated in vacuo and partitioned between ethyl acetate (50 mL) and aqueous sodium 
thiosulfate (1 M, 50 mL). The aqueous layer was further extracted with ethyl acetate (2 x 25 mL) 
and the combined organic extracts washed with water (50 mL), brine (50 mL), dried (MgS04) and 
evaporated in vacuo to furnish the title compound (630 mg, 100%) as a viscous oil (Found: 
[M+H]+, 589.1788. Calc, for C27H33N4O7S2: 589.1785); [a]D25 -73.6 (c 0.50, acetone); Rf 0.30 
(petroleum ether-ethyl acetate 1:1); vmax(CH2Cl2)/cm*1 3117, 2980, 1728, 1583, 1564, 1478, 
1454, 1435, 1367, 1249, 1218, 1172, 1134, 1094, 1021, 991, 913, 856, 763, 733; 6H(400 MHz; 
CDCI3) 8.26 (1 H, s, 6 -thz), 8.21 (1 H, d, J 8.0, pyr-4), 8.05 (1 H, br s, 2-thz), 7.91 (1 H, d, J 8.0, 
pyr-5), 4.69 (0.4 H, br s, Thr 4-H), 4.61 (0.6 H, br s, Thr 4-H), 4.31 (2 H, br q, J6.9, O C H £H 3),
4.15 (1 H, m, Thr 5-H), 3.93 (3 H, s, OCH3), 1.65 (6  H, br s, both Thr 2-Me), 1.50-1.15 (15 H, 
many br s, Thr 5-Me, CMe3, OCH2CH3)\ 6C(100 MHz; CDCI3) 161.8 (C), 152.9 (C), 150.5 (C), 
148.2 (C), 137.9 (CH), 130.3 (CH), 129.1 (CH), 117.9 (CH), 77.3 (CH), 65.9 (CH), 61.8 (CH2),
52.6 (CH3), 28.2 (CH3), 14.6 (CH3); m/z (ES+) 611 ([M+Na]+, 100%), 589 ([M+H]+, 72%), 533 
(10), 489 (73).
2-(6-(2-((4S,5fi)-3-(te/'f-Butoxycarbonyl)-2,2,5-trimethyloxazolidin-4-yl)thiazol-4-yl)-5- 
carboxypyridin-2-yl)thiazole-4-carboxylic acid (183)
h o 2c
c o 2hC 0 2Me
Pyridine bis-ester 171 (1.30 g, 2.21 mmol) was dissolved in methanol-water (5:1, 120 mL) and 
lithium hydroxide monohydrate (1.85 g, 44.17 mmol, 20 equiv) added. The solution was heated 
at reflux for 60 hours, allowed to cool to room temperature and the methanol removed in vacuo. 
The resulting aqueous solution was diluted with water (30 mL) and extracted with ethyl acetate 
(50 mL). The aqueous layer was acidified to pH 3 (10% w/w aq KHSO4) and extracted with ethyl
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acetate (4 x 50 mL). The combined organic extracts were dried (MgS04) and evaporated in 
vacuo to yield the title compound (1.21 g, 100%) as an orange viscous oil (Found: [M+H]+, 
547.1326. Calc, for C24H27N4O7S2: 547.1321); [a]D25 -54.8 (c 0.50, acetone); vmax(CH2Cl2)/cm-1 
3500-2500 br, 3121, 2980, 2934, 2625, 1713, 1584, 1566, 1504, 1369, 1258, 1170, 1138, 1095, 
1023, 984, 912, 856, 772, 732; 5H(400 MHz; CDCI3) 10.0-9.2 (2 H, br s, 2 C 0 2H), 8.73 (1 H, br s,
6 -thz), 8.48 (1 H, app br s, pyr-4), 8.40 (1 H, s, 2-thz), 8.35 (1 H, app br s, pyr-5), 4.86 (0.5 H, br 
s, Thr 4-H), 4.79 (0.5 H, br s, Thr 4-H), 4.28 (1 H, app br s, Thr 5-H), 1.75 (6 H, br s, both Thr 2- 
Me), 1.45 (9 H, brs, CMe3), 1.25 (3 H, app br s, Thr 5-Me); 6C(125 MHz; CDCI3) 168.4 (C), 151.9 
(C), 148.0 (C), 147.9 (C), 144.1 (CH), 131.5 (CH), 119.0 (CH), 77.3 (CH), 65.2 (CH), 30.9 (CH3),
28.3 (CH3), 20.7 (CH3), 17.7 (CH3); m/z (ES+) 564 ([M+NH4]+, 100%), 547 ([M+H]+, 98%), 524 
(18), 507 (62).
(4S,5fi)-fe/t-Butyl 4-(4-(3-carbamoyl-6-(4-carbamoylthiazol-2-yl)pyridin-2-yl)thiazol-2-yl)- 
2,2,5-trimethyloxazolidine-3-carboxylate (184)
1 8 4Boc Boc
Pyridine bis-acid 183 (1.15 g, 2.10 mmol) was dissolved in THF (100 mL) and triethylamine 
(0.616 mL, 447 mg, 4.42 mmol, 2.10 equiv) added. Ethyl chloroformate (0.422 mL, 479 mg, 4.42 
mmol, 2 .10  equiv) was added and the solution stirred at room temperature for 18 hours. 
Aqueous ammonia (35%, 100 mL) was added and the solution stirred vigorously at room 
temperature for 24 hours. The organic solvent was removed in vacuo and the resulting aqueous 
solution filtered and the solid obtained dried in a desiccator under reduced pressure to furnish the 
title compound (710 mg, 62%) as a salmon-coloured solid, mp 139-141 °C (acetone) (Found: 
[M+H]\ 545.1634. Calc, for C24H29N60 5S2: 545.1635); [a]D22 -20.4 (c 0.5, methanol); 
Vmax(CH2CI2)/cm-1 3367, 3167, 2925, 2845, 1694, 1659, 1584, 1458, 1373, 1303, 1253, 1127, 
856; 6h(400 MHz; d6-acetone) 8.21 (1 H, s, 6 -thz), 8.12 (1 H, d, J 7.9, pyr-4), 8.10 (1 H, br s, 
exch D20, NH), 7.92 (1 H, d, J 7.9 pyr-5), 7.64 (1 H, br s, exch D20 , NH), 7.21 (1 H, br s, exch 
D20, NH), 6.82 (1 H, br s, 2-thz), 6.68  (1 H, br s, exch D20, NH), 4.56 (1 H, d, J 7.6, Thr 4-H),
4.16 (1 H, app br s, Thr 5-H), 1.54 (3 H, s, Thr 2-Me), 1.52 (3 H, s, Thr 2-Me), 1.28 (9 H, s, 
CMe3), 1.04 (3 H, app br s, Thr 5-Me); 6C(125 MHz; DMSO) 167.7 (C), 138.5 (CH), 127.3 (CH),
118.6 (CH), 81.3 (C), 80.2 (C), 73.3 (CH), 65.5 (CH), 28.4 (CH3), 25.6 (CH3), 17.9 (CH3) {signals 
absent even at high concentrations and with increased numbers of scans}; m/z (ES+) 545 
([M+H]+, 100%), 141 (16).
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(4S,5fi)-ferf-Butyl 4-(4-(3-cyano-6-(4-cyanothiazol-2-yl)pyridin-2-yl)thiazol-2-yl)-2,2,5-
trimethyloxazolidine-3-carboxylate (185)
h2n o c
C 0N H 2 CN
Boc
Pyridine bis-amide 184 (265 mg, 0.49 mmol) was dissolved in pyridine (20 mL) and phosphorus 
oxychloride (0.23 mL, 373 mg, 2.43 mmol, 5 equiv) added. The solution was stirred at 0 °C for 2 
hours then poured over ice. Water (50 mL) was added and the aqueous solution extracted with 
diethyl ether (3 x 50 mL). The combined organic extracts were washed with aqueous potassium 
hydrogen sulfate (10% w/v, 100 mL) and water (100 mL), dried (MgS04) and evaporated in 
vacuo to afford the title compound (214 mg, 87%) as an off-white solid, mp 53-55 °C (CHCI3) 
(Found: [M+Na]+, 531.1251. Calc, for C24H24N60 3S2Na: 531.1244); [a]D22 -45.6 (c0.5, methanol); 
Vmax(CH2CI2)/cm-1 3156, 2986, 2895, 2243, 1815, 1789, 1639, 1559, 1469, 1378, 1292, 1212, 
1167, 1092, 926, 901; 5H(500 MHz; CDCI3) 8.19 (1 H, s, 6 -thz), 8.16 (2 H, app br s, pyr-4 and 
pyr-5), 8.12 (1 H, s, 2-thz), 4.76 (1 H, br s, Thr 4-H), 4.40 (0.4 H, br s, Thr 5-H), 4,23 (0.6 H, br s, 
Thr 5-H), 1.66 (6 H, br s, both Thr 2-Me), 1.49-1.35 (9 H, br s, CMe3), 1.18 (3 H, app br s, Thr 5- 
Me); 5C(125 MHz; CDCI3) 151.2 (C), 144.5 (CH), 133.5 (CH), 128.6 (C), 117.9 (CH), 113.6 (C),
108.1 (C), 77.3 (CH), 30.3 (CH3), 28.3 (CH3), 17.9 (CH3) {signals absent even at high 
concentrations and with increased numbers of scans}; m/z (ES+) 531 ([M+Na]+, 12%), 138 (32), 
82 (19), 63 (38), 60(100).
(4S,5F?)-terf-Butyl 4-(4-(3-carbamothioyl-6-(4-carbamothioylthiazol-2-yl)pyridin-2-yl)thiazol- 
2-yl)-2,2,5-trimethyloxazolidine-3-carboxylate (186)
Pyridine bis-nitrile (200 mg, 0.393 mmol) was dissolved in methanol (20 mL) and ammonium 
sulfide (50 wt. % in H20; 0.56 mL, 3.932 mmol, 10 equis) added. The solution was stirred at 
room temperature for 18 h then evaporated in vacuo. Purification of the residue by column 
chromatography on silica, eluting with chloroform-methanol (19.1) furnished the title compound 
as a bright yellow solid (160 mg, 70%), mp 114-118 °C (chloroform) (Found: [M+H]\ 577.1183. 
Calc, for C24H29N60 3 S4: 577.1178); [a]D25 -32.0 (c 0.25, acetone); R, 0.20 (chloroform-methanol 
19:1); vmax(CH2CI2)/cm'1 3285, 3168, 2978, 2932, 1691, 1609, 1579, 1493, 1441, 1391, 1368,
h2n s c
c s n h 2
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1309, 1260, 1215, 1170, 1141, 1089, 1022, 980, 909, 852, 733; 5H(500 MHz; CDCI3) 8.61 (1 H, 
s, 6 -thz), 8.45 (1 H, br s, exch D20, NH), 8.42 (1 H, d, J 7.9, pyr-4), 8.33 (1 H, br s, exch D20, 
NH), 8.03 (1 H, br s, exch D20 , NH), 7.92 (1 H, d, J 7.9 pyr-5), 7.85 (1 H, br s, exch D20 , NH), 
7.81 (1 H, br s, 2-thz), 4.68 (0.4 H, br s, Thr 4-H), 4.52 (0.6 H, br s, Thr 4-H), 4.23 (1 H, br s, Thr
5-H), 1.62 (6  H, br s, both Thr 2-Me), 1.38 (9 H, s, CMe3), 1.18 (3 H, app br s, Thr 5-Me); 5C(125 
MHz; CDCI3) 144.0 (CH), 130.0 (CH), 126.2 (CH), 118.3 (CH), 77.3 (CH), 65.7 (CH), 30.3 (CH3),
28.4 (CH3), 17.9 (CH3); m /z{ES+) 577 ([M+H]+, 100%), 143 (17), 141 (47), 130 (28).
(4S,5fl)-terf-Butyl 4-(4-(6-(4-{ethoxycarbonyl)-2,4,-bithiazol-2,-yl)-3-(4-
(ethoxycarbonyl)thiazol-2-yl)pyridin-2-yl)thiazol-2-yl)-2,2,5-trimethyloxazolidine-3- 
carboxylate (168)
Pyridine bis-thioamide 186 (140 mg, 0.24 mmol) was dissolved in anhydrous DME (20 mL) and 
dry potassium hydrogen carbonate (389 mg, 3.88 mmol, 16 equiv) added. Ethyl bromopyruvate 
(0.183 mL, 284 mg, 1.46 mmoL, 6  equiv) was added and the mixture stirred at room temperature 
for 24 hours. The solvent was removed in vacuo and the residue partitioned between water (50 
mL) and diethyl ether (50 mL). The organic extract was dried (MgS04) and evaporated in vacuo, 
and the residue dissolved in anhydrous DME (20 mL). The solution was cooled to 0 °C and 
pyridine (0.353 mL, 346 mg, 4.37 mmol, 18 equiv) and TFAA (0.275 mL, 408 mg, 1.94 mmol, 8 
equiv) added slowly and sequentially. The solution was stirred at 0 °C for 3 hours, allowed to 
warm to room temperature and triethylamine (0.135 mL, 98 mg, 0.97 mmol, 4 equiv) added. The 
solution was stirred at room temperature for 3 hours then evaporated in vacuo. Purification of 
the residue by column chromatography on silica eluting with chloroform-methanol (5:1) afforded 
the title compound (180 mg, 96%) as a yellow solid, mp 49-50 °C (chloroform) (Found: [M+H]+, 
769.1604. Calc, for C^H^NeC^^ 769.1601); [a]D25 -46.0 (c0.10, acetone); Rf0.69 (chloroform- 
methanol, 19:1); vmax(CH2CI2)/cm'1 3438, 2966, 2915, 1734, 1700, 1579, 1464, 1438, 1363, 1298, 
1258, 1091, 1022; 5H(400 MHz; CDCI3) 8.25 (1 H, s, thz), 8.24 (1 H, app br s, pyr-4), 8.20 (1 H, 
s, thz) 8.17 (1 H, s, thz), 7.95 (1 H, app br s, pyr-5), 6.91 (1 H, s, thz), 4.95 (0.6 H, s, Thr 4-H), 
4.83 (0.4 H, d, J11.0, Thr 4-H), 4.39 (2 H, q, J 7.0, O C H £H 3), 4.36 (2 H, q, J 7.0, OCH^CHs), 
4.35 (1 H, br s, Thr 5-H), 1.61 (3 H, br s), 1.51 (6 H, br s), 1.45 (3 H, br s), 1.38 (3 H, t, J 7.0, 
OCH2CH3), 1.31 (3 H, t, J 7.0, OCH2CH3), 1.18 (6 H, br s); 6C(125 MHz; CDCI3) 140.8 (CH),
128.0 (CH), 120.5 (CH), 61.8 (CH2), 28.3 (CH3), 14.4 (CH3); m/z (ES+) 786 (M+Na]+, 45%), 769 
([M+H]+, 100%), 656 (8 ), 639 (8 ), 224 (8 ), 141 (8 ).
H2NSC
c s n h 2
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Synthetic approaches to micrococcinin acid (80) [section 4.8.3]
Method a)
MP1 core domain 168 (15 mg, 21 pmol) was dissolved in hydrochloric acid (6 M, 3 ml.) and 
heated at 110 °C for 2 h. The solution was allowed to cool to room temperature, diluted with 
water (3 mL) and centrifuged at 9000 rpm for 5 minutes, furnishing a yellow solid (3 mg).
Method b)
The yellow solid from the above reaction was dissolved in hydrochloric acid (6 M, 3 mL) and the 
solution heated at reflux for 16 hours, cooled to room temperature and diluted with water (3 mL). 
The resulting yellow precipitate was collected by centrifugation (9000 rpm, 5 mins).
Method c)
MP1 core domain 168 (5 mg, 7 pL) was dissolved a mixture of hydrochloric acid (10.8 M, 1 mL) 
and formic acid (98%, 1 mL) and the solution heated at 110 °C for 6 hours, allowed to cool to 
room temperature and diluted with water (3 mL). The resulting yellow precipitate was washed 
with diethyl ether (2 mL), leaving an off-white solid solid (2 mg).
Attempted selective ester hydrolysis [sections 5.2.1 and 5.2.2]
1 6 8  R1 = Et, R2 = Et 
241  R1 = Et, R2 = H
2 4 4  R1 = H, R2 = Et
2 4 5  R1 = H, R2 = H
s
NBoc
Lithium hydroxide (1 equiv)
MP1 core domain 168 (30 mg, 39 pmol) was dissolved in methanol-water (5:1, 12 mL) and 
lithium hydroxide monohydrate (1.7 mg, 41 pmol, 1.05 equiv) added. The solution was stirred at 
room temperature for 18 h then evaporated in vacuo. The residue was partitioned between ethyl 
acetate (5 mL) and water (5 mL) and the aqueous layer acidified to pH 3 with 10% w/v potassium 
hydrogen sulphate solution. The acidified aqueous layer was extracted with ethyl acetate ( 3 x 5  
mL) and the combined organic extracts dried (MgS04) and evaporated in vacuo to afford a 
mixture of compounds 168, 241, 244 and 245 (21 mg).
Lithium hydroxide (5 equiv)
MP1 core domain 168 (100 mg, 0.13 mmol) was dissolved in methanol-water (5:1, 10 mL) and 
lithium hydroxide monohydrate (27 mg, 0.65 mmol, 5 equiv) added. The solution was stirred at
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room temperature for 18 h then evaporated in vacuo. The residue was partitioned between ethyl 
acetate (10 mL) and water (10 mL) and the aqueous layer acidified to pH 3 with 10% w/v 
potassium hydrogen sulphate solution. The acidified aqueous layer was extracted with ethyl 
acetate ( 3 x 1 0  mL) and the combined organic extracts dried (MgS04) and evaporated in vacuo 
to afford compound 245 (60 mg, 93%) as a pale yellow solid, R/0.05 (chloroform-methanol, 4:1); 
m/z(ES+) 713 ([M+H]+, 11%), 117 (26), 100(100).
Trimethyltin hydroxide (4 x 2  equiv)
To a stirred solution of MP1 core domain 168 (20 mg, 26 pmol) in 1,2-DCE (2 mL) was added 
trimethyltin hydroxide (9.4 mg, 52 pmol) and the solution heated at 50 °C for 1 hour. Portions of 
trimethyltin hydroxide (9.4 mg, 52 pmol) were added after 1 h, 2 h and 3 h, and the solution 
stirred for one further hour. The solvent was removed in vacuo and the residue purified by 
column chromatography on silica, eluting with chloroform-methanol (9:1) to furnish 168 (10 mg, 
50%), 241 and 244 (5 mg, 27%) and 245 (4 mg, 22%).
Trimethyltin hydroxide (2 equiv)
MP1 core domain 168 (50 mg, 65 pmol) was dissolved in 1,2-DCE (5 mL) and trimethyltin 
hydroxide (23 mg, 130 pmol, 2 equiv) added. The solution was stirred at 50 °C for 96 h then 
evaporated in vacuo. Purification of the residue by column chromatography on silica, eluting with 
chloroform-methanol (4:1) afforded 168 (27 mg, 54%), 241 and 244 (16 mg, 34%) and 245 (5 
mg, 11%).
Ethyl 2'-(6-(2-((1 S,2fi)-1 -amino-2-hydroxypropyl)thiazol-4-yl)-5-(4-(ethoxycarbonyl)thiazol- 
2-yl)pyridin-2-yl)-2,4'-bithiazole-4-carboxylate trifluoroacetate (248)
MP1 core domain (90 mg, 117 pmol) was dissolved in dichloromethane (1 mL) and trifluoroacetic 
acid (1 mL) added. The solution was stirred at room temperature for 1 hour then evaporated 
under a stream of nitrogen. Trituration of the residue with diethyl ether ( 2 x 2  mL) furnished the 
title compound (65 mg, 75%) as a beige solid which was used immediately without further 
purification.
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2-((S)-1-(2-((2)-1-((4S,5/:fy-3-(terf-Butoxycarbonyl)-2,2>5-trimethyloxazolidine-4- 
carboxamido)prop-1-enyl)thiazole-4-carboxamido)-2-methylpropyl)thiazole-4-carboxylic 
acid (249)
MP1 backbone peptide 139 (174 mg, 0.27 mmol) was dissolved in methanol-water (5:1, 15 mL) 
and lithium hydroxide monohydrate (57 mg, 1.37 mmol, 5 equiv) added. The solution was stirred 
at room temperature for 16 h then evaporated in vacuo. The residue was partitioned between 
ethyl acetate (10 mL) and water (10 mL) and the aqueous layer acidified to pH 3 with 10% w/v 
potassium hydrogen sulfate solution. The acidified aqueous layer was extracted with ethyl 
acetate ( 3 x 1 0  mL) and the combined organic extracts dried (Na2S 04) and evaporated in vacuo 
to afford the title compound (148 mg, 89%) as a colourless foam, mp 111-114 °C (EtOAc) 
(Found: [M+H]+, 608.2189. Calc, for C27H38N50 7S2: 608.2213); [afo25 +54.4 (c 0.25, acetone); 
Vmax(CH2CI2)/cm'1 3500-2700 br, 3282, 3122, 2976, 2933, 1690, 1534, 1482, 1391, 1368, 1325, 
1215, 1172, 1083, 913; 5H(500 MHz; CDCI3) 8.12 (1 H, s, j), 7.98 (1 H, s, p) 7.91 (2 H, app br s, 
exch. D20 , k, g), 6.53 (1 H, app br m, h), 5.27 (1 H, d, J 7.2, I), 4.39 (1 H, app. br m, e), 4.03 (1 
H, d, J 7.2, f), 2.48 (1 H, m, m), 1.80 (3 H, d, J7.1, i), 1.55 (6 H, s, b, c), 1.38 (9 H, s, a), 1.35 (3 
H, d, J 7.1, d), 0.97 (3 H, d, J 6.7, n), 0.93 (3 H, d, J 6.7, o); 5C(125 MHz; CDCI3) 128.0 (CH),
127.0 (CH), 81.7 (C), 77.3 (CH), 56.7 (CH), 28.3 (CH3), 26.1 (CH3), 19.6 (CH3); m/z (ES+) 625 
([M+NH4]+, 100%), 608 ([M+H]+, 30%), 552 (4), 391 (33), 335 (8).
NBoc
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(4S,5R)-tert-Buty\ 4-((Z)-1 -(4-((S)-1 -(4-((1 S,2F?)-1 -(4-(6-(4-(ethoxycarbonyl)-2,4'-bithiazol-2'- 
yl)-3-(4-(ethoxycarbonyl)thiazol-2-yl)pyridin-2-yl)thiazol-2-yl)-2- 
hydroxypropylcarbamoyl)thiazol-2-yl)-2-methylpropylcarbamoyl)thiazol-2-yl)prop-1- 
enylcarbamoyl)-2,2,5-trimethyloxazolidine-3-carboxylate (250)
PyBOP®-mediated coupling
MP1 backbone carboxylic acid 249 (40 mg, 66 pmol) was dissolved in dichloromethane (5 mL) 
and the solution cooled to 0 °C. PyBOP® (41 mg, 79 pmol, 1.2 equiv) was added followed by 
dropwise addition of a solution of amine 248 (49 mg, 79 pmol, 1.2 equiv) and triethylamine (1 
mL) in dichloromethane (2 mL). The solution was stirred at room temperature for 16 h then 
evaporated in vacuo. Purification of the residue by column chromatography on silica, eluting with 
ethyl acetate furnished the title compound (26 mg, 33%) as a pale yellow solid, mp 141-142 °C 
(EtOAc) (Found: [M+H]+, 1218.2793. Calc, for CgsHeoNnOnSe: 1218.2798); [a]D25 +30.0 (c0.10, 
acetone); Rf 0.38 (ethyl acetate); vmax(CH2Cl2)/crrf1 3386, 3124, 2979, 1709, 1676, 1582, 1535, 
1481, 1422, 1368, 1213, 1096, 1020, 914, 856, 731; 6H(500 MHz; CDCI3) 8.26 (1 H, d, J8.0, y),
8.25 (1 H, s, thz), 8.16 (1 H, d, J 8.0, z), 8.15 (1 H, s, thz), 8.07 (1 H, s, thz), 8.02 (1 H, s, thz), 
7.98 (1 H, s, thz), 7.97 (1 H, br d, J 8.9, q), 7.76 (1 H, s, thz), 7.80 (1 H, br d, J 8.7, k), 7.72 (1 H, 
br s, g), 6.58 (1 H, appbrs, h), 5.27 (1 H, dd, J 8.7, 7.0, I), 5.17 (1 H, dd, J8.9, 7,2, r), 4.40 (2 H, 
q, J7.1, w o re ’), 4.38 (1 H, d, J 7.2, f), 4.21 (1 H, dd, J 7.2, 6.4, s), 4.05 (2 H, q, J7.1, w ore'), 
3.95 (1 H, m, e), 2.51 (1 H, m, m), 2.50 (1 H, br s, u), 1.82 (3 H, d, J 7.1, i), 1.59 (3 H, s, bore),
1.55 (3 H, s, bore) ,  1.35 (15 H, m, a, x, d’), 1.19 (3 H, d, J 7.2, d), 1.16 (3 H, d, J6.4, t), 0.96 (3 
H, d, J 6.8, n or o), 0.94 (3 H, d, J 6.8, n or o); m/z (ES+) 1240 ([M+Na]+, 29%), 1218 ([M+H]+, 
100%), 684 (8), 636 (15), 559 (23), 536 (12), 305 (11), 224 (11), 179 (56).
BocN
O b'
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HATU-mediated coupling
MP1 backbone carboxylic acid 249 (36 mg, 59 pmol, 1.25 equiv) was dissolved in 
dichloromethane (3 mL) and diisopropylethylamine (41 pL, 30 mg, 236 pmol, 5 equiv) added. 
HATU (23 mg, 60 pmol, 1.25 equiv) was added and the solution stirred at room temperature for 1 
hour before the dropwise addition of a solution of 248 (35 mg, 47 pmol, 1 equiv) and 
diisopropylethylamine (41 pL, 30 mg, 236 pmol, 5 equiv) in dichloromethane (2 mL). The 
reaction mixture was stirred at room temperature for 4 hours, evaporated in vacuo and the 
residue purified by chromatography on silica, eluting with ethyl acetate to give the title compound 
(44 mg, 77%) as a pale yellow solid.
2'-(6-(2-((1 S,2fl)-1 -(2-((S)-1 -(2-((Z)-1 -<(2S,3^-2-amino-3-hydroxybutanamido)prop-1 - 
enyl)thiazole-4-carboxamido)-2-methylpropyl)thiazole-4-carboxamido)-2- 
hydroxypropyl)thiazol-4-yl)-5-(4-carboxythiazol-2-yl)pyridin-2-yl)-2,4'-bithiazole-4- 
carboxylic acid hydrochloride (254)
To a stirred solution of MP1 core-backbone fragment 250 (15 mg, 12 pmol) in methanol-water 
(5:1, 3 mL) was added lithium hydroxide monohydrate (5 mg, 123 pmol, 10 equiv) and the 
solution stirred at room temperature for 14 h. The solvent was evaporated in vacuo and ethyl 
acetate (2 mL) added. The mixture was sonicated to produce a fine suspension, to which was 
added hydrogen chloride in ethyl acetate (2 mL). The resulting mixture was stirred at room 
temperature for 1 hour then evaporated under a stream of nitrogen to afford the title compound 
as a bright yellow solid, used immediately without further purification.
BocN BocN
O O O
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Macrocycle 251
o
FDPP-mediated macrocyclisation
Deprotected core-backbone fragment 254 (10 mg, 9.8 pmol) was dissolved in DMF (33 mL) and 
diisopropylethylamine (1 mL) added. FDPP (19 mg, 48.8 pmol, 5 equiv) was added and the 
solution stirred at room temperature for 48 h. The solvent was removed in vacuo and the residue 
triturated with ethyl acetate (2 mL) to afford an off-white solid which was determined to be FDPP.
HATU-mediated macrocyclisation
Deprotected core-backbone fragment 254 (£12.8 mg, 12 pmol) was dissolved in DMF (12 mL) 
and diisopropylethylamine (21 pL, 16 mg, 120 pmol, 10 equiv) added. HATU (19 mg, 60 pmol, 5 
equiv) was added and the solution stirred at room temperature for 45 h. The solvent was 
removed in vacuo and the residue triturated with ethyl acetate (2 mL) to afford an off-white solid 
which was partitioned between chloroform (2 mL) and aqueous acetic acid (5% w/v; 2 mL). The 
solution was filtered to furnish macrocycle 251 (10.4 mg, 85%) as a pale brown solid, mp 200- 
204 °C (CHCI3-Ac0H-H20); m /z{ES+) 1021 ([M+NH4] \  55%), 1004 ([M+H]+, 87%), 995 (23), 980 
(21), 433 (32), 377 (38), 338 (30), 333 (13), 263 (48), 219 (100), 143 (11), 130 (28).
(4S,5F?,2’/:?)-4-[(2-Hydroxypropyl)aminocarbonyl]-2,2,5-trimethyl-3-(te/?-butoxcarb- 
onyl)oxazolidine (259)
o o
259
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Triethylamine (2.78 mL, 2.01 g, 19.9 mmol, 2.07 equiv) was added dropwise over 30 minutes to 
a stirred solution of (4S,5f?)-3-(ferf-butoxycarbonyl)-2,2,5-trimethyloxazolidine-4-carboxylic acid 
(2.49 g, 9.60 mmol, 1.07 equiv), (/7)-1-amino-2-propanol (675 mg, 9.00 mmol, 1 equiv) and 
PyBOP® (5.20 g, 10.00 mmol, 1.11 equiv) in dry dichloromethane (19 mL) at 0 °C. The solution 
was allowed to warm to room temperature and stirred for a further 18 h. After concentrating in 
vacuo, purification by column chromatography on silica, eluting with ethyl acetate gave the title 
compound (2.84 g, 100%) as a colourless solid, mp 118-119 °C (petroleum ether-Et20 ) (Found: 
[M+H]+, 317.2072. Calc, for C15H29N20 5: 317.2071); [a]D31 -62.0 (c 1.50, chloroform); R, 0.29 
(EtOAc); vmax(KBr)/cm'1 3488, 3286, 3116, 2978, 2925, 2865, 1672, 1570, 1366, 1259, 1135, 
989, 967, 945, 909, 855, 781, 765, 690; 6H(400 MHz; CDCI3) 6.44 (1 H, br s, exch D20, NH), 
4.22 (1 H, m, 5-H), 3.91 (1 H, app br s, 2’-H ), 3.76 (1 H, d, J 7.5, 4-H), 3.40 (1 H, br s, 1-CHH), 
3.14 (1 H, m, T -C H H), 2.97 (1 H, br s, exch D20 , OH), 1.60 (3 H, s, 2-Me), 1.58 (3 H, s, 2-Me), 
1.44 (9 H, s, CMe3), 1.37 (3 H, d, J 6.0, 5-Me), 1.17 (3 H, d, J 6.5, 2’-Me); 5C(100 MHz; CDCI3)
170.2 (C), 152.8 (C), 94.7 (C), 81.5 (C), 73.9, (CH), 67.9 (CH), 66.8 (CH), 47.1 (CH2), 28.3 (CH3),
27.6 (CH3), 25.2 (CH3), 20.2 (CH3), 18.6 CH3); m/z (APCI) 317 ([M+H]+, 100%), 261 (28), 217 
(21), 173 (25), 155 (12).
(4S,5/=?,2’fi)-4-[(2-Acetoxypropyl)aininocarbonyl]-2,2,5-trimethyl-3-(te/t-butoxycar- 
bonyl)oxazolidine (256)
o o
256
Acetic anhydride (0.27 mL, 0.29 g, 2.85 mmol, 3 equiv) was added to a solution of alcohol 259 
(300 mg, 0.95 mmol) in dry pyridine (10 mL) and stirred at room temperature for 48 h. The 
solution was evaporated in vacuo and the residue purified by column chromatography on silica, 
eluting with light petroleum-ethyl acetate (1:1) to furnish the title compound (333 mg, 98%) as a 
colourless solid, mp 124-125 °C (petroleum ether-Et20 ) (Found: [M+H]+, 359.2179. Calc, for 
Ci7H3iN20 6: 359.2177); [a]D26 -37.6 (c 1.00, chloroform); Rf 0.24 (petroleum ether-ethyl acetate, 
1:1); vmax(KBr)/cm"1 3382, 2985, 2945, 1735, 1711, 1663, 1532, 1478, 1459, 1376, 1241, 1221, 
1175, 1126, 1096, 1076, 1057, 1026, 986, 972, 954, 894, 857, 783; 6H(400 MHz; CDCI3) 6.36 
(1H, br s, exch D20, NH), 4.99 (1 H, ddq, J6.0, 4.0, 6.0, 2’-H ), 4.22 (1 H, br s, 5-H), 3.70 (1 H, 
d, J 6.5, 4-H), 3.55 (1 H, ddd, J 14.2, 6.0, 4.0, 1-CHH), 3.37 (1 H, ddd, J 14.2, 6.0, 7.0, 1 -  
CHhi), 2.05 (3 H, s, Me), 1.60 (3 H, s, 2-Me) 1.55 (3 H, s, 2-Me), 1.49 (9 H, s, CMe3), 1.42 (3 H, 
d, J 6.0, 2’-Me), 1.30 (3 H, d, J 6.5, 5-Me); 6C(100 MHz; CDCI3) 170.6 (C), 170.0 (C), 166.4 (C),
94.6 (C), 80.7 (C), 73.9 (CH), 69.6 (CH), 67.4 (CH), 43.8 (CH2), 28.2 (CH3), 27.7 (CH3), 25.0
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(CH3), 21.1 (CH3), 18.8 (CH3), 17.5 (CH3); m/z (APCI) 359 ([M+H]+, 100%), 303 (25), 259 (85), 
213(20).
(4S,5F?,2’/:?)-4-[(2-terf-Butyldimethylsilyloxy)aminocarbonyl]-2,2,5-trimethyl-3-(te/?- 
butoxycarbonyl)oxazolidine (258)
o o
258
Imidazole (400 mg, 5.90 mmol, 1.8 equiv), DMAP (122 mg, 1.00 mmol, 0.3 equiv) and TBDMS- 
chloride (690 mg, 4.60 mmol, 1.4 equiv) were added successively to a solution of alcohol 259 
(1.04 g, 3.27 mmol) in DMF (25 mL). The mixture was stirred at room temperature for 36 h, 
acidified with hydrochloric acid (1 M, 80 mL) and extracted with diethyl ether (3 x 90 mL). The 
combined organic extracts were washed with water (3 x 300 mL), dried (Na2S 04) and evaporated 
in vacuo to furnish the title compound (1.39 g, 98%) as a pale yellow-green oil (Found: [M+H]+, 
431.2934. Calc, for C2iH43N205Si: 431.2936); [a]D23 -26.4 (c 0.75, chloroform); vmax(film)/cm'1 
3329, 2976, 2931, 2858, 2359, 1710, 1669, 1530, 1462, 1367, 1258, 1175, 1133, 1006, 940, 
860, 837, 777; 5H(400 MHz; CDCI3) 6.10 (1 H, br s, exch D20, NH), 4.11 (1 H, br s, 5-H), 3.89 (1
H, m, 2’-H ), 3.69 (1 H, br s, 4-H), 3.23 (2 H, 1’-C H 2), 1.55 (3 H, s, 2-Me), 1.52 (3 H, s, 2-Me),
I.36 (9 H, s, OCMe3), 1.32 (3 H, d, J 6.0, 5-Me), 1.07 (3 H, d, J 6.0, 2’-Me), 0.82 (9 H, s, 
SiCMe3), 0.01 (3 H, s, MeSiMe), 0.00 (3 H, s, MeSiMe); 6C(100 MHz; CDCI3) 169.9 (C), 151.5 
(C), 94.9 (C), 80.7 (C), 77.3 (C), 74.7 (CH), 68.1 (CH), 67.2 (CH), 46.3 (CH2), 28.3 (CH3), 25.8 
(CH3), 21.1 (CH3), 19.2 (CH3), 18.0 (CH3), -3 .6  (CH3), -4 .4  (CH3); m/z (APCI) 431 ([M+H]+, 80%), 
375(100), 331 (75), 285 (45).
/V-terf-(Butoxycarbonyl)-0-terf-(butyldimethylsilyl)threomne (260)
BocHN BocHN
O O
260
A/-Boc-L-threonine (5.00 g, 22.81 mmol) was dissolved in dry dichloromethane (75 mL) and 
triethylamine (10.7 mL, 7.77g, 76.77 mmol, 3.37 equiv) added. The solution was cooled to 0 °C 
and TBDMS-triflate (15.72 mL, 18.09 g, 68.43 mmol, 3.00 equiv) added slowly. The mixture was 
stirred at room temperature for 2 hours, quenched with water (75 mL) and the aqueous layer 
extracted with dichloromethane (2 x 25 mL). The combined organic layers were filtered,
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evaporated in vacuo and the residue dissolved in methanol (75 mL). Water (32 mL) and 
potassium carbonate (7.88 g, 57.02 mmol, 2.50 equiv) were added and the solution stirred at 
room temperature for 2 hours, extracted with hexane (100 mL) and acidified to pH 3 with 10% 
w/v aqueous potassium hydrogen sulfate . The acidified water-methanol solution was extracted 
with ethyl acetate (4 x 100 mL) and the combined organic extracts dried (Na2S 04) and 
evaporated in vacuo to yield the title compound (7.61 g, 100%) as a viscous, colourless oil 
(Found: [M+H]+, 334.2049. Calc, for C15H32N05Si: 334.2050); [o]D25 +11.0 (c 4.00, chloroform) 
{lit.,221 +10.7 (c 3.90, chloroform)}; vmax(CH2CI2)/crTV1 3600-2400 br, 3456, 3166, 2955, 2858, 
1722, 1694, 1624, 1504, 1472, 1392, 1367, 1254, 1169, 1101, 1072, 1031, 939, 837, 777; 
6H(400 MHz; CDCI3) 5.16 (1 H, d, J8.4, exch D20, NH), 4.34 (0.8 H, br m, f3-H), 4.30 (0.2 H, br s, 
P-H), 4.15 (1 H, dd, J8.4, 6.7, a-H), 1.36 (9 H, s, OCMe3), 1.10 (3 H, d, J 6.2, HCMe), 0.77 (9 H, 
s, SiCMe3), 0.00 (3 H, s, MeSiMe), -0.06 (3 H, s, MeSiMe)\ 5C(125 MHz; d6-DMSO) 172.6 (C), 
156.0 (C), 78.8 (C), 68.9 (CH), 59.6 (CH), 28.5 (CH3), 26.1 (CH3), 20.8 (CH3), 18.1 (CH3), -4.6 
(CH3), -5.3 (CH3); m/z (APCI) 334 ([M+H]\ 47%), 278 (100), 275 (17), 234 (35).
ferf-Butyl (2S,3fi)-3-(terf-butyldimethylsilyloxy)-1 -((R)-2-hydroxyp ropy lam ino)-1 -oxobutan- 
2-ylcarbamate (261)
Triethylamine (0.96 mL, 698 mg, 6.90 mmol, 2.3 equiv) was added dropwise to a stirred solution 
of W-fert-(butoxycarbonyl)-0-ferf-(butyldimethylsilyl)threonine (1.00 g, 3.00 mmol, 1 equiv), (R )- 
1-amino-2-propanol (225 mg, 3.00 mmol, 1 equiv) and PyBOP® (1.71 g, 3.30 mmol, 1.1 equiv) 
in dry dichloromethane (35 mL) and the solution stirred at room temperature for 18 h. After 
concentrating in vacuo, purification by column chromatography on silica, eluting with ethyl 
acetate gave the title compound (759 mg, 65%) as a colourless oil, [a]D25 -8.8 (c 0.50, acetone); 
R,0.50 (EtOAc); vmax(CH2CI2)/cm'1 3422, 2955, 2931, 2858, 1702, 1664, 1534, 1500, 1392, 1367, 
1255, 1168, 1131, 1100, 1074, 1021, 959, 839, 779; 5H(400 MHz; d6-acetone) 7.22 (1 H, app br 
s, exch D20 , NH), 5.67 (1 H, br d, J 7.2, exch D20 , NH), 4.31 (1 H, m, Thr P-H), 3.94 (1 H, app d, 
J 7.2, Thr a-H), 3.75 (1 H, m, CH2CH(OH)Me), 3.26 (1 H, ddd, J 12.3, 7.0, 6.0, CHH), 2.95 (1 H, 
ddd, J 12.3, 7.0, 5.3, CHH), 2.77 (1 H, s, exch D20, OH), 1.32 (9 H, s, OCMe3), 1.05 (3 H, d, J 
6.3, Thr P-Me), 1.02 (3 H, d, J 6.2, CH(OH)/We), 0.79 (9 H, s, SiCMe3), 0.00 (3 H, s, /WeSiMe), 
0.02 (3 H, s, MeSi Me); 6C(100 MHz; CDCI3) 170.2 (C), 156.0 (C), 79.8 (C), 68.2 (CH), 67.0 (CH), 
66.1 (CH), 47.1 (CH2), 30.8 (CH3), 28.3 (CH3), 25.7 (CH3), 20.7 (CH3), 17.6 (C), -4.7 (CH3), -5.6 
(CH3); m/z (APCI) 391 ([M+Hf, 31%), 335 (69), 291 (75), 219 (9), 117 (100).
TBSO
BocHN
TBSO'
BocHN
O O
261
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(H)-1 -((2S,3R)-2-( te/t-Butoxycarbonylamino)-3-( tert- 
butyldimethylsilyloxy)butanamido)propan-2-yl acetate (257)
BocHN
TBSO'.
BocHN
O O
257
Acetic anhydride (0.18 mL, 196 mg, 2.85 mmol, 3 equiv) was added to a solution of alcohol 261 
(250 mg, 0.64 mmol) in dry pyridine (10 mL) and stirred at room temperature for 48 h. The 
solution was evaporated in vacuo and the residue purified by column chromatography on silica, 
eluting with ethyl acetate to furnish the title compound (234 mg, 84%) as a colourless oil, R^O.72 
(EtOAc); 6h(400 MHz; d6-acetone) 7.26 (1 H, app br s, exch D20, NH), 5.63 (1 H, br d, J 7.5, 
exch D20 , NH), 4.83 (1 H, ddq, J6.3, 4.5, 6.5, CH2CH(OAc)Me), 4.27 (1 H, dq, J 6.2, 2.1, Thr (3- 
H), 3.92 (1 H, dd, J 8.0, 2.1 Thr a-H), 3.46 (1 H, ddd, J12.1, 7.2, 4.5, CHH), 3.07 (1 H, ddd, J 
12.1, 6.5, 5.6, CHH), 1.87 (3 H, s, CH3), 1.33 (9 H, s, OCMe3), 1.07 (3 H, d, J 6.3, CH(OAc)Me), 
1.04 (3 H, d, J 6.2, Thr p-Me), 0.79 (9 H, s, SiCMe3), 0.00 (3 H, s, MeSiMe), 0.02 (3 H, s, 
MeSi Me)] 5C(125 MHz; d6-acetone) 170.2 (C), 169.7 (C), 155.6 (C), 78.7 (C), 78.3 (C), 69.2 
(CH), 68.7 (CH), 59.8 (CH), 43.2 (CH2), 27.6 (CH3), 25.3 (CH3), 23.8 (CH3), 20.3 (CH3), 19.3 
(CH3), 17.6 (CH3), 16.9 (CH3); m/z (APCI) 433 ([M+H]+, 52%), 377 (63), 333 (30), 215 (20), 141 
(100), 126 (52), 118(28).
(H)-1-((2S,3H)-2-amino-3-(fe/?-butyldimethylsilyloxy)butanamido)propan-2-yl acetate (263)
A saturated solution of hydrogen chloride in ethyl acetate (2 mL) was added to side chain 
dipeptide 257 (20 mg, 46 pmol) and the resulting solution stirred at room temperature for 30 
minutes. The solvent was removed in vacuo and the residue used immediately without further
purification; m/z(ES+) 665 ([2M+H]+, 7%), 333 ([M+H]+, 100%), 287 (30), 259 (12), 219 (7), 201
T B S O
BocHN
O O
263
(7), 159 (5).
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One-pot macrolactamisation and side chain coupling (264)
Deprotected core-backbone fragment 254 (60 mg, 57 pmol) was dissolved in DMF (57 mL) and 
diisopropylethylamine (49 pL, 37 mg, 283 pmol, 5 equiv) added. HATU (108 mg, 283 pmol, 5 
equiv) was added and the solution stirred at room temperature for 3 h. A solution of amine 263 
(~63 mg, 170 pmol, 3 equiv) and diisopropylethylamine (49 pL, 37 mg, 283 pmol, 5 equiv) in 
DMF (3 mL) was added and the mixture stirred at room temperature for 36 h. The solvent was 
removed in vacuo and the residue triturated with ethyl acetate (2 mL) to afford an off-white solid 
which was partitioned between chloroform (2 mL) and aqueous acetic acid (5% w/v; 2 mL). The 
solution was filtered to furnish macrocycle 251 (20 mg, 35%) as a pale brown solid.
(2S,3fi)-2-Amino-3-(ferf-butyldimethylsilyloxy)-N-((fi)-2-hydroxypropyl)butanamide (265)
A saturated solution of hydrogen chloride in ethyl acetate (2 mL) was added to side chain 
dipeptide 261 (24 mg, 61 pmol) and the resulting solution stirred at room temperature for 1 hour. 
The solvent was removed in vacuo and the residue used immediately without further purification.
BocHN
O O
265
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Macrocycle-side chain coupling (266)
HNHN
TBSO OHHN HN
265HN, HN,
OHOH
266
N —
HO.
HO
TBSO'O
Macrocycle 251 (~20 mg, 20 pmol) was dissolved in DMF (2 mL) and diisopropylethylamine (17 
pL, 13 mg, 100 pmol, 5 equiv) added. HATU (15 mg, 40 pmol, 2 equiv) was added and the 
solution stirred at room temperature for 1 h. A solution of amine 265 (~20 mg, 61 pmol, 3 equiv) 
and diisopropylethylamine (0.5 mL) in DMF (1 mL) was added and the mixture stirred at room 
temperature for 72 h. The solvent was removed in vacuo and the residue triturated with ethyl 
acetate (2 mL) to afford an off-white solid which was partitioned between chloroform (2 mL) and 
aqueous acetic acid (5% w/v; 2 mL). The solution was filtered to furnish an intractable mixture of 
insoluble products (15 mg) as an off-white solid.
Acetate protection of macrocycle 266
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Acetic anhydride (50 pL, 54 mg, 53 pmol, 45 equiv) was added to a solution of 266 (15 mg, 12 
pmol) in dry pyridine (1 mL) and stirred at room temperature for 62 h. The solution was 
evaporated in vacuo and the residue purified by column chromatography on silica, eluting with 
chloroform-methanol (19:1) to furnish 267 (5 mg, 33%) as an off-white solid, 0.10 (chloroform- 
methanol, 19:1); m/z (ES+) 1330 ([M+H]+, 5%), 817 (5), 709 (5), 627 (5), 487 (7), 452 (10), 430 
(10), 325 (100), 279 (43), 243 (32), 197 (12), 83 (9).
(R)-1-((2S,3/=?)-2-Amino-3-hydroxybutanamido)propan-2-yl acetate (269)
o o
269
A saturated solution of hydrogen chloride in ethyl acetate (2 mL) was added to side chain 
dipeptide 256 (38 mg, 106 pmol) and the resulting solution stirred at room temperature for 1 
hour. The solvent was removed in vacuo and the residue used immediately without further 
purification.
Acetate protection of macrocycle 251 [section 5.6.2]
HNHN OAc
OAc HNHN
269HN,
251
OAcOAc
270268
N—
AcO
HO'
To a stirred solution of 251 (11 mg, 11 pmol) in dry pyridine (2 mL), acetic anhydride (100 pL, 
108 mg, 106 pmol, 96 equiv) was added and the mixture stirred at room temperature for 24 h. 
The solution was evaporated in vacuo and the residue dissolved in DMF (2 mL) and HATU (16 
mg, 52 pmol, 5 equiv) and diisopropylethylamine (18 pL, 14 mg, 106 pmol, 10 equiv) added. 
After 1 hour, a solution of amine 265 (~27 mg, 106 pmol, 10 equiv) and diisopropylethylamine
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(37 pL, 27 mg, 212 pmol, 20 equiv) in DMF (1 mL) was added and the mixture stirred for a 
further 24 h at room temperature. The solvent was removed in vacuo and the residue purified by 
column chromatography on silica, eluting with chloroform-methanol (9:1). The fractions 
containing a blue-fluorescent spot, R/0.30 were mixed and evaporated in vacuo and the residue 
loaded onto silica and washed with ethyl acetate. Removal from silica by eluting with methanol 
furnished an off-white solid (10 mg).
Attempted elaboration of 270 to MP1
MP1 skeleton 270 (~10 mg, 7.5 pmol) was dissolved in dichloromethane (2 mL) and 
triethylamine (50 pL, 36 mg, 359 pmol, 48 equiv) added, followed by dropwise addition of 
methanesulfonyl chloride (25 pL, 37 mg, 359 pmol, 43 equiv). The solution was stirred at room 
temperature for 1 hour, then partitioned between chloroform (5 mL) and water (5 mL). The 
organic layer was dried (Na2S 04) and evaporated in vacuo. The residue was dissolved in 
chloroform (2 mL), DBU (25 pL, 25 mg, 167 pmol, 22 equiv) was added and the solution stirred 
at room temperature for 2 hours, washed with 5% w/v potassium hydrogen sulfate, dried 
(Na2S 04) and evaporated in vacuo. Purification on a silica plug, eluting with ethyl acetate 
followed by removal with methanol furnished a chromatographically homogeneous off-white solid 
(4 mg).
MP1 skeleton 271 (~4 mg, 3 pmol) was dissolved in methanol-water (5:1, 3 mL) and lithium 
hydroxide monohydrate (4 mg, 95 pmol, 32 equiv) added. The solution was stirred at room 
temperature for 12 h then evaporated in vacuo. Water (2 mL) and 10% w/v potassium hydrogen 
sulfate (2 mL) were added and the acidic aqueous solution extracted with ethyl acetate ( 2 x 5  
mL). The combined organic extracts were dried (Na2S 04) and evaporated in vacuo to afford an 
intractable mixture of unidentifiable products as a colourless solid (2 mg).
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Silyl-protection of macrocycle 251 [section 5.6.3]
HIM PH
HN
OH
HO.
O
HN
HN
OTBS
272
N —
HO.
O
TBDMSOTf and Et3N
Macrocycle 251 (9 mg, 9 pmol) was dissolved in DMF (1 mL) and triethylamine (50 pL, 36 mg, 
359 pmol, 40 equiv) added. TBDMS-triflate (50 pL, 58 mg, 217 pmol, 24 equiv) was added and 
the solution stirred at room temperature for 18 hours, evaporated in vacuo and the residue stirred 
at room temperature in methanol (1 mL) and aqueous sodium hydrogen carbonate (1 M, 1 mL) 
for 2 hours. The solution was extracted with hexane (1 mL), acidified to pH 3 with 10% w/v 
potassium hydrogen carbonate, and extracted with chloroform ( 4 x 1  mL). A pale brown 
precipitate (6 mg) was formed on addition of the organic solvent, and was subsequently identified 
as unreacted macrocycle 251.
TBDMSOTf and imidazole
Macrocycle 251 (~5 mg, 5 pmol) was dissolved in d7-DMF (0.5 mL) and imidazole (17 mg, 250 
pmol, 50 equiv) added. TBDMS-triflate (50 pL, 58 mg, 217 pmol, 24 equiv) was added and the 
solution stirred at 50 °C for 24 hours. No product or starting material could be identified in the 
reaction mixture.
(FT)-Methyl 2-(7-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl)thiazole-4-
carboxylate (284)
HN,
284
HN,
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Cyclothiazomycin y-lactam 276 (4.5 mg, 16 pmol) was dissolved in methanol (3 mL) and 
hydrochloric acid (6  M, 0.3 mL) added. The solution was heated at reflux for 3 hours, allowed to 
cool to room temperature, then evaporated in vacuo to furnish the title compound (4 mg, 85%) as 
an off-white solid, [a]D24 +8.00 (c 0.2, chloroform) (Found: [M+H]+, 290.0609. Calc, for 
C13H12N3O3S: 290.0599); vmax(CH2CI2)/cnrf1 2956, 2915, 2845, 1719, 1656, 1598, 1547, 1443, 
1408, 1258, 1082, 1017, 805; 6H(400 MHz; CDCI3) 8.38 (1 H, d, J8.0, pyr-4), 8.27 (1 H, s, thz-4), 
8.16 (1 H, d, J 8.0, pyr-5), 6.35 (1 H, s, exch. D20, NH), 4.72 (1 H, q, J 7.0, CH3CH), 3.94 (3 H, s, 
OMe), 1.57 (2 H, d, J 7.0, C H ^H ); m/z (APCI) 290 ([M+H]\ 100%); spectroscopic properties 
identical to the natural material.
(ft)-Ethyl 4-(fer?-butoxycarbonylamino)-3-oxopentanoate (285)
BocHN BocHN
i) n-Butyllithium in hexanes (2.5 M, 4.00 mL, 10.0 mmol, 2 equiv) was added dropwise to a 
stirred solution of diisopropylamine (1.40 mL, 10.0 mmol, 2 equiv) in dry THF (10 mL) at 0 °C and 
stirred for 30 minutes. The solution was cooled to -7 8  °C and dry ethyl acetate (0.49 mL, 5.01 
mmol, 1 equiv) was added dropwise and stirred for 30 minutes.
ii) Ethyl chloroformate (0.52 mL, 5.5 mmol, 1.1 equiv) was added dropwise to a stirred solution 
of A/-Boc-D.-alanine (946 mg, 5.00 mmol, 1 equiv) and triethylamine (0.77 ml, 5.5 mmol, 1.1 
equiv)) in dry THF (10 mL) at 0 °C and stirred for 30 minutes. The mixture was filtered and 
added dropwise to i.), stirred at -7 8  °C for 1 h, warmed to room temperature and quenched with 
saturated aqueous ammonium chloride (60 mL). The organic solvent was evaporated in vacuo 
and the resulting aqueous solution extracted with ethyl acetate (2 x 30 ml). The combined 
organic layers were washed with brine (40 ml), dried (Na2S 04) and evaporated in vacuo. 
Purification by column chromatography on silica, eluting with petroleum ether-ethyl acetate (2:1) 
gave the title compound (391 mg, 30%) as a pale yellow oil, [a]D25 +17.2 (c 1.00, chloroform) 
{lit.,143 +10.7 (c 2.50, chloroform)}; Rf 0.30 (petroleum ether-ethyl acetate, 2:1); 6H(250 MHz; 
CDCI3) 5.10 (1 H, br s, NHBoc), 4.54 (1 H, s, =CH), 4.32 (1 H, q, J7.1, CHMe), 4.12 (2 H, q, J 
7.2, CH2CH3), 1.37 (9 H, s, CMe3), 1.29 (3 H, d, J7.1, CH Me), 1.21 (3 H, t, J 7.2, CH2C H3)\ 6C(67 
MHz; CDCI3) 172.9 (C), 166.9 (C), 155.2 (C), 80.1 (CH), 80.0 (C), 55.4 (CH2), 45.8 (CH), 28.3 
(CH3), 17.1 (CH3), 14.1 (CH3).
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(f?)-Methyl 2-(7-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl)thiazole-4-
carboxylate (284)
o o
Bocl O BocHN
EtO
288
C02Me
HN
C 0 2Me
To a stirred solution of {R)-ethyl 4-(te/t-butoxycarbonylamino)-3-oxopentanoate (30 mg, 116 
pmol) in ethanol (10 mL) was added ammonium acetate (45 mg, 578 pmol, 5 equiv) and the 
solution stirred at 50 °C for 20 hours, allowed to cool to room temperature, and methyl 2- 
(propynoyl)thiazole-4-carboxylate (34 mg, 174 pmol, 1.5 equiv) added. The solution was stirred 
for 2.5 hours, cooled to 0 °C and A/-iodosuccinimide (26 mg, 116 pmol, 1 equiv) added. The 
mixture was stirred for 30 minutes, evaporated in vacuo and partitioned between ethyl acetate 
(15 mL) and saturated aqueous sodium hydrogen carbonate (10 mL). The aqueous layer was 
further extracted with ethyl acetate (10 mL) and the combined organic extracts washed with 
water (10 mL) and brine (10 mL), dried (Na2S 0 4) and evaporated in vacuo. Purification by 
column chromatography on silica, eluting with petroleum ether-ethyl acetate (2:1) furnished 
compound 288 (18 mg, 36%) as a pale yellow solid, R/0.30 (petroleum ether-ethyl acetate, 2:1).
Pyridine 288 (5 mg, 12 pmol) was stirred in hydrochloric acid (6 M, 3 mL) at room temperature for 
6 hours. The solution was neutralised by addition of aqueous sodium hydroxide (5 M) and 
extracted with dichloromethane ( 3 x 5  mL). The combine organic extracts were dried (Na2S 04) 
and evaporated in vacuo to furnish the title compound (4 mg, 85%) as an off-white solid, [a]D22 
+59.20 (c 0.20, chloroform); spectroscopic properties identical to the previously prepared 
synthetic material.
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Appendix One -  Mass Spectrum of Macrocycle 251 
Appendix Two -  Mass Spectrum illustrating Selective Boc- 
Deprotection of Side Chain Fragment 257 
Appendix Three -  Mass Spectrum of Acetate-protected 
Macrocycle 267
Appendix Four -  Proton NMR Spectra of Lactam 284 
derived from Cyclothiazomycin B1 and synthetic 284
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Mass spectrum illustrating selective Boc-deprotection of side chain fragment 257
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Proton NMR spectra of lactam 284 derived from cyclothiazomycin B1
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Proton NMR spectrum of synthetic lactam 284
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